Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives

ABSTRACT

Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson&#39;s disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula:   &lt;IMAGE&gt;

This is a divisional of U.S. Ser. No. 08/372,064, filed Jan. 12, 1995,now abandoned, which is a continuation-in-part of U.S. application Ser.Nos. 08/179,539 and 08/179,607, both filed Jan. 10, 1994, both nowabandoned, the contents of which are hereby incorporated by reference.

Throughout this application, various references are referred to.Disclosures of these publications in their entireties are herebyincorporated by reference into this application to more fully describethe state of the art to which this invention pertains.

BACKGROUND OF THE INVENTION

Various procedures for treating Parkinson's Disease have beenestablished and many of them are currently in widespread use. EuropeanPatent No. 436492B provides a detailed discussion of treatmentsavailable and summarizes many of their drawbacks. There remains a needfor a drug therapy that provides a prolonged and sustained ameliorationof the symptoms associated with Parkinson's Disease.

A variety of substituted 1-aminoindans have been proposed to have someactivity in the central nervous system (CNS). This group of compoundshave a wide range of activities, for example, U.S. Pat. No. 4,096,173discloses 1-aminoindans with ring chloro substituents as havinganti-allergic, anti-spasmodic and local anesthetic activities, whereasU.S. Pat. No. 3,886,168 discloses the anti-inflammatory and vasodilatoryactivity of certain 1-aminomethylindans. It is hypothesized therein thatthe activity may be based in the CNS though no evidence is provided orsuggested to support the hypothesis. British Patent No. 852,735discloses 1-aminoindans with a lower alkoxy group in the 5 position asbeing active in dilating coronary blood vessels.

U.S. Pat. No. 3,637,740 discloses 4-alkoxy-5-chloro-1-aminoindans asanti-depressants or anti-anxiety agents, although no clear evidence isprovided of either activity.

Horn et al. (J.Pharm.Exp.Ther. 1972 180(3) 523) have shown that2-aminoindan is a far superior inhibitor of catecholamine uptake than1-aminoindan and therefore dismissed the latter as a candidate for usein the treatment of Parkinson's Disease. Martin et al. (J.Med.Chem. 197316(2) 147 & J.Med.Chem 1974 17(4) 409) describe experiments whereinN-methyl-5-methoxy derivatives of 1-aminoindan are investigated ashaving monoamine oxidase (MAO) inhibitory activity.

Oshiro et al. (J.Med.Chem. 1991 34 2004-2013) disclose a wide range of7-hydroxy-1-aminoindan derivatives that they subjected to screening foruse as a cerebroprotective agent using an antihypoxic test and as a CNSstimulatory agent using a cerebral trauma test. In the resultantstructure-activity-analysis undertaken it was found that replacement ofthe 7-hydroxy group by a methoxy group resulted in loss of activity inthe antihypoxic test but not in the cerebral trauma test. Theirconclusion was that the 7-hydroxy group is essential to obtain thedesired activity. This is evident from their subsequent paper wherein abroader range of 7-hydroxy derivatives are screened (J.Med.Chem 1991 342014-2020). These 7-hydroxy-1-aminoindans are defined in U.S. Pat. Nos.4,788,130, 4,792,628, 4,895,847, 5,055,474 and 5,242919 all assigned toOtsuka Pharmaceutical Co. Japan.

It has surprisingly been found that a range of substituted andunsubstituted 1-aminoindans have activity in suppressing the symptomsemanating from the dopaminergic hypofunction that is associated withParkinson's Disease; in improving cognition in dementias such as seniledementia, Parkinson-type dementia and dementia of the Alzheimer's type;in providing protection against epilepsy, convulsions, seizures; and inimproving post-head trauma motor function, and reducing trauma-inducedcerebral oedema.

The present invention also relates to a process for the synthesis ofoptically active aminoindan derivatives that have been described aspossessing utility in the treatment of Parkinson's Disease, dementia,epilepsy, convulsions or seizures.

Several methods of preparing optically active derivatives of1-aminoindan have been described in the art which include, for example,the method of Lawson and Rao, Biochemistry, 19, 2133 (1980), methods inreferences cited therein, and the method of European patent No. 235,590.

Optically active compounds containing an amine group attached to achiral carbon atom may be prepared by the resolution of a racemicmixture of the R and S enantiomers. Such a resolution can beaccomplished by resolution methods well known to a person skilled in theart, such as the formation of diastereomeric salts with chiral acids, orthose described in U.S. Pat. No. 4,833,273, issued May 23, 1989 (Goel)and those listed in J. Jacques, A. Collet and S. Wilen, "Enantiomers,Racemates and Resolutions" Wiley, New York (1981) such as tartaric,malic, mandelic acid, or N-acetyl derivatives of amino acids, such asN-acetyl leucine, followed by re-crystallization to isolate thediastereomeric salt of the desired enantiomer.

Kipping and Hall, J. Chem. Soc.(1901) 79 430, succeeded in the formationof diastereomeric alpha-bromocamphor-sulphonic acid salts of thecompound

N-benzyl-1-aminoindan. Isolation of the individual enantiomers by theaddition of barium hydroxide failed and the racemate was obtained.

The preparation of the S enantiomer of the benzoate salt ofN-benzyl-1-aminoindan from (S)-1-aminoindan has been described byTakaneda S et al. JCS Perkin II (1978) 95-99.

It is an object of this invention to provide an economical, commerciallyuseful method for preparing optically active enantiomers of 1-aminoindanand derivatives thereof.

It has been surprisingly observed that by using a particular resolvingagent on a particular class of 1-aminoindan derivative, a resolution iseffected that produces high yields of optically active enantiomer.

SUMMARY OF THE INVENTION

This invention provides a method for treating Parkinson's disease,dementia, epilepsy, convulsions, or seizures in a subject comprisingadministering to the subject a therapeutically effective amount of acompound of the formula: ##STR2## or a pharmaceutically acceptable saltthereof; wherein n is 0, 1 or 2; R₁ and R₂ are each independentlyhydrogen, hydroxy, substituted or unsubstituted C₁ -C₄ alkyl,substituted or unsubstituted C₁ -C₄ alkoxy, halogen, nitro, NH--R₃,C(O)--R₃, or C(O)--NR₉ R₁₀ ; R₃ is hydrogen, substituted orunsubstituted C₁ -C₄ alkyl, hydroxy, substituted or unsubstituted C₁₋₄alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl; and R₄ and R₅ areeach independently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, --C(O)--R₆, --Y--C(O)--R₇, or Y--(SO₂)NR₉ R₁₀ ; whereinR₆ is hydrogen, hydroxy, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or A--NR₉ R₁₀, wherein A is substituted orunsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl,substituted or unsubstituted C₇ -C₁₂ aralkyl, and R₉ and R₁₀ are eachindependently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or indanyl; Y is substituted or unsubstituted C₁ -C₁₂alkyl, substituted or unsubstituted C₆ -C₁₂ aryl or substituted orunsubstituted C₇ -C₁₂ aralkyl, and R₇ is hydrogen, hydroxy, substitutedor unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl or NR₉ R₁₀, whereinR₉ and R₁₀ are each independently hydrogen, substituted or unsubstitutedC₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl, substituted orunsubstituted C₇ -C₁₂ aralkyl, or indanyl.

This invention provides a method for treating epilepsy, convulsions, orseizures in a subject comprising administering to the subject atherapeutically effective amount of a compound of the formula: ##STR3##or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2;R₁ and R₂ are each independently hydrogen, hydroxy, substituted orunsubstituted C₁ -C₄ alkyl, substituted or unsubstituted C₁ -C₄ alkoxy,halogen, nitro, NH--R₃, C(O)--R₃, or C(O)--NR₉ R₁₀ ; R₃ is hydrogen,substituted or unsubstituted C₁ -C₄ alkyl, hydroxy, substituted orunsubstituted C₁₋₄ alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl;and R₄ and R₅ are each independently hydrogen, substituted orunsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl,substituted or unsubstituted C₇ -C₁₂ aralkyl, alkynyl, --C(O)--R₆,--Y--C(O)--R₇, or Y--(SO₂)NR₉ R₁₀ ; wherein R₆ is hydrogen, hydroxy,substituted or unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstitutedC₆ -C₁₂ aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl, or A--NR₉R₁₀, wherein A is substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, and R₉ and R₁₀ are each independently hydrogen,substituted or unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstitutedC₆ -C₁₂ aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl, or indanyl;Y is substituted or unsubstituted C₁ -C₁₂ alkyl, substituted orunsubstituted C₆ -C₁₂ aryl or substituted or unsubstituted C₇ -C₁₂aralkyl, and R₇ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl, substituted orunsubstituted C₇ -C₁₂ aralkyl or NR₉ R₁₀, wherein R₉ and R₁₀ are eachindependently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or indanyl.

This invention provides a compound selected from the group consisting of7-methyl-1-aminoindan, 5-methyl-1-aminoindan,(R)-6-hydroxy-1-aminoindan, 3,5,7-trimethyl-1-aminoindan,4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan,(S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan,6-hydroxy-5-methoxy-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan,(R)-N-formyl-1-aminoindan, (S)-N-formyl-1-aminoindan,(R)-N-acetyl-1-aminoindan, N-acetyl-7-methyl-1-aminoindan,N-acetyl-6-fluoro-1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan,(S)-6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan,(R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-(2-acetamido)-1-aminoindan,(R)-N-(2-acetamido)-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan,N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan,N-(2-acetamido)-1-aminotetralin, N-(2-N-Boc-aminoacetyl)-1-aminoindan,N-(2-Aminoacetyl)-1-aminoindan, N-Benzoyl-1-aminoindan,N-(2-n-Propylpentanoyl)-1-aminoindan, N-methyl-N-acetyl-1-aminoindan,(R)-N-methyl-N-acetyl-1-aminoindan, N-(2-propionamido)-1-aminoindan,N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan,N-(4'-fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-aminoindan,(S)-(1-indanyl)-glycine, N,N-di-(2-acetamido)-1-aminoindan,N-(1-indanyl)-aminoacetonitrile 6-cyano-N-acetyl-1-aminoindan,6-carboxamido-N-acetyl-1-aminoindan,6-ethoxycarbonyl-N-acetyl-1-aminoindan,2-(1-indanamino)-N-isopropylethanesulfonamide,2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,(R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan,N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide,N,N'-bis(R)-(1-indanyl)succinamide,trans-2-methyl-N-acetyl-1-aminoindan,cis-2-methyl-N-acetyl-1-aminoindan, and salts thereof.

The compounds of general formula 1 possess neuroprotective activity.Accordingly, this invention provides a method for treating acuteneurological traumatic disorder or neurotrauma in a subject comprisingadministering to the subject a therapeutically effective amount of acompound of the formula: ##STR4## or a pharmaceutically acceptable saltthereof; wherein n is 0, 1 or 2; R₉ and R₂ are each independentlyhydrogen, hydroxy, substituted or unsubstituted C₁ -C₄ alkyl,substituted or unsubstituted C₁ -C₄ alkoxy, halogen, nitro, NH--R₃,C(O)--R₃, or C(O)--NR₉ R₁₀ ; R₃ is hydrogen, substituted orunsubstituted C₁ -C₄ alkyl, hydroxy, substituted or unsubstituted C₁₋₄alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl; and R₄ and R₅ areeach independently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, --C(O)--R₆, --Y--C(O)--R₇, or Y--(SO₂)NR₉ R₁₀ ; whereinR₆ is hydrogen, hydroxy, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or A--NR₉ R₁₀, wherein A is substituted orunsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl,substituted or unsubstituted C₇ -C₁₂ aralkyl, and R₉ and R₁₀ are eachindependently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or indanyl; Y is substituted or unsubstituted C₁ -C₁₂alkyl, substituted or unsubstituted C₆ -C₁₂ aryl or substituted orunsubstituted C₇ -C₁₂ aralkyl, and R₇ is hydrogen, hydroxy, substitutedor unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl or NR₉ R₁₀, whereinR₉ and R₁₀ are each independently hydrogen, substituted or unsubstitutedC₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl, substituted orunsubstituted C₇ -C₁₂ aralkyl, or indanyl.

This invention provides a method for preparing an optically activeenantiomer of a compound of the formula: ##STR5## wherein the enantiomeris optically active at the C₁ position; n is 0, 1 or 2; R₁ and R₂ areeach independently hydrogen, hydroxy, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₁ -C₄ alkoxy, or halogen; andR₃ is hydrogen or unsubstituted C₁ -C₄ alkyl; comprising incubating in areaction mixture a racemic N-benzyl analog of the compound with anoptically active enantiomer of mandelic acid; converting the opticallyactive ammonium salt obtained to its corresponding optically activebase; and reducing the base to the optically active enantiomer of thecompound.

This invention provides a method for preparing racemicN-benzyl-1-aminoindan comprising reacting 1-chloroindane withbenzylamine in an inert solvent.

DESCRIPTION OF THE FIGURES

FIG. 1: Experiment 1A: α-MpT-induced hypokinesia in hypoxic rat. Effectof the hypoxic episode as compared to control animals. X-axis: hoursafter α-MpT injection. Y-axis: percent of respective control recorded astotal movements.

FIG. 2: Experiment 1A: α-MpT-induced hypokinesia in hypoxic rat. Effectof the drug treated group as compared to the untreated hypoxic group.X-axis: hours after α-MpT injection. Y-axis: percent of respectivecontrol recorded as total movements.

FIG. 3: Experiment 1A: α-MpT-induced hypokinesia in hypoxic rat. Effectof the hypoxic episode as compared to control animals. X-axis: hoursafter α-MpT injection. Y-axis: percent of respective control recorded asbig movements.

FIG. 4: Experiment 1A: α-MpT-induced hypokinesia in hypoxic rat. Effectof the drug treated group as compared to the untreated hypoxic group.X-axis: hours after α-MpT injection. Y-axis: percent of respectivecontrol recorded as big movements.

FIG. 5: Experiment 1B: α-MpT-induced hypokinesia in hypoxic rat. Effectof the drug treated group as compared to the untreated hypoxic group.X-axis: hours after α-MpT injection. Y-axis: percent of respectivecontrol recorded as total movements.

FIG. 6: Experiment 1B: α-MpT-induced hypokinesia in hypoxic rat. Effectof the drug treated group as compared to the untreated hypoxic group.X-axis: hours after α-MpT injection. Y-axis: percent of respectivecontrol recorded as big movements.

FIG. 7: Experiment 3B: Water Maze Working Memory Test. X-axis: watermaze - working memory performance. Y-axis: ratio of averages oflatencies of run2/run1 in four sessions. Bars are, from left to right:control; hypoxia; hypoxia+AI; hypoxia+deprenyl

FIG. 8: Experiment 1C: α-MpT-induced hypokinesia in hypoxic rat. Effectof the drug treated group as compared to the untreated hypoxic group.Y-axis: total movements over 10 hours. The drugs tested are identifiedin the figure legend using codes, identified as follows:(R)-1-aminoindan, (RAI), 0.8 mg/kg, n=5; 4,5-dimethoxy-1-aminoindan,(31), 0.8 mg/kg, n=6; 6-fluoro-(R)-1-aminoindan, (FAI), 1.2 mg/kg, n=3;(R)-N-acetyl-1-aminoindan, (18), 0.8 mg/kg, n=2;(R)-6-hydroxy-1-aminoindan, (35), 1.2 mg/kg, n=3.

FIG. 9: Experiment 2C: Effect of 1-Aminoindans on Amphetamine-InducedStereotype Behavior in Rats. Y-axis: number of head movements perminute, measured 45 minutes after amphetamine injection. The drugstested are identified in the figure legend using codes, identified asfollows: (R)-N-acetyl-1-aminoindan (18), (R)-4,5-dimethoxy-1-aminoindan(29), (R)-1-aminoindan (R-AI), (R)-6-hydroxy-1-aminoindan (35),(R)-6-fluoro-1-aminoindan (R-FAI), (S)-4,5-dimethoxy-1-aminoindan (30).

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method for treating Parkinson's disease,dementia, epilepsy, convulsions, or seizures in a subject comprisingadministering to the subject a therapeutically effective amount of acompound of the formula: ##STR6## or a pharmaceutically acceptable saltthereof; wherein n is 0, 1 or 2; R₁ and R₂ are each independentlyhydrogen, hydroxy, substituted or unsubstituted C₁ -C₄ alkyl,substituted or unsubstituted C₁ -C₄ alkoxy, halogen, nitro, NH--R₃,C(O)--R₃, or C(O)--NR₉ R₁₀ ; R₃ is hydrogen, substituted orunsubstituted C₁ -C₄ alkyl, hydroxy, substituted or unsubstituted C₁₋₄alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl; and R₄ and R₅ areeach independently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, --C(O)--R₆, --Y--C(O)--R₇, or Y--(SO₂)NR₉ R₁₀ ; whereinR₆ is hydrogen, hydroxy, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or A--NR₉ R₁₀, wherein A is substituted orunsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl,substituted or unsubstituted C₇ -C₁₂ aralkyl, and R₉ and R₁₀ are eachindependently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or indanyl; Y is substituted or unsubstituted C₁ -C₁₂alkyl, substituted or unsubstituted C₆ -C₁₂ aryl or substituted orunsubstituted C₇ -C₁₂ aralkyl, and R₇ is hydrogen, hydroxy, substitutedor unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl or NR₉ R₁₀, whereinR₉ and R₁₀ are each independently hydrogen, substituted or unsubstitutedC₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl, substituted orunsubstituted C₇ -C₁₂ aralkyl, or indanyl.

One of skill in the art will appreciate that substituted orunsubstituted alkyl refers to both straight-chain and branched-chainalkyl groups. Halogen is used herein to refer to fluoro, chloro, bromo,and iodo groups.

The subject is any animal, preferably a mammal. In an embodiment, thesubject is a human subject. In another embodiment, the subject is amouse or a rat.

The administering can be performed according to techniques well known tothose of skill in the art. In embodiments of this invention theadministering comprises administering orally, rectally, transdermally,or parenterally.

In an embodiment the therapeutically effective amount is from about 1 mgto about 1000 mg, preferably from about 10 mg to about 100 mg.

Pharmaceutically acceptable salts and their preparation are well knownto those of skill in the art. Examples of pharmaceutically acceptablesalts are a hydrochloride salt, a mesylate salt, an ethylsulphonatesalt, or a sulfate salt.

In an embodiment of this invention n is 1. In another embodiment n is 2.

This invention provides the above method wherein R₁ and R₂ are eachindependently hydrogen, fluoro, hydroxy, methyl or methoxy.

In an embodiment of this invention R₃ is hydrogen or methyl.

In an embodiment of this invention R₄ and R₅ are each independentlyhydrogen, or substituted or unsubstituted C₁ -C₁₂ alkyl.

In an embodiment of this invention R₄ is C₁ -C₁₂ alkyl substituted witha lipophilic group, C₆ -C₁₂ aryl substituted with a lipophilic group, orC₇ -C₁₂ aralkyl substituted with a lipophilic group. In preferredembodiments the lipophilic group is selected from the group consistingof piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl,quinuclidinyl, and substituted derivatives thereof.

In another embodiment of this invention R₅ is C₁ -C₁₂ alkyl substitutedwith a lipophilic group, C₆ -C₁₂ aryl substituted with a lipophilicgroup, or C₇ -C₁₂ aralkyl substituted with a lipophilic group. Inpreferred embodiments the lipophilic group is selected from the groupconsisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl,adamantyl, quinuclindyl, and substituted derivatives thereof.

This invention provides the above method wherein A is substituted orunsubstituted C₁ -C₁₂ alkyl.

This invention provides the above method wherein Y is substituted orunsubstituted C₁ -C₁₂ alkyl.

This invention provides the above method wherein R₇ is substituted orunsubstituted C₁ -C₁₂ alkyl.

In an embodiment R₄ is --C(O)--R₆, wherein R₆ is alkyl or ANR₉ R₁₀,wherein A is alkyl, and R₉ and R₁₀ are each independently hydrogen, orsubstituted or unsubstituted C₁ -C₁₂ alkyl. In another embodiment R₅ is--C(O)--R₆, wherein R₆ is alkyl or ANR₉ R₁₀, wherein A is alkyl, and R₉and R₁₀ are each independently hydrogen, or substituted or unsubstitutedC₁ -C₁₂ alkyl.

In an embodiment R₄ is --Y--C(O)--R₇, wherein Y is substituted orunsubstituted C₁ -C₁₂ alkyl and R₇ is NR₉ R₁₀. In another embodiment R₅is --Y--C(O)--R₇, wherein Y is substituted or unsubstituted C₁ -C₁₂alkyl and R7 is NR₉ R₁₀.

In a specific embodiment of this invention R₃ and NR₄ R₅ are in a cisspatial configuration. In another specific embodiment R₃ and NR₄ R₅ arein a trans spatial configuration. The compound may also be a mixture ofthe cis and trans isomers.

In the method of this invention the compound may be a racemate of the Rand S enantiomers. In a specific preferred embodiment the compound is anR enantiomer.

In a specific embodiment of this invention the compound is selected fromthe group consisting of 1-aminoindan, (R)-1-aminoindan, 1-aminotetralin,1-aminobenzocyclobutane, 6-hydroxy-1-aminoindan,(R)-6-hydroxy-1-aminoindan, 7-hydroxy-1-aminoindan,6-fluoro-1-aminoindan, (R)-6-fluoro-1-aminoindan,5-methoxy-1-aminoindan, 7-methyl-1-aminoindan, 5-methyl-1-aminoindan,4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan,(S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan,6-hydroxy-5-methoxy-1-aminoindan, trans-2-methyl-1-aminoindan,cis-2-methyl-1-aminoindan, 3,5,7-trimethyl-1-aminoindan,N-methyl-1-aminoindan, (R)-N-methyl-1-aminoindan,N,N-dimethyl-1-aminoindan, N-formyl-1-aminoindan,(R)-N-formyl-1-aminoindan, N-acetyl-1-aminoindan,(R)-N-acetyl-1-aminoindan, N-acetyl-7-methyl -1-aminoindan, N-acetyl-6-fluoro -1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan,6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan,(R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-butyryl-1-aminoindan,N-benzyl-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan,N-(2-acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-aminoindan,N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan,N-(4-butanamido)-1-aminoindan, N-(2-acetamido)-1-aminotetralin,N,N-Di-(1-indanyl)amine, N-(2-N-Boc-aminoacetyl)-1-aminoindan,N-(2-Aminoacetyl)-1-aminoindan, N-Benzoyl-1-aminoindan,N-(2-n-Propylpentanoyl)-1-aminoindan, N-acetyl-6-nitro-1-aminiondan,6-amino-N-acetyl-1-aminoindan, 6-acetamido-N-acetyl-1-aminoindan,cis-3-(methoxycarbonyl)-1-N-acetyl-1aminoindan,cis-1-aminoindan-3-carboxylic acid,trans-2-methyl-N-acetyl-1-aminoindan, cis-2-methyl-N-acetyl-1-aminoindan, (R)-N-trifluoroacetyl-1-aminoindan,N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan,N-methyl-N-acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan,N-(2-proprionamido)-1-aminoindan, N-(2-phenylacetyl)-1-aminoindan,N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminoindan,N-(p-4-toluoyl)-1-aminoindan, N,N-di-(2-acetamido)-1-aminoindan,N-(1-indanyl)-aminoacetonitrile, 6-cyano-N-acetyl-1-aminoindan,6-carboxamido-N-acetyl-1-aminoindan,6-ethoxycarbonyl-N-acetyl-1-aminoindan,2-(1-indanamino)-N-isopropylethanesulfonamide,2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,(R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide,N,N'-bis-(R)-(1-indanyl)succinamide, and pharmaceutically acceptableacid addition salts thereof.

This invention provides the above method for treating Parkinson'sdisease in a subject. For treating Parkinson's disease in a subject thecompound is preferably an R enantiomer.

The method of the present invention may involve the administration ofany one of the compounds of formula 1 alone or in combination withconventional L-DOPA treatments. In combination treatments the compoundof formula 1 may be administered before, after, or together with theconventional L-DOPA treatments.

This invention also provides the above method which further comprisesadministering to the subject a therapeutically effective amount ofLevodopa. In a preferred embodiment the therapeutically effective amountof Levodopa is from about 50 mg to about 250 mg.

Another embodiment further comprises administering to the subject atherapeutically effective amount of decarboxylase inhibitor. Thedefinition of a decarboxylase inhibitor, as well as the identity ofspecific decarboxylase inhibitors, is well known in the art to whichthis application pertains.

In a specific embodiment the decarboxylase inhibitor is L-Carbidopa. Inan embodiment the therapeutically effective amount of L-Carbidopa isfrom about 10 mg to about 25 mg.

In a specific embodiment the decarboxylase inhibitor is benserazide. Inan embodiment the therapeutically effective amount of benserazide isfrom about 12.5 mg to about 50 mg.

This invention provides the above method for treating dementia,epilepsy, convulsions, or seizures in a subject. In an embodiment thecompound is an R enantiomer. In another embodiment the compound is an Senantiomer.

In a specific embodiment the compound is selected from the groupconsisting of (S)-1-aminoindan, (S)-6-fluoro-1-aminoindan,(S)6-methoxy-1-aminoindan, (S)-4,5-dimethoxy-1-aminoindan,(S)-N-methyl-1-aminoindan, (R)-N-acetyl-1-aminoindan,(S)-N-acetyl-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan,N-formyl-1-aminoindan, (R)-N-formyl-1-aminoindan,(S)-N-formyl-1-aminoindan, (S)-(1-indanyl)-glycine, and pharmaceuticallyacceptable acid addition salts thereof.

This invention provides the above method for treating Parkinson's-typedementia. This invention also provides the above method for treatingsenile dementia in a subject. This invention also provides the abovemethod for treating Alzheimer's-type dementia in a subject.

This invention provides a method for treating epilepsy, convulsions, orseizures in a subject comprising administering to the subject atherapeutically effective amount of a compound of the formula: ##STR7##or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2;R₁ and R₂ are each independently hydrogen, hydroxy, substituted orunsubstituted C₁ -C₄ alkyl, substituted or unsubstituted C₁ -C₄ alkoxy,halogen, nitro, NH--R₃, C(O)--R₃, or C(O)--NR₉ R₁₀ ; R₃ is hydrogen,substituted or unsubstituted C₁ -C₄ alkyl, hydroxy, substituted orunsubstituted C₁₋₄ alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl;and R₄ and R₅ are each independently hydrogen, substituted orunsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl,substituted or unsubstituted C₇ 14 C₁₂ aralkyl, alkynyl, --C(O)--R₆,--Y--C(O)--R, or Y--(SO₂)NR₉ R₁₀ ; wherein R₆ is hydrogen, hydroxy,substituted or unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstitutedC₆ -C₁₂ aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl, or A--NR₉R₁₀, wherein A is substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, and R₉ and R₁₀ are each independently hydrogen,substituted or unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstitutedC₆ -C₁₂ aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl, or indanyl;Y is substituted or unsubstituted C₁ -C₁₂ alkyl, substituted orunsubstituted C₆ -C₁₂ aryl or substituted or unsubstituted C₇ -C₁₂aralkyl, and R₇ is hydrogen, hydroxy, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₁ -C₁₂ aryl, substituted orunsubstituted C₇ -C₁₂ aralkyl or NR₉ R₁₀, wherein R₉ and R₁₀, are eachindependently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or indanyl.

In a specific embodiment the subject is a human subject.

In an embodiment n is 1. In another embodiment wherein n is 2.

In an embodiment R₁ and R₂ are each independently hydrogen, fluoro,hydroxy, methyl or methoxy. In another embodiment R₃ is hydrogen ormethyl.

This invention provides the above method wherein R₄ is propargyl. Thisinvention also provides the above method wherein R₅ is propargyl.

In an embodiment R₃ and NR₄ R₅ are in a cis spatial configuration. Inanother embodiment R₃ and NR₄ R₅ are in a trans spatial configuration.

In a specific embodiment the compound is an R enantiomer.

In another embodiment the compound is an S enantiomer.

This invention provides the above method for treating epilepsy in asubject.

This invention also provides the above method for treating convulsionsor seizures in a subject.

This invention provides a compound selected from the group consisting of7-methyl-1-aminoindan, 5-methyl-1-aminoindan,(R)-6-hydroxy-1-aminoindan, 3,5,7-trimethyl-1-aminoindan,4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan,(S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan,6-hydroxy-5-methoxy-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan,(R)-N-formyl-1-aminoindan, (S)-N-formyl-1-aminoindan,(R)-N-acetyl-1-aminoindan, N-acetyl-7-methyl-1-aminoindan,N-acetyl-6-fluoro-1-aminoindan, (R)-N-acetyl-6-fluoro-1-aminoindan,(S)-6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan,(R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-(2-acetamido)-1-aminoindan,(R)-N-(2-acetamido)-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan,N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan,N-(2-acetamido)-1-aminotetralin, N-(2-N-Boc-aminoacetyl)-1-aminoindan,N-(2-Aminoacetyl)-1-aminoindan, N-Benzoyl-1-aminoindan,N-(2-n-Propylpentanoyl)-1-aminoindan, N-methyl-N-acetyl-1-aminoindan,(R)-N-methyl-N-acetyl-1-aminoindan, N-(2-propionamido)-1-aminoindan,N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan,N-(4'-fluorobenzoyl)-1-aminoindan, N-(p-4-toluoyl)-1-aminoindan,(S)-(1-indanyl)-glycine, N,N-di-(2-acetamido)-1-aminoindan,N-(1-indanyl)-aminoacetonitrile 6-cyano-N-acetyl-1-aminoindan,6-carboxamido-N-acetyl-1-aminoindan,6-ethoxycarbonyl-N-acetyl-1-aminoindan,2-(1-indanamino)-N-isopropylethanesulfonamide,2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,(R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan,N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide,N,N'-bis(R)-(1-indanyl)succinamide,trans-2-methyl-N-acetyl-1-aminoindan,cis-2-methyl-N-acetyl-1-aminoindan, and salts thereof.

For those above-listed compounds where no indication as to the nature ofthe isomerism is given, this invention provides for the racemic mixture,the R enantiomer, and the S enantiomer.

In an embodiment the salt is a hydrochloride salt, a mesylate salt, anethylsulfonate salt, or a sulfate salt.

This invention also provides a pharmaceutical composition comprising atherapeutically effective amount of the above-listed compounds and apharmaceutically acceptable carrier.

This invention provides for the pharmaceutical composition thepharmaceutically acceptable carrier is a solid and the pharmaceuticalcomposition is a tablet. In an embodiment the therapeutically effectiveamount is from about 1 mg to about 1000 mg. In a more specificembodiment the therapeutically effective amount is from about 10 mg toabout 100 mg.

In another embodiment of the pharmaceutical composition thepharmaceutically acceptable carrier is a liquid and the pharmaceuticalcomposition is an injectable solution.

In a specific embodiment the therapeutically effective amount is fromabout 1 mg/ml to about 1000 mg/ml. In a more specific embodiment thetherapeutically effective amount is from about 10 mg/ml to about 100mg/ml.

In an embodiment of the pharmaceutical composition the carrier is a geland the pharmaceutical composition is a suppository.

This invention further provides for the above pharmaceuticalcomposition, further comprising a therapeutically effective amount ofLevodopa.

This invention also provides for an embodiment of the pharmaceuticalcomposition further comprising a therapeutically effective amount of adecarboxylase inhibitor.

In a specific embodiment the decarboxylase inhibitor is L-Carbidopa. Ina specific embodiment of the pharmaceutical composition the effectiveamount of the compound is from about 1 mg to about 1000 mg, thetherapeutically effective amount of Levodopa is from about 50 mg toabout 250 mg, and the therapeutically effective amount of L-Carbidopa isfrom about 10 mg to about 25 mg.

In an embodiment of the pharmaceutical composition the decarboxylaseinhibitor is benserazide. In a specific embodiment the therapeuticallyeffective amount of the compound is from about 1 mg to about 1000 mg,the therapeutically effective amount of Levodopa is from about 50 mg toabout 200 mg, and the therapeutically effective amount of benserazide isfrom about 12.5 mg to about 50 mg.

The compounds of general formula 1 possess neuroprotective activity.Accordingly, this invention provides a method for treating acuteneurological traumatic disorder or neurotrauma in a subject comprisingadministering to the subject a therapeutically effective amount of acompound of the formula: ##STR8## or a pharmaceutically acceptable saltthereof; wherein n is 0, 1 or 2; R₁ and R₂ are each independentlyhydrogen, hydroxy, substituted or unsubstituted C₁ -C₄ alkyl,substituted or unsubstituted C₁ -C₄ alkoxy, halogen, nitro, amino,NH--R₃ or C(O)--R₃, or C(O)--NR₉ R₁₀ ; R₃ is hydrogen, substituted orunsubstituted C₁ -C₄ alkyl, hydroxy, substituted or unsubstituted C₁ -C₄alkoxy, or substituted or unsubstituted C₆₋₁₂ aryl; and R₄ and R₅ areeach independently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, --C(O)--R₆, --Y--C(O)--R₇, or Y--(SO₂)NR₉ R₁₀ ; whereinR₆ is hydrogen, hydroxy, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or A--NR₉ R₁₀, wherein A is substituted orunsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl,substituted or unsubstituted C₇ -C₁₂ aralkyl, and R₉ and R₁₀, are eachindependently hydrogen, substituted or unsubstituted C₁ -C₁₂ alkyl,substituted or unsubstituted C₆ -C₁₂ aryl, substituted or unsubstitutedC₇ -C₁₂ aralkyl, or indanyl; Y is substituted or unsubstituted C₁ -C₁₂alkyl, substituted or unsubstituted C₆ -C₁₂ aryl or substituted orunsubstituted C₇ -C₁₂ aralkyl, and R₇ is hydrogen, hydroxy, substitutedor unsubstituted C₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂aryl, substituted or unsubstituted C₇ -C₁₂ aralkyl or NR₉ R₁₀, whereinR₉ and R₁₀ are each independently hydrogen, substituted or unsubstitutedC₁ -C₁₂ alkyl, substituted or unsubstituted C₆ -C₁₂ aryl, substituted orunsubstituted C₇ -C₁₂ aralkyl, or indanyl.

The subject is any animal, preferably a mammal. In an embodiment, thesubject is a human subject. In another embodiment, the subject is amouse or a rat.

The administering can be performed according to techniques well known tothose of skill in the art. In embodiments of this invention theadministering comprises administering orally, rectally, transdermally,or parenterally.

In an embodiment the therapeutically effective amount is from about 1 mgto about 1000 mg, preferably from about 10 mg to about 100 mg.

Pharmaceutically acceptable salts and their preparation are well knownto those of skill in the art. Examples of pharmaceutically acceptablesalts are a hydrochloride salt, a mesylate salt, an esylate salt, or asulfate salt.

In an embodiment of this invention n is 1. In another embodiment n is 2.

This invention provides the above method wherein R₁ and R₂ are eachindependently hydrogen, fluoro, hydroxy, methyl or methoxy. In aspecific embodiment R₁ is 4-fluoro, 6-fluoro, 4-hydroxy, 6-hydroxy,4-methyl, 6-methyl, 4-methoxy, or 6-methoxy. In another embodiment R₂ is4-fluoro, 6-fluoro, 4-hydroxy, 6-hydroxy, 4-methyl, 6-methyl, 4-methoxy,or 6-methoxy.

In an embodiment of this invention R₃ is hydrogen or methyl.

In an embodiment of this invention R₄ and R₅ are each independentlyhydrogen, or substituted or unsubstituted C₁ -C₁₂ alkyl.

In an embodiment of this invention R₄ is C₁ -C₁₂ alkyl substituted witha lipophilic group, C₆ -C₁₂ aryl substituted with a lipophilic group, orC₇ -C₁₂ aralkyl substituted with a lipophilic group. In preferredembodiments the lipophilic group is selected from the group consistingof piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl,quinuclindyl, and substituted derivatives thereof.

In another embodiment of this invention R₅ is C₁ -C₁₂ alkyl substitutedwith a lipophilic group, C₆ -C₁₂ aryl substituted with a lipophilicgroup, or C₇ -C₁₂ aralkyl substituted with a lipophilic group. In apreferred embodiments the lipophilic group is selected from the groupconsisting of piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl,adamantyl, quinuclindyl, and substituted derivatives thereof.

This invention provides the above method wherein A is substituted orunsubstituted C₁ -C₁₂ alkyl.

This invention provides the above method wherein Y is substituted orunsubstituted C₁ -C₁₂ alkyl.

This invention provides the above method wherein R₇ is substituted orunsubstituted C₁ -C₁₂ alkyl.

In an embodiment R₄ is --C(O)--R₆, wherein R₆ is alkyl or ANR₉ R₁₀,wherein A is alkyl, and R₉ and R₁₀ are each independently hydrogen, orsubstituted or unsubstituted C₁ -C₁₂ alkyl. In another embodiment R₅ is--C(O)--R₆, wherein R₆ is alkyl or ANR₉ R₁₀, wherein A is alkyl, and R₉and R₁₀ are each independently hydrogen, or substituted or unsubstitutedC₁ -C₁₂ alkyl.

In an embodiment R₄ is --Y--C(O)--R₇, wherein Y is substituted orunsubstituted C₁ -C₁₂ alkyl and R₇ is NR₉ R₁₀.

In another embodiment R₅ is --Y--C(O)--R₇, wherein Y is substituted orunsubstituted C₁ -C₁₂ alkyl and R₇ is NR₉ R₁₀.

In a specific embodiment of this invention R₃ and NR₄ R₅ are in a cisspatial configuration. In another specific embodiment R₃ and NR₄ R₅ arein a trans spatial configuration. The compound may also be a mixture ofthe cis and trans isomers.

In a specific embodiment the compound is an R enantiomer. In anotherembodiment the compound is an S enantiomer.

In an embodiment of the above method the compound is selected from thegroup consisting of 1-aminoindan, (R)-1-aminoindan, (S)-1-aminoindan,1-aminotetralin, 1-aminobenzocyclobutane, 6-hydroxy-1-aminoindan,(R)-6-hydroxy-1-aminoindan, 6-fluoro-1-aminoindan,(R)-6-fluoro-1-aminoindan, (S)-6-fluoro-1-aminoindan,5-methoxy-1-aminoindan, (S)-6-methoxy-1-aminoindan,7-methyl-1-aminoindan, 5-methyl-1-aminoindan,4,5-dimethoxy-1-aminoindan, (R)-4,5-dimethoxy-1-aminoindan,(S)-4,5-dimethoxy-1-aminoindan, 4-hydroxy-5-methoxy-1-aminoindan,6-hydroxy-5-methoxy-1-aminoindan, trans-2-methyl-1-aminoindan,cis-2-methyl-1-aminoindan, 3,5,7-trimethyl-1-aminoindan,N-methyl-1-aminoindan, (R)-N-methyl-1-aminoindan,(S)-N-methyl-1-aminoindan, N,N-dimethyl-1-aminoindan,N-formyl-1-aminoindan, (R)-N-formyl-1-aminoindan,(S)-N-formyl-1-aminoindan, N-acetyl-1-aminoindan,(R)-N-acetyl-1-aminoindan, (S)-N-acetyl-1-aminoindan,N-acetyl-7-methyl-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan,(R)-N-acetyl-6-fluoro-1-aminoindan, 6-Methoxy-1-aminoindan,(S)-6-Methoxy-1-aminoindan, N-acetyl-6-methoxy-1-aminoindan,(R)-N-acetyl-4,5-dimethoxy-1-aminoindan, N-butyryl-1-aminoindan,N-benzyl-1-aminoindan, N-(4-aminobutanoyl)-1-aminoindan,N-(2-acetamido)-1-aminoindan, (R)-N-(2-acetamido)-1-aminoindan,N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan,N-(4-butanamido)-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan,N-(2-acetamido)-1-aminotetralin, N,N-Di-(1-indanyl)amine,N-(2-N-Boc-aminoacetyl)-1-aminoindan, N-(2-Aminoacetyl)-1-aminoindan,N-Benzoyl-1-aminoindan, N-(2-n-Propylpentanoyl)-1-aminoindan,N-acetyl-6-nitro-1-aminiondan, 6-amino-N-acetyl-1-aminoindan,6-acetamido-N-acetyl-1-aminoindan, cis-3-(methoxycarbonyl)-1-aminoindan,cis-1-aminoindan-3-carboxylic acid,trans-2-methyl-N-acetyl-1-aminoindan,cis-2-methyl-N-acetyl-1-aminoindan, (R)-N-trifluoroacetyl-1-aminoindan,N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan,N-methyl-N-acetyl-1-aminoindan, (R)-N-methyl-N-acetyl-1-aminoindan,N-(2-proprionamido)-1-aminoindan, N-(2-phenylacetyl)-1-aminoindan,N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminoindan,N-(p-4-toluoyl)-1-aminoindan, (S)-(1-indanyl)-glycine,N,N-di-(2-acetamido)-1-aminoindan, N-(1-indanyl)-aminoacetonitrile,6-cyano-N-acetyl-1-aminoindan, 6-carboxamido-N-acetyl-1-aminoindan,6-ethoxycarbonyl-N-acetyl-1-aminoindan,2-(1-indanamino)-N-isopropylethanesulfonamide,2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,(R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide,N,N'-bis-(1-indanyl)adipamide, N,N'-bis-(R)-(1-indanyl)adipamide,N,N'-bis-(R)-(1-indanyl)succinamide, and pharmaceutically acceptableacid addition salts thereof.

This invention provides the above method for treating acute neurologicaltraumatic disorder in a subject.

This invention provides the above method for treating neurotrauma in asubject. In a still more specific embodiment the neurotrauma is causedby a closed head injury.

The subject invention further provides a method of treating a subjectafflicted with a memory disorder which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat the memory disorder in the subject.

The subject invention further provides a method of treating a subjectafflicted with dementia which comprises administering to the subject anamount of a compound of general formula 1 or the pharmaceuticallyacceptable salt thereof of the subject invention effective to treatdementia in the subject. In one embodiment, the dementia is of theAlzheimer type (DAT).

The subject invention further provides a method of treating a subjectafflicted with depression which comprises administering to the subjectan amount of a compound of general formula 1 or the pharmaceuticallyacceptable salt thereof of the subject invention effective to treatdepression in the subject.

The subject invention further provides a method of treating a subjectafflicted with hyperactive syndrome which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat hyperactive syndrome in the subject.

The administering may comprise orally administering, rectallyadministering, or parenterally administering.

The subject invention further provides a method of treating a subjectafflicted with an affective illness which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat the affective illness in the subject.

The subject invention further provides a method of treating a subjectafflicted with a neurodegenerative disease which comprises administeringto the subject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat the neurodegenerative disease in the subject.

The subject invention further provides a method of treating a subjectafflicted with a neurotoxic injury which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat the neurotoxic injury in the subject.

The subject invention further provides a method of treating a subjectafflicted with brain ischemia which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat brain ischemia in the subject.

The subject invention further provides a method of treating a subjectafflicted with a head trauma injury which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat the head trauma injury in the subject.

The subject invention further provides a method of treating a subjectafflicted with a spinal trauma injury which comprises administering tothe subject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat the spinal trauma injury in the subject.

The subject invention further provides a method of treating a subjectafflicted with schizophrenia which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat schizophrenia in the subject.

The subject invention further provides a method of treating a subjectafflicted with an attention deficit disorder which comprisesadministering to the subject an amount of a compound of general formula1 or the pharmaceutically acceptable salt thereof of the subjectinvention effective to treat the attention deficit disorder in thesubject.

The subject invention further provides a method of treating a subjectafflicted with multiple sclerosis which comprises administering to thesubject an amount of a compound of general formula 1 or thepharmaceutically acceptable salt thereof of the subject inventioneffective to treat multiple sclerosis in the subject.

The subject invention further provides a method of preventing nervedamage in a subject which comprises administering to the subject anamount of general formula 1 or the pharmaceutically acceptable saltthereof of the subject invention effective to prevent nerve damage inthe subject.

In one embodiment, the nerve damage is structural nerve damage. Inanother embodiment, the structural nerve damage is optic nerve damage.

The subject invention further provides a method of treating a subjectsuffering from symptoms of withdrawal from an addictive substance whichcomprises administering to the subject an amount of a compound ofgeneral formula 1 or the pharmaceutically acceptable salt thereof of thesubject invention effective to treat the symptoms of wi thdrawal in thesubject.

As used herein, the term "symptoms of withdrawal" refers to physicaland/or psychological symptoms, including drug craving, depression,irritability, anergia, amotivation, appetite change, nausea, shaking andsleep irregularity.

As used herein, the term "addictive substance" includes, by way ofexample, (a) addictive opiates such as opium, heroin and morphine, (b)psychostimulants such as cocaine, amphetamines and methamphetamines, (c)alcohol, (d) nicotine, (e) barbiturates and (f) narcotics such asfentanyl, codeine, diphenoxylate and thebaine.

In one embodiment, the addictive substance is cocaine. In anotherembodiment, the addictive substance is alcohol.

This invention provides a method for preparing an optically activeenantiomer of a compound of the formula: ##STR9## wherein the enantiomeris optically active at the C₁ position; n is 0, 1 or 2; R₁ and R₂ areeach independently hydrogen, hydroxy, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₁ -C₄ alkoxy, or halogen; andR₃ is hydrogen or unsubstituted C₁ -C₄ alkyl; comprising incubating in areaction mixture a racemic N-benzyl analog of the compound with anoptically active enantiomer of mandelic acid; converting the opticallyactive ammonium salt obtained to its corresponding optically activebase; and reducing the base to the optically active enantiomer of thecompound.

It is preferred that the racemic N-benzyl analog is reacted with theoptically active enantiomer of mandelic acid in a solvent. Suitablesolvents include ethanol; ethanol and acetone; and ethanol andacetylacetate, as well as other solvents that can be identified by oneof ordinary skill in the art. Most preferably, the solvent is ethanol.

In a preferred embodiment, the optically active salt is isolated priorto its conversion to its corresponding optically active base.

In an embodiment, the reaction mixture of the mandelic acid and theracemic N-benzyl analog is heated prior to the isolation of the saltuntil complete dissolution of the reactants is observed, and thencooled. Preferably, the reaction mixture is heated to a temperature fromabout 68° C. to about 78° C., preferably about 75° C., and then cooledover a period of several hours to a temperature from about 5° C. toabout 20° C., preferably about 10° C.

It is also preferable that the isolated optically active salt isrecrystallized prior to its conversion to its corresponding base.

Preferably, the optically active salt is converted to its correspondingbase by the addition of a basic reagent. In a more specific embodiment,the basic reagent is an organic or inorganic base. Suitable basesinclude sodium hydroxide, sodium carbonate, potassium hydroxide,potassium carbonate and triethylamine, as well as other suitable basesthat can be identified by one of skill in the art. Preferably the baseis sodium hydroxide.

Preferably, the optically active salt is suspended in a mixture of waterand a water immiscible solvent, such as toluene, prior to the additionof the basic reagent. Preferably, the toluene:water ratio is about75:70.

Preferably, the optically active base is isolated prior to its reductionto the optically active enantiomer of the compound. Any known system forperforming reduction may be used. In an embodiment, the optically activebase is reduced by reaction with hydrogen gas in the presence of apalladium/carbon catalyst, preferably under increased pressure.

It is preferred that n is 1, and R₁, R₂ and R₃ are hydrogen. In such aninstant the optically active salt is R(+) or S(-)-N-benzyl-1-aminoindan-mandelate ethanolate and the optically active base is R-(+) orS-(-)-N-benzyl-1-aminoindan.

In one embodiment, the optically active enantiomer of mandelic acid isL-(+)-mandelic acid, the optically active salt isR-(+)-N-benzyl-1-aminoindan-mandelate ethanolate, and the opticallyactive base is R-(+)-N-benzyl-1-aminoindan.

In another embodiment, the optically active enantiomer of mandelic acidis D-(-)mandelic acid, the optically active salt isS-(-)-N-benzyl-1-aminoindan-mandelate ethanolate, and the opticallyactive base is S-(-)-N-benzyl-1-aminoindan.

This invention provides method for preparing an optically activemandalate salt of a compound of the formula: ##STR10## wherein the saltis optically active at the C₁ position; n is 0, 1, or 2; R₁, R₂, and R₃are each independently hydrogen, hydroxy, substituted or unsubstitutedC₁ -C₄ alkyl, substituted or unsubstituted C₁ -C₄ alkoxy, or halogen;and R₃ is hydrogen, or unsubstituted C₁ -C₄ alkyl; comprising reacting aracemic mixture of the compound with an optically active enantiomer ofmandelic acid, and recovering the optically active mandelate salt. In anembodiment, n is 1; and R₁, R₂ and R₃ are hydrogen.

This invention further provides a method for preparing an opticallyactive free base of the formula: ##STR11## comprising converting theoptically active mandalate salt from the above-described method to itscorresponding optically active base. This invention also providesR-(+)-N benzyl-1-aminoindan and S-(-)-N-benzyl-1-aminoindan, whenprepared in accordance with this method.

This invention provides R-(+)-N-benzyl-1-aminoindan,R-(+)-N-benzyl-1-aminoindan-L-mandelate ethanolate, andS-(-)-N-benzyl-1-aminoindan-D-mandelate ethanolate.

This invention provides a method for preparing racemicN-benzyl-1-aminoindan comprising reacting 1-chloroindane withbenzylamine in an inert solvent. Preferably, the 1-chloroindane andbenzylamine are combined at a temperature of about 90° C. It is alsopreferable that the temperature is raised to about 115° C. for a periodof about ten hours following the combining of the 1-chlorindane with thebenzylamine. This invention provides N-benzyl-1-aminoindan when preparedin accordance with the above-described method.

This invention will be better understood from the Experimental Detailswhich follow. However, one skilled in the art will readily appreciatethat the specific methods and results discussed are merely illustrativeof the invention as described more fully in the claims which followthereafter.

EXPERIMENTAL DETAILS

A. SYNTHESIS OF COMPOUNDS

Preparation of 1-Aminoindans:

The R-1-aminoindan starting material can be prepared by methods known inthe art which include, by way of example, the method of Lawson and Rao,Biochemistry, 19, 2133 (1980), methods in references cited therein, andthe method of European Patent No. 235,590.

R-1-aminoindan can also be prepared by resolution of a racemic mixtureof the R and S enantiomers, which involves, for example, the formationof diastereomeric salts with chiral acids, or any other known methodsuch as those reported in J. Jacques, et al., ibid. Alternatively,R-1-aminoindan may be prepared by reacting 1-indanone with an opticallyactive amine, followed by reduction of the carbon nitrogen double bondof the resulting imine by hydrogenation over a suitable catalyst, suchas palladium on carbon, platinum oxide or Raney nickel. Suitableoptically active amines include, for example, one of the antipodes ofphenethylamine or an ester of an amino acid, such as valine orphenylalanine. The benzylic N--C bond may be cleaved subsequently byhydrogenation under non-vigorous conditions.

An additional method for preparing R-1-aminoindan is the hydrogenationof indan-1-one oxime ethers as described above, wherein the alkylportion of the ether contains an optically pure chiral center.Alternatively, a non-chiral derivative of indan-1-one containing acarbon-nitrogen double bond, such as an imine or oxime, can be reducedwith a chiral reducing agent, e.g., a complex of lithiumaluminum-hydride and ephedrine.

Resolution of Enantiomers:

The R- and S- enantiomers of each compound may be obtained by opticalresolution of the corresponding racemic mixtures. Such a resolution canbe accomplished by any conventional resolution method well known to aperson skilled in the art, such as those described in U.S. Pat. No.4,833,273, issued May 23, 1989 (Goel) and in J. Jacques, A. Collet andS. Wilen, "Enantiomers, Racemates and Resolutions," Wiley, New York(1981). For example, the resolution may be carried out by preparativechromatography on a chiral column. Another example of a suitableresolution method is the formation of diastereomeric salts with a chiralacid such as tartaric, malic, mandelic acid or N-acetyl derivatives ofamino acids, such as N-acetyl leucine, followed by recrystallization toisolate the diastereomeric salt of the desired R enantiomer.

The racemic mixture of R and S enantiomers of N-propargyl-1-aminoindan(PAI) may be prepared, for example, as described in GB 1,003,676 and GB1,037,014. The racemic mixture of PAI can also be prepared by reacting1-chloroindan with propargylamine. Alternatively, this racemate may beprepared by reacting propargylamine with 1-indanone to form thecorresponding imine, followed by reduction of the carbon-nitrogen doublebond of the imine with a suitable agent, such as sodium borohydride.

The 1-aminoindans of general formula 1 where R₁ and R₂ are as indicatedand R₄ and R₅ are hydrogen may be prepared by the chemical reduction ofthe relevant oximes, by means of zinc/acetic acid or by catalytichydrogenation. The oximes may be prepared by reaction of thecorresponding indan-1-ones with hydroxylamine hydrochloride. Theindan-1-ones may be prepared by Friedal-Crafts cyclization ofsubstituted dihydrocinnamic acids or the corresponding chlorides usingaluminum trichloride or other Lewis acids, such as polyphosphoric acidor methanesulphonic acid as condensing agents, for example according toprocedures described in J. Org. Chem. 46, 2974 (1981) and in J. Chem.Soc. Perkin Trans, 1, 151 (1972).

N-methyl-1-aminoindan may be prepared from 1-aminoindan according to theprocedure described in J.Med.Chem.9, 830 (1966).

N,N-dimethyl-1-aminoindan may be prepared from 1-aminoindan according tothe procedure described in Yakugaku Zasshi, 82 1597 (1962)--Chem. Abs.59 611f. N-formyl and N-acyl derivatives of 1-aminoindan and1-aminotetralin may be prepared from the corresponding 1-aminoindan or1-aminotetralin using the methods described in J.Med.Chem. 9, 830(1966), J.chromatog. 502, 154 (1990) or Boll.Chim.Farm. 115, 489 (1976).

The compounds of general formula 1, where R₄ is hydrogen or lower alkyland R₅ is C(O)--R₆, and R₆ is A--NR₉ R₁₀ are indanylamides of aminoacids, and may be prepared by procedures known to those skilled in theart, for example, by reacting the aminoindan with an activated form ofthe amino acid in the presence or absence (as necessary) of acylationcatalysts such as 4-N,N-dimethylaminopyridine.

Thus the aminoindan is reacted with an amino acid anhydride having theamino terminus protected by a suitable radical such as t-butoxycarbonyl(Boc), in the presence of for example DMAP, in an aprotic organicsolvent such as THF, at a temperature within the range of 0°-50° C.,preferably from 25°-40° C., for a period of from 1-24 hours, preferablyfrom 5-10 hours.

Alternatively, the 1-aminoindan may be reacted with an N-hydroxysuccinimide ester of an amino acid having the terminal amino groupprotected as above, in an aprotic solvent such as 1,2-dimethoxyethane(DME), at a temperature within the range of 0°-70° C., preferably from25°-50° C., for a period of from 12-48 hours, preferably from 24-36hours.

The product may be purified by column chromatography and/or bycrystallization. Removal of the protecting group may be accomplished bysubjecting said group to acidic conditions for example to hydrochloricacid or trifluoroacetic acid in a suitable organic solvent such asisopropanol or dioxane. The desired products are then obtained as theiracid addition salts.

The compounds of general formula 1 wherein R₁ or R₂ are hydrogen orlower alkyl, R₄ is hydrogen and R₅ is Y--C(O)--R₇ and R₇ is NR9R10, areN-indanyl derivatives of amino acid amides, and may be prepared byreacting the relevant amino acid amide with a 1-halogeno-indan or with a1-indanone. In the latter case, the resulting Schiff base is furtherreduced, by a suitable reducing agent such as sodium borohydride, toafford the desired amine. Alternatively these compounds may be preparedby reacting the 1-aminoindan with an omega-halogeno derivative of therelevant amino acid amide, in an alcoholic solvent such as ethanol inthe presence of a base such as potassium carbonate, at a temperaturewithin the range of 50°-100° C., preferably at the reflux temperature ofthe solvent, for a period of from 12-36 hours, preferably 24 hours. Theproduct may then be converted into its acid addition salt. The R and Senantiomers of each of these compounds may be resolved using proceduresknown to those skilled in the art.

The following list provides an Example number, a European PatentApplication number or a Chemical Abstracts Registry Number for some ofthe compounds of general formula 1 that are of interest in the presentinvention. A Chem. Abs. number with an asterisk indicates the number ofa closely related compound.

1-aminoindan, EP 436492 34698-41-4*

(R)-1-aminoindan, 10305-73-4

(S)-1-aminoindan, 32457-23-1

1-aminotetralin, 49800-23-9

1-aminobenzocyclobutene, EXAMPLE 27

6-hydroxy-1-aminoindan, EXAMPLE 34

(R)-6-hydroxy-1-aminoindan, EXAMPLE 35

7-hydroxy-1-aminoindan, EXAMPLE 42 EP 173 331

6-fluoro-1-aminoindan, EP 538 134

(R)-6-fluoro-1-aminoindan, EP 538 134

(S)-6-fluoro-1-aminoindan, EP 538 134

5-methyl-1-aminoindan, EXAMPLE 38

5-methoxy-1-aminoindan, EXAMPLE 36 41566-77-6

6-methoxy-1-aminoindan, EXAMPLE 25 103028-80-4

(S)-6-methoxy-1-aminoindan, EXAMPLE 24

7-methyl-1-aminoindan, EXAMPLE 28

3,5,7-trimethyl-1-aminoindan, EXAMPLE 41

4,5-dimethoxy-1-aminoindan, EXAMPLE 31

(R)-4,5-dimethoxy-1-aminoindan, EXAMPLE 29

(S)-4,5-dimethoxy-1-aminoindan, EXAMPLE 30

4-hydroxy-5-methoxy-1-aminoindan, EXAMPLE 33

6-hydroxy-5-methoxy-1-aminoindan, EXAMPLE 32

trans-2-methyl-1-aminoindan EXAMPLE 39 13943-76-6*

cis-2-methyl-1-aminoindan, EXAMPLE 40 13943-41-4*

N-methyl-1-aminoindan, EXAMPLE 12 90874-50-3

(R)-N-methyl-1-aminoindan, EXAMPLE 13 10277-78-7*

(S)-N-methyl-1-aminoindan, EXAMPLE 14 68533-22-2

N,N-dimethyl-1-aminoindan, EXAMPLE 15 10277-80-2*

N-formyl-1-aminoindan, EXAMPLE 8 10277-75-5

(R)-N-formyl-1-aminoindan, EXAMPLE 9

(S)-N-formyl-1-aminoindan, EXAMPLE 10

N-acetyl-1-aminoindan, EXAMPLE 17 127761-17-5

(R)-N-acetyl-1-aminoindan, EXAMPLE 18 71744-38-2*

(S)-N-acetyl-1-aminoindan, EXAMPLE 19 61899-41-0

N-acetyl-7-methyl-1-aminoindan, EXAMPLE 20

N-acetyl-6-methoxy-1-aminoindan, EXAMPLE 26

N-acetyl-6-fluoro-1-aminoindan, EXAMPLE 22

(R)-N-acetyl-6-fluoro-1-aminoindan, EXAMPLE 23

(R)-N-acetyl-4,5-dimethoxy-1-aminoindan, EXAMPLE 21

N-butyryl-1-aminoindan, EXAMPLE 11 144602-65-3

N-benzyl-1-aminoindan, EXAMPLE 16 66399-68-6*

N-benzoyl-1-aminoindan, EXAMPLE 46

N-(4-aminobutyryl)-1-aminoindan, EXAMPLE 7

N-(2-acetamido)-1-aminoindan, EXAMPLE 3

(R)-N-(2-acetamido)-1-aminoindan, EXAMPLE 1

(S)-N-(2)acetamido)-1-aminoindan, EXAMPLE 2

N-(2-acetamido)-6-fluoro-1-aminoindan, EXAMPLE 5

N-(2-acetamido)-1-aminotetralin, EXAMPLE 4

N-(2-aminoacetyl)-1-aminoindan, EXAMPLE 45

N-(3-cyanopropyl)-1-aminoindan, EXAMPLE 37

N,N-di-(1-indanyl)amine EXAMPLE 43 113535-01-6*

N-(2-n-Propylpentanoyl)-1-aminoindan EXAMPLE 47

N-methyl-N-acetyl-1-aminoindan, EXAMPLE 48

(R)-N-methyl-N-acetyl-1-aminoindan, EXAMPLE 49

N-(2-propionamido)-1-aminoindan, EXAMPLE 50

N-(2-phenylacetyl)-1-aminoindan, EXAMPLE 51 EP488, 616

N-(m-anisoyl)-1-aminoindan, EXAMPLE 52

N-(4'-fluorobenzoyl)-1-aminoindan, EXAMPLE 53

N-(p-4-toluoyl)-1-aminoindan, EXAMPLE 54

(S)-(1-indanyl)-glycine, EXAMPLE 55

N,N-di-(2-acetamido)-1-aminoindan, EXAMPLE 56

N-(1-indanyl)-aminoacetonitrile EXAMPLE 57

N-acetyl-6-nitro-1-aminoindan, EXAMPLE 58

6-amino-N-acetyl-1-aminoindan, EXAMPLE 59

6-acetamido-N-acetyl-1-aminoindan, EXAMPLE 60

6-cyano-N-acetyl-1-aminoindan, EXAMPLE 61

6-carboxamido-N-acetyl-1-aminoindan, EXAMPLE 62

6-ethoxycarbonyl-N-acetyl-1-aminoindan, EXAMPLE 63

cis-3-(methoxycarbonyl)-1-aminoindan, EXAMPLE 64

cis-1-aminoindan-3-carboxylic acid, EXAMPLE 65

trans-2-methyl-N-acetyl-1-aminoindan, EXAMPLE 66

cis-2-methyl-N-acetyl-1-aminoindan, EXAMPLE 67

(R)-N-trifluoroacetyl-1-aminoindan, EXAMPLE 68

N-(4-(di-n-propylsulfamoyl)benzoyl)-1-aminoindan, EXAMPLE 69

2-(1-indanamino)-N-isopropylethanesulfonamide, EXAMPLE 70

2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, EXAMPLE 71

(R,R)-2-(1-indanamino)-N-(1-indanyl)ethanesulfonamide, EXAMPLE 72

N,N'-bis-(1-indanyl)adipamide, EXAMPLE 73

N,N'-bis-(R)-(1-indanyl)adipamide, EXAMPLE 74

N,N'-bis-(R)-(1-indanyl)succinamide, EXAMPLE 75

The following examples provide additional data relating to specificcompounds of this invention.

EXAMPLE 1 (R)-N-(2-Acetamido)-1-aminoindan.HCl

A mixture of(R)-1-aminoindan (5.5 g, 40.7 mmole), 2-chloro-acetamide(3.7 g, 39.6 mmole), sodium bicarbonate (3.7 g, 44 mmole) and absoluteethanol (80 ml) was stirred under reflux for 24 hr. The reaction mixturewas then filtered hot, the filtrate ice-cooled for 1 hr, and filtered.The solid was collected and washed with ether. The crude product wasdissolved in isopropanol (135 ml), and 25% w/v isopropanolic HCl (6.5ml, 44 mmole) was added; the mixture was stirred for 3 hr under icecooling and filtered. The solid was washed with ether/hexane (5:1, 50ml) and dried to afford 3.4 g (37%), m.p.: 224°-5° C.

¹ H NMR δ (DMSO): 9.60 (br s, 2H, NH₂ ⁺), 8.04, 7.58 (s, 2H, CONH₂),7.70 (d, 1H, Ph), 7.34 (m, 3H, Ph), 4.80 (br s, 1H, C1-H), 3.62 (m, 1H,CH₂), 3.14 (m, 1H, C3-H), 2.84 (m, 1H, C3-H'), 2.38 (m, 1H, C2-H), 2.23(m, 1H, C2-H') ppm. MS: 191 (MH⁺, 58), 117 (100). IR (KBr): 3391, 3252,3193, 2947, 2807, 1692, 1616, 1559, 1443, 1381, 1339 cm⁻¹.

EXAMPLE 2 (S)-N-(2-Acetamido)-1-aminoindan.HCl

The title compound was obtained from (S)-1-aminoindan in a manneranalogous to that described in Ex. 1, m.p.: 222°-3°. The NMR, MS and IRspectral data are identical to those given in Example 1.

Anal. calc. for C₁₁ H₁₅ ClN₂ O:C,58.29; H,6.66; N,12.35. Found: C,58.51;H,6.71; N,12.31.

EXAMPLE 3 (rac)-N-(2-Acetamido)-1-aminoindan.HCl

The title compound was prepared from (rac)-1-aminoindan in a manneranalogous to that described in Example 1, m.p.: 201°-2° C. The free basemelted at 131°-3° C.

Found: C,58.58; H,6.77; N,12.35. The NMR, MS and IR spectral data areidentical to those given in Example 1.

EXAMPLE 4 (rac)-N-(2-Acetamido)-1-aminotetralin

The title compound was prepared in 25% yield from 1-aminotetralin and2-chloroacetamide according to the procedure described in Example 1. Thebase was purified by filtration through silica with acetone as eluent,to give a white solid, m.p.: 139°-41° C.

Anal. calcd. for C₁₂ H₁₆ N₂ O:C,70.59; H,7.84; N,13.72. Found: C,70.58;H,7.83; N,13.80. ¹ H NMR δ (CDCl₃): 7.36 (m, 1H, Ph), 7.20 (m, 3H, Ph,CONH₂), 7.10 (m, 1H, Ph), 5.52 (br s, 1H, CONH₂), 3.78 (br t, 1H, C1-H),3.39 (s, 2H, CH₂), 2.78 (m, 2H, C4-H), 1.96-1.70 (m, 4H, C2-H, C3-H)ppm. MS: 205 (MH⁺, 100), 146 (10), 131 (13), 93 (47) IR (KBr): 3382,3183, 2936, 1632, 1487, 1445, 1395, 1333 cm⁻¹.

EXAMPLE 5 (rac)-6-Fluoro-N-(2-acetamido)-1-aminoindan.HCl

A mixture of 6-fluoro-1-aminoindan (10.6 g, 70.2 mmole),2-chloroacetamide (6.4 g, 68 mmole), sodium bicarbonate (6.4 g, 76mmole) and absolute ethanol (130 ml) was refluxed for 22 hr. Thereaction mixture was then filtered, ice-cooled and gaseous HCl wasbubbled through for 40 min. The solid was collected, washed withether/hexane and dried. Crystallization from 2:1 MeOH:EtOH afforded thetitle compound (3.4 g, 21%). M.p. of the free base: 100°-102° C.

Anal. calcd. for C₁₁ H₁₄ ClFN₂ O: C,53.99; H,5.77; N,11.45; F,7.77.Found: C,53.91; H,5.63; N,11.24; F,8.12. ¹ H NMR δ (D₂ O): 7.38 (m, 1H,Ph), 7.28 (m, 1H, Ph), 7.15 (m, 1H, Ph), 4.91 (m, 1H, C1-H), 3.92 (m,2H, CH₂), 3.08 (m, 1H, C3-H), 2.96 (m, 1H, C3-H'), 2.63 (m, 1H, C2-H),2.28 (m, 1H, C2-H') ppm. MS: 209 (MH⁺,100), 150 (10), 135 (6). IR (KBr):3360, 3190, 3020, 2910, 2410, 1690, 1600, 1500, 1405 cm⁻¹.

EXAMPLE 6 (rac)-N-(N-Boc-4-aminobutyryl)-1-aminoindan

A solution of Boc-GABA anhydride (4.46 g, 11.5 mmole, prepared from BocGABA and DCC in CH₂ Cl₂) in dry THF (15 ml) was added to a solution of1-aminoindan (1.5 g, 11.2 mmole) in dry THF (15 ml), and DMAP (1.5 g,12.3 mmole) was then added in one portion. The reaction mixture wasstirred at RT for 6 hr, filtered and the filtrate was evaporated todryness. The residue was dissolved in CH₂ Cl₂ (25 ml), the solution wasthen washed with 10% NaHCO₃ (25 ml) and H₂ O (15 ml), dried over MgSO₄and evaporated to dryness. The residue was treated with hexane/ether(1:1, 100 ml), and the resultant crude product was filtered, dried andpurified by filtering-column chromatography (Silica, 1:1 hexane/EtOAc aseluent), and crystallized from hexane:EtOAc, to give 2.5 g (7.84 mmole,71%) of a white crystalline solid, m.p.: 118°-20° C.

¹ H NMR δ (DMSO): 8.15 (d, 1H, NHCO), 7.20 (m, 4H, Ph), 6.80 (br t, 1H,NHCOO), 5.26 (q, 1H, C1-H), 2.92 (m, 3H, CH₂ NHBoc, C3-H), 2.78 (m, 1H,C3-H'), 2.36 (m, 1H, C2-H), 2.11 (m, 2H, CH₂ CONH), 1.76 (m, 1H, C2-H'),1.64 (m, 2H, CH₂ CH₂,CH₂ NHBoc), 1.38 (s, 9H, Boc) ppm. MS: 319 (MH⁺,100), 263 (MH⁺ -CH₂ ═CMe₂, 68), 219 (263-CO₂, 30).

EXAMPLE 7 (rac)-N-(4-Aminobutyryl)-1-aminoindan.HCl

Also called N-(4-aminobutanoyl)-1-aminoindan.HCl.N-(N-Boc-4-aminobutyryl)-1-aminoindan (2.50 g, 7.8 mmole) was dissolvedin dry dioxane (20 ml), and 1.7N HCl in dioxane (20 ml) was added. Thesolution was stirred at ambient temperature for 4 hr, evaporated todryness, and the residue taken up in CH₂ Cl₂ :H₂ O mixture (1:1, 160ml). The aqueous phase was separated, filtered through millipore andevaporated to dryness in vacuo. The crude product was crystallized from40:60 EtOAc:ethanol to give 1.55 g (78%) white crystalline solid, m.p.:168° C.

Anal. calcd. for C₁₃ H₁₉ ClN₂ O: C,61.28; H,7.51; N,10.99; Found:C,61.37; H,7.66; N,11.11. ¹ H NMR δ (DMSO): 8.37 (d, 1H, NHCO), 8.00 (brs, 3H, NH₃ ⁺), 7.20 (m, 4H, Ph), 5.28 (q, 1H, C1-H), 2.92 (m, 1H, C₃-H), 2.80 (m, 3H, C3-H', CH₂ NH₃ +), 2.37 (m, 1H, C2-H), 2.26 (t, 2H,CH₂ CONH), 1.85 (m, 2H, CH₂ CH₂ CONH), 1.77 (m, 1H, C2-H') ppm. MS: 219(MH⁺, 100), 202 (14), 117 (31) IR (KBr): 3272, 3235, 3032, 1644, 1628,1553, 1462, 1454 cm⁻¹.

EXAMPLE 8 (rac)-N-Formyl-1-aminoindan

The title compound was prepared from 1-aminoindan according to theprocedure described in J.Med.Chem., 9, 830 (1966), and crystallized fromEtOAc (40% overall yield), m.p.: 105° C.

Anal. calcd. for C₁₀ H₁₁ NO: C,74.50; H,6.88; N,8.69. Found: C,74.59;H,6.88; N,8.67. ¹ H NMR δ (CDCl₃): 8.26 (m, 1H, HCO), 7.25 (m, 4H, Ph),5.80 (br s, 1H, NH), 5.56, 5.00 (q, 1H, C1-H,2 rotamers), 3.01 (m, 1H,C3-H), 2.88 (m, 1H, C3-H'), 2.62 (m, 1H, C2-H), 1.85 (m, 1H, C2-H') ppm.MS: 162 (MH⁺, 30), 117 (MH⁺ -HCONH₂, 100). IR (KBr): 3270, 3040, 2960,1635, 1545, 1400, 1245 cm⁻¹.

EXAMPLE 9 (R)-N-Formyl-1-aminoindan

The title compound was obtained from (R)-1-aminoindan in a manneranalogous to that described in Ex. 8, m.p.: 123°-5° C.

Anal. found: C, 74.61; H, 6.97; N, 8.76.

The NMR, MS and IR spectral data are identical to those given in Ex. 8.

EXAMPLE 10 (S)-N-Formyl-1-aminoindan

The title compound was obtained from (S)-1-aminoindan in a manneranalogous to that described in Ex. 8, m.p.: 124°-125° C.

Anal. found: C, 74.70; H, 7.13; N, 8.94. The NMR, MS and IR spectraldata are identical to those given in Ex. 8.

EXAMPLE 11 (rac)-N-Butyryl-1-aminoindan

A solution of butyryl chloride (5.33 g, 50 mmole) in anh. DME (60 ml)was added slowly to a stirred and ice-cooled solution of 1-aminoindan(6.66 g, 50 mmole) and Et₃ N (10.0 g, 100 mmole) in anh. DME (75 ml),and the mixture stirred at ambient temperature for 24 hr. After removalof volatiles under reduced pressure, the residue was taken up in 1:1water/EtOAc mixture (300 ml). The organic layer was separated, dried onNa₂ SO₄ and evaporated to dryness. The crude product was crystallizedfrom EtOAc, to give 5.9 g (58%) of the title compound as a white solid,m.p.: 84°-5° C.

Anal. calcd. for C₁₃ H₁₇ NO: C,76.81; H,8.43; N,6.89. Found: C,77.18;H,8.48; N,7.08. ¹ H NMR δ (CDCl₃): 7.24 (m, 4H, Ph), 5.73 (br d, 1H,NH), 5.48 (q, 1H, C1-H), 2.97 (m, 1H, C3-H), 2.85 (m, 1H, C3-H'), 2.59(m, 1H, C2-H), 2.19 (t, 2H, CH₂ CO), 1.78 (m, 1H, C2-H'), 1.70 (m, 2H,CH₃ CH₂), 0.97 (t, 3H, CH₃) ppm. MS: 204 (MH⁺, 100), 179 (12), 160 (18).IR (KBr): 3279, 2961, 1640, 1545, 1481, 1458 cm⁻¹.

EXAMPLE 12 (rac)-N-Methyl-1-aminoindan.HCl

The title compound was prepared from (rac)-1-aminoindan, according toJ.Med.Chem., 9, 830 (1963), and crystallized from iPrOH/Et₂ O (overallyield 25%), m.p.: 147°-9° C.

¹ H NMR δ (CDCl₃): 9.81 (br s, 2H, NH₂, ), 7.80 (d, 1H, Ph), 7.28 (m,3H, Ph), 4.65 (m, 1H, C1-H), 3.28 (m, 1H, C3-H), 2.93 (m, 1H, C3-H'),2.47 (t, 4H, CH₃, C2-H), 2.36 (m, 1H, C2-H') ppm. MS: 148 (MH⁺, 100),117 (18) IR (KEr): 2934, 2751, 2694, 1462, 1431, 1414, 1339 cm⁻¹.

EXAMPLE 13 (R)-N-Methyl-1-aminoindan.HCl

The title compound was prepared from (R)-1-aminoindan in a manneranalogous to that described in Example 12, m.p.: 153° C.

Anal. calcd. for C₁₀ H₁₄ ClN: C,65.39; H,7.68; N,7.63; Cl,19.30. Found:C,65.66; H,7.89; N,7.57; Cl,19.80. The NMR, MS and IR spectral data areidentical to those given in Example 12.

EXAMPLE 14 (S)-N-Methyl-1-aminoindan.HCl

The title compound was prepared from (S)-1-aminoindan in a manneranalogous to that described in Example 12, m.p.: 154° C.

Found: C,65.30; H,7.83; N,7.77; Cl,19.48.

The NMR, MS and IR spectral data are identical to those given in Example12.

EXAMPLE 15 (rac)-N,N-Dimethyl-1-aminoindan.HCl

The title compound was prepared from 1-aminoindan, according to YakugakuZasshi, 82, 1597 (1962), Chem.Abs., 59, 611f (1963) and crystallizedfrom iPrOH/Et₂ O (40% overall yield), m.p.: 195°-7° C.

Anal. calcd. for C₁₁ H₁₆ ClN: C,66.82; H,8.16; N,7.09; Cl,17.93. Found:C,66.86; H,8.33; N,6.85; Cl,18.30. ¹ H NMR δ (CDCl₃): 7.93 (d, 1H, Ph),7.35 (m, 3H, Ph), 4.95 (dd, 1H, C1-H), 3.15 (m, 1H, C3-H), 3.02 (m, 1H,C3-H'), 2.71 (s, 6H, CH₃), 2.55 (m, 1H, C2-H), 2.46 (m, 1H, C2-H') ppm.MS: 162 (MH⁺, 100), 117 (MH⁺ -Me₂ NH,19). IR (KBr): 2932, 2561, 2525,2467, 1478, 1422, 1362, 1192 cm⁻¹.

EXAMPLE 16 (rac)-N-Benzyl-1-aminoindan.HCl

A solution of 1-chloroindan (7.6 g, 49.7 mmole) and benzylamine (21.3 g,199 mmole) in toluene (55 ml) was refluxed for 10 hr. The reactionmixture was filtered, water (50 ml) was added to the filtrate andacidified to pH=2.5 by means of 33% H₂ SO₄. The aqueous phase wasseparated, its pH was adjusted to 6-6.5 by means of 25% NH₄ OH, andextracted with toluene. The organic phase was dried and evaporated todryness (8.2 g, 74%). 1.7 g of the crude free base was converted to theHCl salt by means of isopropanolic HCl, affording 1.3 g (66%) of a whitecrystalline solid, m.p.: 180° C.

Anal. calcd. for C₁₆ H₁₈ ClN: C,73.96; H,6.98; N,5.39; Cl,13.65. Found:C,73.93; H,7.04; N,5.63; Cl,13.62. ¹ H NMR δ (DMSO): 10.0 (br d, 2H, NH₂⁺), 7.90-7.25 (m, 9H, Ph), 4.74 (br s, 1H, C1-H), 4.15 (br s, 2H,PhCH₂), 3.16 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.40 (m, 2H, C2-H) ppm.MS: 224 (MH⁺, 100), 117 (MH⁺ -PhCH₂ NH₂, 68). IR (KBr): 2886, 2776,2759, 2730, 2629, 2552, 1582, 1484, 1458, 1433, 1424, 1383, 1210 cm⁻¹.

EXAMPLE 17 (rac)-N-Acetyl-1-aminoindan

The title compound was obtained in 52% yield by acetylation of1-aminoindan, according to J.Med.Chem., 9, 830 (1966), m.p.: 124°-5° C.

¹ H NMR δ (CDCl₃): 7.25 (m, 4H, Ph), 5.78 (br s, 1H, NH), 5.46 (q, 1H,C1-H), 2.98 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.58 (m, 1H, C2-H), 2.01(s, 3H, CH₃), 1.80 (m, 1H, C2-H') ppm. MS: 176 (MH⁺, 100), 117 (MH⁺ -CH₃CONH₂, 100). IR (KBr): 1632, 1551, 1481, 1458, 1437, 1372, 1290 cm⁻¹.

EXAMPLE 18 (R)-N-Acetyl-1-aminoindan

The title compound was obtained from (R)-1-aminoindan in a manneranalogous to that described in Example 17, m.p.: 152°-3° C.

Anal. calcd. for C₁₁ H₁₃ NO: C,75.40; H,7.48; N,8.00. Found: C,75.42;H,7.43; N,7.80. The NMR, MS and IR spectral data are identical to thosegiven in Example 17.

EXAMPLE 19 (S)-N-Acetyl-1-aminoindan

The title compound was obtained from (S)-1-aminoindan in a manneranalogous to that described in Example 17, m.p.: 154° C.

Anal. calcd. for C₁₁ H₁₃ NO: C,75.40; H,7.48; N,8.00. Found: C,75.68;H,7.66; N,7.99. The NMR, MS and IR data are identical to those given inExample 17.

EXAMPLE 20 (rac)-7-Methyl-N-acetyl-1-aminoindan

The title compound was prepared in 55% yield according to the proceduredescribed in Example 17, m.p.: 166°-7° C.

Anal. calcd. for C₁₂ H₁₅ NO: C,75.87; H,7.77; N,7.54. Found: C,76.16;H,7.98; N,7.40. ¹ H NMR δ (CDCl₃): 7.10 (m,3H, Ph), 5.60 (br d, 1H, NH),5.48 (m, 1H, C1-H), 3.03 (m, 1H, C3-H), 2.86 (m, 1H, C3-H'), 2.43 (m,1H, C2-H), 2.29 (s, 3H, PhMe), 2.01 (m, 1H, C2-H'), 1.96 (s, 3H, CH₃)ppm. MS: 190 (MH⁺, 100), 182 (35), 165 (11). IR: 3281, 2919, 1636, 1547,1375, 1291 cm⁻¹.

EXAMPLE 21 (R)-4,5-Dimethoxy-N-acetyl-1-aminoindan

The title compound was prepared in 66% yield according to the proceduredescribed in Example 17, m.p.: 175° C.

Anal. calcd. for C₁₃ H₁₇ NO₃ : C,66.6; H,7.43; N,6.06. Found: C,66.37;H,7.43; N,5.95. ¹ H NMR δ (CDCl₃): 6.95 (d, 1H, Ph), 6.77 (d, 1H, Ph),5.82 (br d, 1H, NH), 5.38 (m, 1H, C1-H), 3.84 (s, 6H, OMe), 3.0 (m, 1H,C3-H), 2.84 (m, 1H, C3-H'), 2.56 (m, 1H, C2-H), 2.01 (s, 3H, Me), 1.80(m, 1H, C2-H') ppm. MS: 236 (MH⁺, 11), 177 (MH⁺ -CH₃ CONH₂, 100). IR:3281, 2959, 2835, 1638, 1551, 1495, 1296, 1260, 1217 cm⁻¹.

EXAMPLE 22 (rac)-6-Fluoro-N-acetyl-1-aminoindan

The title compound was prepared in 51% yield according to the proceduredescribed in Example 17, m.p.: 139°-141° C.

Anal. calcd. for C₁₁ H₁₂ FNO: C,68.37; H,6.26; F,9.84; N,7.25. Found:C,68.50; H,6.48; F,10.25; N,7.44. ¹ H NMR δ (CDCl₃): 7.15 (dd, 1H, Ph),6.93 (m, 2H, Ph), 5.78 (br s, 1H, NH), 2.92 (m, 1H, C3-H), 2.82 (m, 1H,C3-H'), 2.03 (s, 3H, Me), 2.60 (m, 1H, C2-H), 1.82 (m, 1H, C2-H') ppm.MS: 194 (MH⁺, 100), 135 (MH⁺ -AcNH₂, 31). IR (KBr): 3279, 2963, 1634,1551, 1489, 1373, 1296 cm⁻¹.

EXAMPLE 23 (R)-6-Fluoro-N-acetyl-1-aminoindan

The title compound was obtained in 47% yield from(R)-6-fluoro-1-aminoindan in a manner analogous to that described inExample 17, m.p.: 181°-3° C. The NMR, MS and IR spectral data areidentical to those given in Example 22.

Anal. found for C₁₁ H₁₂ FNO: C,68.31; H,6.22; N,7.31, F,10.23.

EXAMPLE 24 (S)-6-Methoxy-1-aminoindan.HCl

The title compound was prepared in 53% yield from 6-methoxy-1-indanone(prepared via the methods described in J.Org.Chem., 46,2974 (1981) andin J.Chem.Soc. Peskin Trans I, 151 (1972)) in a manner analogous to thatdescribed in Eur.Pat.Appl. 436492, m.p.: 239°-242° C. (dec.).

Anal. calcd. for C₁₀ H₁₄ ClNO: C, 60.15; H, 7.02; N, 7.02; Cl, 17.79.Found: C, 60.46; H, 7.15; N, 7.11; Cl, 17.53. ¹ H NMR δ (D₂ O): 7.35(1H, Ph), 7.12 (1H, Ph), 7.06 (1H, Ph), 4.85 (m, 1H, C1-H), 3.85 (s, 3H,OMe), 3.08 (m, 1H, C3-H), 2.95 (m, 1H, C3-H'), 2.62 (m, 1H, C2-H), 2.17(m, 1H, C2-H') ppm. MS: 162 (M-H, 63), 147 (100). IR (KBr): 2940, 1609,1500, 1250 cm⁻¹.

EXAMPLE 25 (rac)-6-Methoxy-1-aminoindan.HCl

The title compound was prepared in 72% from 6-methoxy-1-indanone in amanner analogous to that described in Ex. 24, except that6-methoxy-1-oximinoindan was reduced by hydrogen over Pd on charcoal;m.p.: 244°-5° C.

The NMR, MS and IR data are identical to those described in Ex. 24.

Found for C₁₀ H₁₄ ClNO: C, 60.22; H, 6.97; N, 6.83; Cl, 17.59.

EXAMPLE 26 (rac) 6-methoxy-N-acetyl-1-aminoindan

The title compound was prepared in 27% yield from (rac)-6-methoxyaminoindan according to the procedure described in Example 17, m.p.:131°-2° C.

Anal. calcd. for C₁₂ H₁₅ NO₂ : C, 70.22; H, 7.37; N, 6.82. Found: C,70.22; H, 7.41; N, 6.84. ¹ H NMR δ (CDCl₃): 7.12 (d, 1H, Ph), 6.80 (m,2H, Ph), 5.77 (br d, 1H, NH), 5.43 (m, 1H, C1-H), 3.78 (s, 3H, OMe),2.90 (m, 1H, C3-H), 2.78 (m, 1H, C3-H'), 2.58 (m, 1H, C2-H), 2.02 (s,3H, Me), 1.80 (m, 1H, C2-H') ppm. IR: 3283, 3075, 3002, 2963, 2940,2836, 1638, 1551, 1489, 1372, 1327, 1294, 1240, 1146 cm⁻¹.

EXAMPLE 27 1-Aminobenzocyclobutene.HCl

The title compound was prepared from benzocyclobutene-1-carboxylic acidin 44% yield, according to the procedure described in J.Med.Chem., 8,255(1965); m.p.: 184° C.

Anal. calcd. for C₈ H₁₀ ClN: C,61.74; H,6.48; N,9.0. Found: C, 61.04;H,6.59; N,9.30. ¹ H NMR δ (DMSO): 8.96 (br s, 3H, NH₃ ⁺), 7.40-7.20 (m,4H, Ph), 4.71 (m, 1H, C1-H), 3.55 (dd, 1H, C2-H), 3.24 (dd, 1H, C2-H')ppm. MS: 120 (MH⁺, 79), 103 (M-NH₃, 100). IR (KBr): 2963, 2942, 1601,1584, 1495, 1458, 1368 cm⁻¹.

EXAMPLE 28 (rac)-7-Methyl-1-aminoindan.HCl

3-Methyl benzaldehyde was converted to a mixture of 5-methyl-1-indanoneand 7-methyl-1-indanone according to the procedure described in Ex. 24.The two isomers were separated by column chromatography (hexane:CH₂ Cl₂)and the latter was converted to the title compound as in Ex. 24. Overallyield 18%, m.p.: >280° C. (dec.).

Anal. calcd. for C₁₀ H₁₄ ClN: C, 65.4; H, 7.63; N, 7.63; Cl, 19.35.Found: C, 65.62; H, 7.66; N, 7.66; Cl, 18.99.

EXAMPLE 29 (R)-4,5-Dimethoxy-1-aminoindan.HCl

The title compound was prepared in 24% yield from(rac)-4,5-dimethoxy-1-aminoindan (Ex. 31), m.p.: 213°-4° C. (dec.).

Anal. calcd. for C₁₁ H₁₆ ClNO₂ : C, 57.52; H, 7.02; N, 6.10. Found: C,57.18; H, 7.08; N, 6.38. ¹ H NMR δ (D₂ O): 7.29 (d, 1H, Ph), 7.10 (d,1H, Ph), 4.85 (m, 1H, C1-H), 3.95 (s, 3H, OMe), 3.88 (s, 3H, OMe), 3.20(m, 1H, C3-H), 3.07 (m, 1H, C3-H'), 2.65 (m, 1H, C2-H) 2.20 (m, 1H,C2-H') ppm. MS: 192 (M-H⁺, 100), 177 (61). IR (KBr): 3262, 2928, 1620,1605, 1532, 1489, 1443, 1432, 1375 cm⁻¹.

EXAMPLE 30 (S)-4,5-Dimethoxy-1-aminoindan.HCl

The title compound was prepared in a manner analogous to that describedin Example 29, m.p.: 209°-10° C. (dec.).

The NMR, MS and IR spectral data are identical to those described inExample 29.

Found for C₁₁ H₁₆ ClNO₂ : C, 56.36; H, 7.00; N, 6.22.

EXAMPLE 31 (rac)-4,5-Dimethoxy-1-aminoindan.HCl

The title compound was prepared in 70% yield from 2,3-dimethoxybenzaldehyde in a manner analogous to that described in Ex. 24, m.p.:202°-4° C. (dec.).

Anal. calcd. for C₁₁ H₁₆ ClNO₂ : C, 57.51; H, 7.02; N, 6.10. Found: C,57.58; H, 6.99; N, 5.69. The NMR, MS and IR spectral data are identicalto those described in Ex. 29.

EXAMPLE 32 (rac)-6-Hydroxy-5-methoxy-1-aminoindan.HCl

The title compound was prepared in 5 yield from3-methoxy-4-hydroxy-benzaldehyde in a manner analogous to that describedin Ex. 24.

Anal. calcd. for: C₁₀ H₁₃ NO₂ (free base): C, 67.02; H, 7.31; N, 7.81.Found: C, 66.97; H, 7.39; N, 7.88. ¹ H NMR δ (D₂ O): 7.08, 7.01 (s, 2H,Ph), 4.80 (m, 1H, C1-H) 3.91 (s, 3H, OMe), 3.12 (m, 1H, C3-H), 2.95 (m,1H, C3-H'), 2.60 (m, 1H, C2-H), 2.15 (m, 1H, C2-H') ppm. IR (KBr): 3485,3413, 3009, 2943, 1611, 1509, 1456, 1442, 1379, 1325, 1269, 1233 cm⁻¹.

EXAMPLE 33 (rac)-4-Hydroxy-5-methoxy-1-aminoindan.HCl

The title compound was prepared in 45% yield from4-benzyloxy-5-methoxy-1-indanone oxime, m.p.: 188°-90° C. (dec.).

¹ H NMR δ (D₂ O): 7.05 (m, 2H, Ph), 4.80 (m, 1H, C1-H), 3.88 (s, 3H,OMe), 3.05 (m, 1H, C3-H), 2.92 (m, 1H, C3-H'), 2.63 (m, 1H, C2-H), 2.18(m, 1H, C2-H') ppm. MS: 178 (M-H⁺, 100), 148 (12). IR (KBr): 3401, 2932,1615, 1526, 1487, 1425, 1279 cm⁻¹.

EXAMPLE 34 (rac)-6-Hydroxy-1-aminoindan.HCl

The title compound was prepared in 45% yield from(rac)-6-methoxy-1-aminoindan, m.p.: 202°-3° C. (dec.).

Anal. calcd. for C₉ H₁₂ ClNO: C, 58.22; H, 6.52; N, 7.55. Found: C,58.08; H, 6.41; N, 7.39. ¹ H NMR δ (D₂ O): 7.15 (d, 1H, Ph), 6.90 (s,1H, Ph), 6.80 (d, 1H, Ph), 4.67 (m, 1H, C1-H), 3.05 (m, 1H, C3-H), 2.86(m, 1H, C3-H'), 2.55 (m, 1H, C2-H), 2.06 (m, 1H, C2-H') ppm. MS: 148(M-H⁺, 65), 132 (100). IR (KBr): 3297, 3044, 1615, 1499, 1460, 1451,1375, 1281, 1213 cm⁻¹.

EXAMPLE 35 (R)-6-Hydroxy-1-aminoindan.HCl

The title compound was prepared in 43% yield from(R)-6-methoxy-1-aminoindan, m.p.: 199°-200° C.

Found for: C₉ H₁₂ ClNO: C, 57.98; H, 6.30; Cl, 18.88; N, 7.55. The NMRand MS spectral data are identical to those described in Ex. 34.

EXAMPLE 36 (rac)-5-Methoxy-1-aminoindan.HCl

The title compound was prepared in 25% yield from 5-methoxy-1-indanonein a manner analogous to that described in Ex. 24, m.p.: 225°-7° C.(dec.).

Anal. calcd. for C₁₀ H₁₄ ClNO: C, 60.15; H, 7.02; N, 7.02, Cl, 17.79.Found: C, 59.77; H, 6.94; N, 7.08; Cl, 17.5 ¹ H NMR δ (D₂ O): 7,43 (d,1H, Ph), 7.00 (d, 1H, Ph), 6.93 (m, 1H, Ph), 4.85 (m, 1H, C1-H), 3.85(s, 3H, OMe), 3.15 (m, 1H, C3-H), 2.98 (m, 1H, C3-H'), 2.63 (m, 1H,C2-H) 2.17 (m, 1H, C2-H') ppm. MS: 162 (M-H⁺, 100), 147 (100). IR (KBr):2900, 1602, 1509, 1500, 1300, 1252 cm⁻¹.

EXAMPLE 37 (rac)-N-(3-Cynaopropyl)-1-aminoindan

Potassium carbonate (15.5 g, 112 mmole) and 4-chlorobutyronitrile (11.58g, 112 mmole) was added to a solution of 1-aminoindan (5.0 g, 37.6mmole) in acetonitrile (50 ml), and the mixture refluxed for 2 hr. Asecond portion of 4-chlorobutyronitrile (5.0 g) was then added, themixture further heated for 24 hr, filtered and the filtrate evaporatedto dryness. Unreacted 4-chlorobutyronitrile was removed by treating theresidue (20 g) with isopropanolic HCl (16.7 ml, 24%) followed bysuccessive extractions with ether (3×150 ml). The crude product thusobtained was further purified by column chromatography (Silica, CH₂ Cl₂:MeOH 98:2) to afford 3.7 g (49%) of tan-colored crystalline mass.

¹ H NMR δ (CDCl₃): 7.32 (m, 1H, Ph), 7.20 (m, 3H, Ph), 4.22 (t, 1H,C1-H), 2.98 (m, 1H, C3-H), 2.85 (m, 2H, CH₂ NH), 2.81 (m, 1H, C3-H'),2.49 (t, 2H, CH₂ CN), 2.42 (m, 1H, C2-H), 1.83 (m, 2H, CH₂ CH₂ CH₂),1.77 (m, 1H, C2-H') ppm. MS: 201 (MH⁺, 63), 117 (63), 85 (100).

EXAMPLE 38 (rac)-5-Methyl-1-aminoindan.HCl

5-Methyl-1-indanone, obtained from 3-methyl benzaldehyde as described inEx. 28, was converted to the title compound according to the proceduredescribed in Ex. 24 (overall yield 6%), m.p.: 247°-9° C. (dec.).

Anal. calcd. for C₁₀ H₁₄ ClN: C, 65.40; H, 7.63; N, 7.63; Cl, 19.35Found: C, 65.12; H, 7.36; N, 7.58; Cl 19.18. ¹ H NMR δ (D₂ O): 7.45 (d,1H, Ph), 7.25 (s, 1H, Ph), 7.20 (d, 1H, Ph), 4.81 (m, 1H, C1-H), 3.22(m, 1H, C3-H), 2.90 (m, 1H, C3-H'), 2.56 (m, 1H, C2-H), 2.35 (s, 3H,CH₃) 2.12 (m, 1H, C2-H') ppm.

EXAMPLE 39 (rac)-trans-2-Methyl-1-aminoindan.HCl

2-Methyl-1-indanone was prepared from benzene and α-bromoisobutyrylbromide, as in Polish J. Chem. 52, 2059 (1978), and converted to theoximino derivative, from which the title compound was obtained byreduction with Zn/HOAc. The overall yield was 14%, m.p.: >275° C.(dec.). Anal. calcd. for C₁₀ H₁₄ NCl: C, 65.40; H, 7.63; N, 7.63; Cl,19.35. Found: C, 65.49; H, 7.90; N, 7.68; Cl, 19.14. ¹ H NMR δ (D₂ O):7.60-7.25 (m, 4H, Ph) ; 4.70 (d, 1H, C1-H) 3.17 (dd, 1H, C3-H), 2.87 (m,1H, C2-H), 2.79 (dd, 1H, C3-H'), 1.19 (d, 3H, CH₃) ppm.

EXAMPLE 40 (rac)-cis-2-Methyl-1-aminoindan.HCl

The title compound was prepared according to procedure described in Ex.39, except that 2-methyl-1-oximinoindan was reduced by hydrogenerationover Pd on charcoal, m.p. 235°-7° C. (dec.).

Found for C₁₀ H₁₄ Cl,N: C, 65.78; H, 7.93; N, 7.72; Cl, 19.39. ¹ H NMR δ(D₂ O): 7.60-7.25 (m, 4H, Ph), 4.45 (d, 1H, C1-H) 3.33 (dd, 1H, C3-H),2.68 (dd, 1H, C3-H'), 2.58 (m, 1H, C2-H), 1.25 (d, 3H, CH₃) ppm.

EXAMPLE 41 (rac)-3,5,7-Trimethyl-1-aminoindan.HCl

The title compound was prepared in 9% yield from m-xylene and crotonicacid, according to the procedures described in Ex. 24, m.p.: >275° C.(dec.).

Anal. calcd. for C₁₂ H₁₈ NCl: C, 68.08; H, 8.51; N, 6.62; Cl, 16.78.Found: C, 68.11; H, 8.46; N, 6.73; Cl, 17.08. ¹ H NMR δ (D₂ O): 7.10 (s,H, Ph), 7.05 (s, H, Ph), 4.89 (m, 1H, C1-H), 3.25 (m, 1H, C3-H), 2.90(m, 1H, C2-H), 2.37 (s, 3H, CH3), 2.33 (s, 3H, CH₃), 1.70 (m, 1H,C2-H'), 1.34 (d, 3H, CH₃) ppm.

EXAMPLE 42 (rac)-7-Hydroxy-1-aminoindan.HCl

The title compound was prepared in 6% yield from phenol and3-chloro-propionylchloride according to the procedures described in Ex.24, m.p.: 179°-81° C.

Anal. calcd. for C₉ H₁₂ ClNO: C, 58.22; H, 6.52; N, 7.55; Cl, 19.10.Found: C, 58.15; H, 6.47; N, 7.42; Cl, 19.39. ¹ H NMR δ (D₂ O): 7.29 (t,1H, Ph), 6.93 (d, 1H, Ph), 6.78 (d, 1H, Ph), 4.94 (m, 1H, C1-H), 3.12(m, 1H, C3-H), 2.97 (m, 1H, C3-H'), 2.61 (m, 1H, C2-H), 2.12 (m, 1H,C2-H') ppm.

EXAMPLE 43 (rac)-N,N-Di-(1-indanyl)amine.HCl

A solution of (rac)-1-chloroindan (9.2 g, 60 mmole) in acetonitrile (25ml) was added dropwise (10 min.) to a stirred and heated (65° C.)suspension of (rac)-1-aminoindan (8.0 g, 60 mmole), K₂ CO₃ (8.3 g, 60mmole) in acetonitrile (100 ml), under N₂ atmosphere. The mixture wasfurther stirred at 65° C. for 24 hrs; the solvent was removed underreduced pressure and the residue was partitioned between 10% NaOH (100ml) and CH₂ Cl₂ (100 ml). The aqueous layer was separated, extractedwith CH₂ Cl₂ (50 ml), and the combined organic layer was dried (Na₂ SO₄)and evaporated to dryness. The crude product was purified by flashcolumn chromatography (silica, hexane:ETOAc 80:20), to give 5.4 g (36%)of the free base, which was converted to its HCl salt by dissolving itin Et₂ O (60 ml) and adding to it an Et₂ O solution saturated with HClgas (75 ml). The resulting suspension was filtered, and the collectedsolid was crystallized from EtOH/iPrOH, to give 4.90 g (79%) of thetitle compound as a mixture of two diastereomers, white crystallinesolid, m.p.: 226°-8° C.

Anal. calcd. for C₁₈ H₂₀ NCl: C, 75.64; H, 7.05; N, 4.90; Cl, 12.41.Found: C, 75.90; H, 6.85; N, 4.96; Cl, 12.34. ¹ H NMR δ (DMSO): 9.80,9.60 (brs, 2H, NH₂ ⁺), 7.80, 7.78 (d,d, 2H, Ph), 7.36, 7.28 (m, m, 6H,Ph), 4.93, 4.87 (m, m, 2H, C1-H), 3.24, 2.91 (m, 2H, C3-H), 2.91 (m, 2H,C3-H'), 2.52 (m, 2H, C2-H), 2.38 (m, 2H, C2-H') ppm. MS: 250 (MH⁺, 100)IR: 3455, 2938, 2786, 2692, 2625, 1578, 1482, 1460, 1435, 1425, 1358,1028 cm⁻¹.

EXAMPLE 44 (rac)-N-(2-N-Boc-aminoacetyl)-1-aminoindan

A mixture of (rac)-1-aminoindan (2.5 g, 18.8 mmole),N-Boc-glycin-N-hydroxysuccinimide ester (5.0 g, 17.7 mmole), DMAP (2.5g, 20.5 mmole) in 1,2-dimethoxyethane (30 ml) was stirred at ambienttemperature for 20 hrs and evaporated to dryness under reduced pressure.The residue was taken up in Et₂ O (30 ml) and water (15 ml); the organicphase was separated, washed with 0.1N HCl (15 ml), 10% NaHCO₃ (15 ml)and water (20 ml), dried (MgSO₄) and evaporated to dryness under reducedpressure. The residue was treated (30 min. stirring, RT) with hexane (30ml) to give 4.55 g (15.7 mmole, 88%) of a white solid, m.p.: 82°-4° C.

¹ H NMR δ (CDCl₃): 7.22 (m, 4H, Ph), 6.45 (br d, 1H, CONH), 5.47 (m, 1H,C1-H), 5.25 (br s, 1H, Boc NH), 3.82 (d, 2H, CH₂), 2.95 (m, 1H, C3-H),2.86 (m, 1H, C3-H'), 2.58 (m, 1H, C2-H), 1.79 (m, 1H, C2-H') ppm. MS:291 (MH⁺, 32), 235 (MH⁺ -Me₂ CCH₂, 100), 119 (48), 117 (59).

EXAMPLE 45 (rac)-N-(2-Aminoacetyl)-1-aminoindan.HCl

To a solution of (rac)-N-(2-N-Boc-aminoacetyl)-1-aminoindan (5.9 g,20.34 mmole) in iPrOH (60 ml) was added 24% isorpopanolic HCl (12.5 ml).The mixture was stirred at ambient temperature for 20 hrs and evaporatedto dryness under reduced pressure. The residue was taken up in a 1:1water/CH₂ Cl₂ (400 ml) mixture. The aqueous layer was separated,filtered through millipore and evaporated to dryness under reducedconditions. The crude product was crystallized from EtOH to give 2.7 g(59%), white crystalline solid, m.p.: 201°-5° C.

Anal. calcd. for C₁₀ H₁₃ ClN₂ O: C, 58.54; H, 6.25; N, 12.41; Cl, 15.71.Found: C, 58.24; H, 6.50; N, 12.44; Cl, 15.47. ¹ H NMR δ (DMSO): 8.93(d, 1H, CONH), 8.35 (brs, 3H, NH₃ ⁺), 5.31 (m, 1H, C1-H), 3.58 (m, 2H,CH₂), 2.95 (m, 1H, C3-H), 2.83 (m, 1H, C3-H'), 2.40 (m, 1H, C2-H), 1.84(m, 1H, C2-H') ppm. MS: 191 (MH⁺, 100). IR: 3241, 3000, 2978, 1659,1613, 1562, 1478 cm⁻¹.

EXAMPLE 46 (rac)-N-Benzoyl-1-aminoindan

The title compound was prepared in 77% from (rac)-1-aminoindan (1.0 g,7.5 mmole) and benzoyl chloride (2.1 g, 15 mmole), under theSchotten-Bauman conditions, according to J.Chem.Soc. 71, 251 (1897) andJ.Org.Chem. 27, 4465 (1962), m.p.: 140°-2° C.

Anal. calcd. for C₁₆ H₁₅ NO: C, 80.98; H, 6.37; N, 5.90. Found: C,80.11; H, 6.42; N, 5.89. ¹ H NMR δ (CDCl₃): 7.90-7.20 (m, 9H, Ph), 6.40(br d, 1H, NH), 5.70 (m, 1H, C1-H), 3.05 (m, 1H, C3-H), 2.92 (m, 1H,C3-H'), 2.72 (m, 1H, C2-H), 1.97 (m, 1H, C2-H') ppm. MS: 238 (MH⁺, 100)122 (48).

EXAMPLE 47 N-(2-n-Propylpentanoyl)-1-aminoindan

A solution of valproyl chloride (1.55 g, 9.6 mmole) in toluene (25 ml)was added dropwise to a stirred and ice-cooled solution of 1-aminoindan(1.47 g, 10.0 mmole) and Et₃ N (1.11 g, 11 mmole). The mixture wasstirred at ambient temperature for 17 hours, EtOAc (60 ml) and water (50ml) were added and the phases were separated. The organic phase waswashed successively with 0.1N HCl (40 ml), 0.1N NaHCO₃ (40 ml) andsaturated NaCl (40 ml), dried over magnesium sulphate and evaporated todryness under reduced pressure. The residue was treated with hexane (15ml, 30 min stirring, RT) and filtered. The crude product wascrystallized from hexane:EtOAc (70:30 mixture), to give 1.72 g (6.65mmole, 69%) of a white crystalline solid, mpt: 133°-4° C.

Anal. Calcd. for C₁₇ H₂₅ NO: C, 78.71; H, 9.72; N, 5.40. Found: C,78.83; H, 9.69; N, 5.55. ¹ H-NMR δ (CDCl₃): 7.23 (m, 4H, Ph), 5.65 (brd, 1H, C2-H) 5.53 (m, 1H, C1-H), 2.97,2.86 (m, 2H, C3-H,H'), 2.61 (m,1H, C2-H), 2.03 (m,1H, Pr₂ CH), 1.77 (m, 1H, C2-H'), 1.66,1.63 (m, 8H,CH₃ CH₂ CH₂), 0.93 (t, 3H, CH₃), 0.90 (t, 3H, CH₃) ppm. MS: 260 (MH⁺,100), 172 (9), 144 (48), 117 (14). IR: 3270, 2955, 2932, 1640, 1545,1481, 1458, 1257 cm⁻¹.

EXAMPLE 48 (rac)-N-Methyl-N-acetyl-1-aminoindan

(rac)-N-Methyl-1-aminoindan.HCl ((1.0 g, 5.4 mmole), prepared from(rac)-1-aminoindan, as described in Ex. 12) was acetylated by Ac₂ O in amanner analogous to that described in Ex. 17, to give 0.7 g (3.7 mmole,69%) of a white solid, melting at ambient temperature.

¹ H NMR δ (CDCl₃), a mixture of 2 rotamers: 7.30-7.07 (m, 4H, Ph), 6.30,5.42 (t, 1H, C1-H), 3.02 (m, 1H, C3-H), 2.88 (m, 1H, C3-H'), 2.69, 2.64(s, 3H, Me), 2.42 (m, 1H, C2-H), 2.29, 2.18 (s, 3H, Ac), 2.05, 1.86 (m,1H, C2-H') ppm. MS: 190 (MH⁺, 34), 174 (M⁺ -CH₃, 15), 132 (16), 116(27).

EXAMPLE 49 (R)-N-Methyl-N-acetyl-1-aminoindan

The title compound was prepared in 73% from(R)-N-methyl-1-aminoindan.HCl (2.8 g, 15.2 mmole) as described in Ex.48, to give 2.1 g (11.1 mmole) of an off-white crystalline solid, mp:34°-6° C.

NMR and MS identical to those given in Ex. 48.

IR: 3472, 2944, 1650, 1480, 1402, 1330, 1291, 1155, 1122, 1020, 766cm⁻¹.

EXAMPLE 50 (rac)-N-(2-Propionamido)-1-aminoindan.HCl.H₂ O

A mixture of 2-bromopropionamide (3.19 g, 21.3 mmole),(rac)-1-aminoindan (3.0 g, 22.2 mmole), sodium bicarbonate (2.0 g, 23.8mmole) and absolute ethanol (45 ml) was stirred under reflux for 24 hrs.The reaction mixture was then filtered hot, and the filtrateconcentrated in vacuo to about 1/3 of its initial volume, and filtered.The collected solid was dissolved in CH₂ Cl₂ and washed successivelywith 0.1N HCl and water. The aqueous phase was basified to pH 12-13, andfiltered. The solid was dried, dissolved in CH₂ Cl₂ (30 ml) andconverted to the HCl salt by isopropanolic HCl. The latter was collectedby filtration, washed with CH₂ Cl₂ (3 ml) and dried, to give 2.4 g (9.3mmole, 44%) of a white solid, mp: 245° C.

Anal. calc. for C₁₂ H₁₉ ClN₂ O₂ : C, 55.7; H, 7.4; N, 10.8. Found: C,55.3; H, 6.5; N, 10.8. ¹ H NMR δ (DMSO), two diastereomers: 9.86, 9.54,9.30, 9.18 (br m, 2H, NH₂ ⁺), 8.34, 8.28, 7.72, 7.68 (br s, 2H, CONH₂),7.70, 7.40-7.22 (m, 4H, Ph), 4.65 (br s, 1H, C1-H), 3.98 (br m, 1H,Cα-H), 3.20 (m, 1H, C₃ -H), 2.84 (m, 1H, C₃ -H'), 2.40 (m, 1H, C2-H),2.26 (m, 1H, C2-H'), 1.52, 1.48 (d, 3H, Me) ppm. MS: 205 (MH⁺, 72), 160(MH⁺ -HCONH₂, 8), 132 (6), 117 (24). IR (KBr): 3409, 3253, 3133, 2757,1687, 1553, 1533, 1458, 1400, 1378, 1332, 1256, 1143, 1091, 1035, 762,641 cm⁻¹.

EXAMPLE 51 (rac)-N-(2-Phenylacetyl)-1-aminoindan.HCl

Phenylacetyl chloride (4.76 g, 30.8 mmole) was added dropwise to anice-cooled solution of (rac)-1-aminoindan (4.0 g, 30 mmole) and Et₃ N(6.0 g) in 1,2-dimethoxyethane (40 ml). After completion of addition,the reaction mixture was stirred for 5 hrs at 70° C. and filtered. The1solid was dissolved in CH₂ Cl₂ (100 ml), washed successively with 0.3NHCl, 10% NaHCO₃, water (50 ml each) and dried. The crude product wascrystallized from 1:1 hexane:EtOAc (90 ml) to give 2.9 g (11.6 mmole,39%) white solid, mp: 145°-7° C.

Anal. calc. for C₁₇ H₁₇ NO: C, 81.24; H, 6.82; N, 5.57. Found: C, 81.31;H, 6.97; N, 5.69. ¹ H NMR δ (CDCl₃): 7.40-7.10 (m, 9H, Ph), 5.62 (br d,1H, CONH), 5.48 (q, 1H, C1-H), 3.62 (AB q, 2H, CH₂), 2.86 (m, 2H, C3-H,H'), 2.58 (m, 1H, C2-H), 1.65 (m, 1H, C2-H') ppm. IR (KBr): 3275, 1638,1545, 1456, 1364, 748, 710 cm⁻¹.

EXAMPLE 52 (rac)-N-(m-Anisoyl)-1-aminoindan

The title compound was prepared from (rac)-1-aminoindan (1.6 g, 12.3mmole) and m-anisoyl chloride (1.9 g, 13.54 mmole) as in Ex. 46;crystallization from EtOAc:hexane gave 2.0 g (7.2 mmole, 59%) whitesolid, mp: 140° C.

Anal. calc. for Cl₇ H₁₇ NO₂ : C, 76.38; H, 6.4; N, 5.2. Found: C, 76.55;H, 5.75; N, 5.63. ¹ H NMR δ (CDCl₃): 7.45-7.18 (m, 7H, Ph), 7.04 (m, 1H,Ph) 6.35 (br d, 1H, CONH), 5.68 (q, 1H, C1-H), 3.84 (s, 3H, OMe), 2.98(m, 2H, C3-H, H'), 2.70 (m, 1H, C2-H), 1.92 (m, 1H, C2-H') ppm. MS: 268(MH⁺, 100), 152 (7) IR (KBr), 3268, 1632, 1586, 1543, 1481, 1350, 1246,1038, 758, 743, 725 cm⁻¹.

EXAMPLE 53 (rac)-N-(4'-Fluorobenzoyl)-1-aminoindan

The title compound was prepared from (rac)-1-aminoindan (1.7 g, 12.85mmole) and 4-fluorobenzoyl chloride (2.24 g, 14.1 mmole) as in Ex. 52;1.71 g(6.7 mmole, 52%), mp: 109°-1° C.

¹ H NMR δ (CDCl₃): 8.15 (td, 1H, Ph), 7.55-7.05 (m, 7H, Ph), 6.95 (m,1H, CONH), 5.74 (m, 1H, C1-H), 2.98 (m, 2H, C3-H, H'), 2.75 (m, 1H,C2-H), 1.94 (m, 1H, C2-H') ppm. MS: 256 (MH⁺, 100), 140 (9). IR (KBr):3233, 1638, 1541, 1229, 756, 745 cm⁻¹.

EXAMPLE 54 (rac)-N-(p-Toluoyl)-1-aminoindan

The title compound was prepared from (rac)-1-aminoindan (5.0 g, 37.6mmole) and p-toluoyl chloride (5.2 g, 33.8 mmole) as in Ex. 52; 4.8 g(19.1 mmole, 57%), mp: 140° C.

Anal. calc. for C₁₇ H₁₇ NO: C, 81.24; H, 6.82; N, 5.57. Found: C, 80.98;H, 6.80; N, 5.48. ¹ H NMR δ (CDCl₃): 7.68, 7.34, 7.30-7.16 (m, 8H, Ph),6.34 (br d, 1H, CONH), 5.69 (q, 1H, C1-H), 2.96 (m, 2H, C3-H,H'), 2.70(m, 1H, C2-H), 2.40 (s, 3H, Me), 1.92 (m, 1H, C2-H') ppm. MS: 504 (MMH⁺,38), 252 (MH⁺, 100). IR (KBr): 3273, 3025, 2964, 1630, 1532, 1294, 830,742 cm⁻¹.

EXAMPLE 55 (S)-(1-Indanyl)-glycine.HCl

A mixture of N-(2-acetamindo)-1-aminoindan (4.95 g, 26 mmole, preparedas described in Ex. 2) in conc. HCl (25 ml) was stirred under reflux for3 hrs, and evaporated to dryness under reduced pressure. The residue wasdissolved in water (30 ml) and the solution was basified to pH 9 by 10%NaOH. Volatiles were stripped under reduced pressure and the residue wasdissolved in water, brought to pH 2 by 2.5N HCl and the solutionevaporated to dryness. The crude product was slurried in ethanol (60ml), collected by filtration and dried, to give 2.75 g (12.1 mmole, 46%)white solid.

¹ H NMR δ (DMSO): 7.70 (d, 1H, Ph), 7.60-7.20 (m, 6H, Ph, NH₂,), 4.77(m, 1H, C1-H), 3.66 (AB q, 2H, CH₂), 3.14 (m, 1H, C3-H), 2.85 (m, 1H,C3-H'), 2.40 (m, 1H, C2-H), 2.22 (m, 1H, C2-H') ppm.

EXAMPLE 56 (rac)-N,N-di-(2-Acetamido)-1-aminoindan.HCl.H₂ O.

A mixture of (rac)-1-aminoindan (10.0 g, 75.1 mmole), 2-chloroacetamide(14.8 g, 159.1 mmole), NaHCO₃ (15.8 g) in water (200 ml) was stirredunder reflux for 3 hrs, cooled to RT and filtered. The solid was dried,slurried in methanol, filtered and dried. The free base was converted tothe HCl salt by isopropanolic HCl (5 ml) in ethanol (120 ml); furthertreatment with water afforded the title product as a hydrate, 5.2 g(18.3 mmole, 24%), mp: 148°-15° C.

Anal. calc. for C₁₃ H₁₈ ClN₃ O₂.H₂ O: C, 51.74; H, 6.68; N, 13.92.Found: C, 50.96; H, 6.45; N, 14.16. ¹ H NMR δ (DMSO): 7.92 (br s, 2,CONH₂), 7.62 (br s, 2H, CONH₂), 3.58 (d, 1H, Ph), 7.48-7.25 (m, 3H, Ph),5.04 (m, 1H, C1-H), 3.95 (d, 2H, CH₂), 3.75 (d, 2H, CH₂), 3.10 (m, 1H,C3-H), 2.95 (m, 1H, C3-H'), 2.46 (m, 1H, C2-H), 2.36 (m, 1H, C2-H') ppm.MS: 248 (MH⁺, 67), 231 (MH⁺ -NH₃, 15), 203 (MH⁺ -HCONH₂, 8) 132 (100),117 (47). IR (KBr): 3390, 3220, 3088, 1713, 1688, 1400, 1377, 1215, 723,691 cm⁻¹.

EXAMPLE 57 (rac)-N-(1-Indanyl)-aminoacetonitrile.HCl

A mixture of (rac)-1-aminoindan (5.0 g, 37.6 mmole),2-chloroacetonitrile (2.84 g, 37.6 mmole), NaHCO₃ (3.5 g) in ethanol (20ml) was stirred under reflux for 3 hrs, filtered hot, and the filtratewas evaporated to dryness. The residue was treated with Et₂ O (20 ml,1/2 hr, RT) and filtered; the filtrate was evaporated to dryness and theoily residue was taken up in 60 ml 1:1 toluene: H₂ O mixture, and the pHof the aqueous phase was adjusted to 7.5. The organic layer wasseparated and evaporated to dryness. The free base thus obtained wasdissolved in CH₂ Cl₂ (15 ml) and converted to the hydrochloride withisopropanolic HCl. The solid product was collected by filtration anddried, to give 4.5 g (17.9 mmole, 48%), mp: >250° C.

Anal. calc. for C₁₁ H₁₃ ClN₂ : C, 63.31: H, 6.28; N, 13.42. Found: C,63.01; H, 6.22; N, 13.34. ¹ H NMR δ (DMSO): 7.77 (d, 1H, Ph), 7.42-7.25(m, 3H, Ph), 4.80 (m, 1H, C1-H), 4.35 (s, 2H, CH₂), 3.16 (m, 1H, C3-H),2.88 (m, 1H, C3-H'), 2.40 (m, 1H, C2-H), 2.28 (m, 1H, C2-H') ppm. MS:173 (MH⁺, 8), 146 (MH⁺ -CN, 100), 117 (35). IR (KBr): 2972, 2936, 2910,2721, 2631, 2569, 2432, 1582, 1445, 1372, 1022, 758 cm⁻¹.

EXAMPLE 58 N-Acetyl-6-nitro-1-aminoindan

To an ice-cooled suspension of (rac)-N-acetyl-1-aminoindan (Ex. 17, 17.5g, 0.1 mole) in nitromethane (165 ml), was added dropwise a nitratingmixture (H₂ SO₄, HNO₃, H₂ O) while the temperature was kept between 8°C. and 2° C. Stirring was continued for 1.5 hours in the ice-bath andthe mixture was then poured on to a mechanically stirred mixture of ice(500 g) and water (1300 ml), stirring being continued for 1 hour. Thesuspension was filtered, the white solid washed with water and dried(14.05 g, 63.9%). It is sufficiently pure for hydrogenation (Ex. 59).

Crystallization from EtOAc/EtOH/Toluene afforded analytically purecompound, mp: 179° C.

Anal. calc. for C₁₁ H₁₂ N₂ O₃ : C, 59.99; H, 5.59; N, 12.72. Found: C,60.10; H, 5.38; N, 12.70. ¹ H NMR δ (CDCl₃): 8.09 (br, 2H, C5-H, C7-H),7.35 (d, 1H, C4-H), 5.88 (br d, 1H, CONH), 5.55 (q, 1H, C1-H), 3.07,2.94 (m, 2H, C3-H, H'), 2.71 (m, 1H, C2-H), 2.09 (s, 3H, Me), 1.90 (m,1H, C2-H') ppm. MS: 221 (MH⁺, 100). IR (KBr): 3267, 1643, 1556, 1516cm⁻¹.

EXAMPLE 59 (rac)-6-Amino-N-acetyl-1-aminoindan.HCl.1/2 H₂ O.

(rac)-6-Nitro-N-acetyl-1-aminoindan (Ex. 58, 14.0 g, 64 mmole) washydrogenated in EtOH (1.3 g, 5% Pd/C) for 3.5 hrs. The mixture wasfiltered through filter aid and the ethanol thoroughly evaporated invacuo. The solid residue was crystallized from boiling water (100 ml)and the crystallizing mixture refrigerated (for 2 days). The solid wasfiltered off, washed with cold water and dried (10.65 g, 84.1%), mp:161° C.

The free base was dissolved in CH₂ Cl₂ (250 ml) and converted to thehydrochloride by isopropanolic HCl (9.4 g, 61.8 mmole). The crude HClsalt was crystallized from EtOH/EtOAc: 9.9 g (42.1 mmole, 66%), mp:224°-5° C.

Anal. calc. for C₁₁ H₁₅ ClN₂ O.1/2 H₂ O: C, 56.05; H, 6.84; N, 11.88;Cl, 15.04. Found: C, 56.48; H, 6.55; N, 11.82; Cl, 15.38. ¹ H NMR δ (D₂O): 7.45 (d, 1H, C4-H), 7.31, 7.29 (s, dd, 2H, C5-H, C7-H), 5.36 (t, 1H,C1-H), 3.07 (m, 1H, C3-H), 2.93 (m, 1H, C3-H'), 2.53 (m, 1H, C2-H), 2.09(s, 3H, Me), 1.97 (m, 1H, C2-H') ppm. MS: 191 (MH⁺). IR (KBr): 1621,1548 cm⁻¹.

EXAMPLE 60 (rac)-1,6-Bis (acetylamino) indan

1-Acetylamino-6-aminoindan (Ex. 59, 1.90 g, 0.01 mole) was stirred witha solution of sodium hydroxide (0.8 g, 0.02 mole) in water (5 ml); ethylacetate (5 ml) was then added and the mixture ice-cooled, and aceticanhydride (1.3 ml, 0.014 mole) was added slowly, and the mixture stirredfor 0.5 hr. The flask was washed down with water, ethyl acetate removedin vacuo and the solid filtered off, washed with water and oven-dried(2.0 g) in vacuo.

The crude solid was crystallized from ethanol (28 ml). Filtration,washing with ice-cold ethanol and vacuum oven-drying gave the titlecompound (1.54 g, 65.8%), mp: 225°-6° C.

Anal. calc. for C₁₃ H₁₆ N₂ O₂ : C, 67.22; H, 6.94; N, 12.06. Found: C,67.20; H, 6.99; N, 11.76. ¹ H NMR δ (CDCl₃): 7.41 (br s, 1H, C7-H), 7.35(dd, 1H, C5-H), 7.18 (d, 1H, C4-H), 5.74 (br d, 1H, NHCO), 5.44 (q, 1H,C1-H), 3.49 (br d, 1H, ArNHCO), 2.93 (m, 2H, C3-H, H'), 2.80 (m, 1H,C2-H), 2.61 (m, 1H, C2-H'), 2.15 (s, 3H, ArNHCOMe), 2.03 (s, 3H, Me)ppm. MS: 233 (MH⁺, 45). IR (KBr): 1676, 1649, 1602, 1551 cm⁻¹.

EXAMPLE 61 (rac)-6-Cyano-N-acetyl-1-aminoindan

1-Acetylamino-6-aminoindan (Ex. 59, 11.42 g, 0.060 mole) wasmechanically stirred with water (15.5 ml) in an ice-salt bath andtreated with conc. hydrochloric acid (15.5 ml, 0.16 mole) to give auniform thick suspension which was allowed to cool to ca 0° C. It wasthen treated dropwise with a solution of sodium nitrite (4.46 g, 0.063mole) in water (9 ml) so that the temperature stayed below 5° C. Aftercomplete addition, the mixture was neutralized by the portionwiseaddition of sodium carbonate (3.1 g). The resulting solution was addedin portions to a previously warmed (65° C.) solution prepared from KCN(9.45 g, 0.145 mole) and CuCN (6.94 g, 0.078 mole) in water (23 ml). Thesuspension was heated for 15 min, then cooled to 40° C., and the solidwas collected by filtration, washed with water, dried and extracted withacetone (100 ml). The latter was evaporated to dryness and the residuepurified by flash column chromatography (silica, EtOAc:CH₂ Cl₂ 2:1). Thecrude product was crystallized from iPrOH to give 7.50 g (37.5 mmole,62.5%) of a yellow crystalline solid, mp: 175°-6° C.

Anal. calc. for C₁₂ H₁₂ N₂ O: C, 71.98; H, 6.04; N, 13.99. Found: C,71.97; H, 6.03; N, 13.85. ¹ H NMR δ (CDCl₃): 7.55 (br s, 1H, C7-H), 7.49(dd, 1H, C5-H), 7.32 (d, 1H, C4-H), 5.97 (br d, 1H, CONH), 5.49 (q, 1H,C1-H), 3.04 (m, 1H, C3-H), 2.92 (m, 1H, C3-H'), 2.64 (m, 1H, C2-H), 2.06(s, 3H, Me), 1.85 (m, 1H, C2-H') ppm. IR (KBr): 2227, 1645, 1557 cm⁻¹.

EXAMPLE 62 (rac)-6-Carboxamido-N-acetyl-1-aminoindan

(rac)-6-Cyano-N-acetyl-1-aminoindan (Ex. 61, 2.50 g, 0.0125 mole) wassuspended in ethanol (15 ml) and treated with 25% sodium hydroxide (0.63ml, 0.005 mole). The mixture was warmed to 40° C. and 30% hydrogenperoxide solution (6.5 ml) added in small portions while the temperaturewas kept at 40°-50° C. The mixture was stirred for 3 hrs, neutralizedwith 5% sulfuric acid (4.5 ml, pH 6), cooled to 2° C., filtered, and thewhite solid washed with water. It was dissolved in acetic acid (10 ml)at 40° C., filtered through "hiflo", and washed with acetic acid (2×2ml). The filtrate was warmed to 70° C., treated with water (35 ml) andcooled; the solid was filtered off, washed with acetic acid/water 5:30v/v and finally water, and dried to give 2.0 g (9.2 mmole, 73%), mp:250°-2° C.

Anal. calc. for C₁₂ H₁₄ N₂ O₂ : C, 66.04; H, 6.47; N, 12.83. Found: C,66.14; H, 6.51; N, 12.78. ¹ H NMR δ (DMSO): 8.24 (d, 1H, MeCONH), 7.92(br s, 1H, ArCONH), 7.74 (d, 1H, C5-H), 7.72 (s, 1H, C7-H), 7.29 (d, 1H,C4-H), 7.25 (br s, 1H, ArCONH), 5.29 (br q, 1H, C1-H), 2.94 (m, 1H,C3-H), 2.81 (m, 1H, C3-H'), 2.41 (m, 1H, C2-H), 1.89 (s, 3H, Me), 1.77(m, 1H, C2-H') ppm. MS: 437 (MMH⁺, 10), 236 (MNH⁺ ₄, 100), 219 (MH⁺,10). IR (KBr): 1654, 1554, 1409 cm⁻¹.

EXAMPLE 63 (rac)-6-Ethoxycarbonyl-N-acetyl-1-aminoindan

(rac)-6-Cyano-N-acetyl-1-aminoindan (Ex. 61, 2.575 g, 0.013 mole) wassuspended in ethanol (10 ml) and a mixture of 98% sulfuric acid (4 ml)and ethanol (4 ml) was added. The mixture was stirred (internal temp.80° C.) overnight and poured into ice water (120 ml) with stirring. Thethick grey slurry was filtered and the grey solid filtered off, washedthoroughly with water and dried in vacuo at 50° C. The crude product wascrystallized from EtOAc, then from HOAc/water and dried, to give 1.5 g(6.1 mmole, 47%), mp: 146°-7° C.

Anal. calc. for C₁₄ H₁₇ NO₃ : C, 67.99; H, 6.93; N, 5.67 Found: C,67.78; H, 6.97; N, 5.78. ¹ H NMR δ (CDCl₃): 7.94 (m, 2, C5-H, C7-H),7.29 (d, 1H, C4-H), 5.69 (br d, 1H, NHCO), 5.51 (q, 1H, C1-H), 4.37 (dq,2H, Et), 3.01 (m, 1H, C3-H), 2.89 (m, 1H, C3-H'), 2.66 (m, 1H, C2-H),2.05 (s, 3H, Me), 1.83 (m, 1H, C2-H'), 1.40 (t, 3H, Et) ppm. MS: 248(MH⁺, 100), 247 (M⁺, 25), 189 (MH⁺ -MeCONH₂, 50) 188 (M⁺ -MeCONH₂, 70),202 (MH⁺ -EtOH, 25), 201 (M⁺ -EtOH, 10). IR (KBr): 1711 (ester), 1634,1558 (amide) cm⁻¹.

EXAMPLE 64 (cis)-3-(Methoxycarbonyl)-1-aminoindan.HCl

The title compound was prepared in 70% from phenylsuccinic anhydride,according to the procedure described in J.Med.Chem., 31, 433 (1988), mp:216°-7° C.

Anal. calc. for C₁₁ H₁₄ ClNO₂ : C, 58.02; H, 6.15; N, 6.15; Cl, 15.60Found: C, 57.82; H, 6.20; N, 6.27; Cl, 15.68 ¹ H NMR δ (DMSO): 8.80 (brs, 3H, NH₃ ⁺), 7.75, 7.40 (m, 4H, Ph), 4.70 (t, 1H, C1-H), 4.18 (t, 1H,C3-H), 3.74 (s, 3H, Me), 2.78 (m, 1H, C2-H), 2.26 (m, 1H, C2-H') ppm.MS: 192 (MH⁺, 63), 175 (100), 160 (82), 143 (27), 131 (74), 115 (59). IR(KBr): 3000-2700, 2024, 1744, 1616, 1381, 1289, 1179, 772 cm⁻¹.

EXAMPLE 65 (cis)-1-Aminoindan-3-carboxylic acid.HCl

The title compound was prepared in 86% from(cis)-3-(methoxycarbonyl)-1-aminoindan.HCl, according to the proceduredescribed in J.Med.Chem., 31, 433 (1988), mp: 217°-8° C.

Anal. calc. for C₁₀ H₁₂ ClNO₂ : C, 56.21; H, 5.62; N, 6.56;, Cl, 16.53Found: C, 56.05; H, 5.79; N, 6.80; Cl, 16.71. ¹ H NMR δ (DMSO): 8.76 (brs, 3H, NH₃ ⁺), 7.73, 7.54-7.30 (m, 4H, Ph), 4.67 (br t, 1H, C1-H), 4.06(t, 1H, C3-H), 2.73 (m, 1H, C2-H), 2.25 (m, 1H, C2-H') ppm. MS: 178(MH⁺, 100), 160 (MH⁺ -H₂ O, 80), 130 (61), 115 (42). IR (KBr):3150-2700, 1963, 1732, 1711, 1481, 1397, 1366, 1188, 875, 773, 752 cm⁻¹.

EXAMPLE 66 (rac),(trans)-2-Methyl-N-acetyl-1-aminoindan

The title compound was prepared in 59% yield from(rac),(trans)-2-methyl-1-aminoindan (Ex. 40, 3.0 g) according to theprocedure described in Ex. 17, mp: 137° C.

Anal. calc. for C₁₂ H₁₅ NO: C, 76.16; H, 7.99; N, 7.40. Found: C, 76.14;H, 8.14; N, 7.49. ¹ H NMR δ (CDCl₃): 7.24 (m, 4H, Ph), 5.64 (br d, 1H,CONH), 5.45 (m, 1H, C1-H), 3.04 (dd, 1H, C3-H), 2.79 (m, 1H, C2-H), 2.59(dd, 1H, C3-H'), 0.97 (d, 3H, Me) ppm. MS: 190 (MH⁺, 45), 146 (MH⁺ -CH₃COH, 11), 130 (M+--CH₃ CONH₂, 100 ). IR (KBr): 3300, 2939, 1646, 1547,1370, 745 cm⁻¹.

EXAMPLE 67 (rac),(cis)-2-Methyl-N-acetyl-1-aminoindan

To a solution of Ac₂ O (1.45 g, 14.2 mmole) in toluene (12 ml), wasadded dropwise a solution of (rac), (cis)-2-methyl-1-aminoindan (Ex. 39,1.85 g, 12.6 mmole). The mixture was heated at 90° C. for 15 min, cooledto 70° C., and a solution of 1.1 g KOH in 8.3 ml water was added. Thereaction mixture was stirred at ambient temperature for 2 hrs; the solidwas collected by filtration, washed with toluene (10 ml), dried andcrystallized from hexane:EtOAc, to give 1.85 g (9.8 mmole, 78%), mp:146°-7° C.

Anal. calc. for C₁₂ H₁₅ NO: C, 76.16; H, 7.99; N, 7.40 Found: C, 76.16;H, 7.80; N, 7.45. ¹ H NMR δ (CDCl₃): 7.24 (m, 4H, Ph), 5.70 (br d, 1H,CONH), 5.15 (t, 1H, C1-H), 3.10 (dd, 1H, C3-H), 2.57 (dd, 1H, C3-H'),2.22 (m, 1H, C2-H), 2.10 (s, 3H, Ac), 1.30 (d, 3H, Me) ppm. MS: 190(MH⁺, 7), 131 (48, 130 (100).

EXAMPLE 68 (R)-N-Trifluoroacetyl-1-aminoindan

The title compound was prepared in 67% yield from (R)-1-aminoindan (3.35g, 25.2 mmole) and trifluoroacetic anhydride (5.75 g, 27.4 mmole), asdescribed in Ex. 67; mp: 152°-3° C.

Anal. calc. for C₁₁ H₁₀ NO: C, Found: ¹ H NMR δ (CDCl): 7.28 (m, 4H,Ph), 6.50 (br s, 1H, CONH) 5.49 (q, 1H, C1-H), 3.05, 2.94 (m, 2H, C3-H,H'), 2.65 (m, 1H, C2-H), 1.92 (m, 1H, C2-H') ppm. MS: 230 (MH⁺, 0.3),229 (M⁺, 0.4), 228 (6), 117 (72), 116 (100).

EXAMPLE 69 (rac)-N-(4-(di-n-ProPylsulfamoyl)benzoyl)-1-aminoindan

The title compound was prepared in 63% yield from (rac)-1-aminoindan(10.0 g, 75.2 mmole) and 4-(di-n-propylsulfamoyl) benzoyl chloride (16.3g, 53.6 mmole, prepared from probenecid and SOCl₂) via a procedureanalogous to that described in Ex. 46, followed by crystallization fromhexane:EtOAc, mp: 124°-5° C.

Anal. calc. for C₂₂ H₂₈ N₂ O₃ S: C, 65.97; H, 7.05; N, 7.0; S, 8.0Found: C, 65.70; H, 6.91; N, 7.03; S, 7.70. ¹ H NMR δ (CDCl₃): 7.94-7.80(m, 4H, Ph), 7.35 (m, 1H, Ph) 7.32-7.20 (m, 3H, Ph), 6.44 (br d, 1H,CONH), 5.69 (q, 1H, C1-H), 3.08 (m, 4H, CH₃ CH₂ CH₂ N), 3.06 (m, 1H,C3-H), 2.95 (m, 1H, C3-H'), 2.71 (m, 1H, C2-H), 1.96 (m, 1H, C2-H'),1.54 (m, 4H, CH₃ CH₂ CH₂ N), 0.86 (t, 6H, Me)ppm. MS: 401 (MH⁺, 100),371 (39), 285 (56), 236 (9).

EXAMPLE 70 2-(1-Indanamino)-N-isopropylethanesulphonamide.HCl

2-Chloroethanesulphonyl chloride (8.15 g, 50 mmoles) in ether (60 ml)was cooled to -2° C., stirred mechanically and treated dropwise withisopropylamine (12.75 ml, 150 mmoles) in ether (40 ml). After completeaddition (15 min) the mixture was allowed to stir at -2° C. for 30 min.and allowed to warm to 20° C. 1-Indanamine (6.71 g 50 mmoles) in ether(20 ml) was added dropwise followed by stirring for one hour. Themixture was filtered and the solid isopropylamine hydrochloride washedthoroughly with ether. The combined filtrates were evaporated to drynessand the residue (11.3 g) was chromatographed on silica gel (257 g) usingethyl acetate/hexane 4:1 v/v. The fractions immediately following theyellow band were evaporated to give the base (2.85 g). The base wasdissolved in isopropanol (20 ml) and converted to the HCl salt with 24%isopropanolic HCl (16 ml). The combined solution was then treated slowlywith ether (ca 40 ml) and the solid was filtered, washed with coldethanol/ether and finally ether. It was dried in vacuo at 50° C. andleft in vacuo for several days (3.0 g, 9.4 mmole, 19%). Melting point177.2°-177.8° C.

Anal. calc. for C₁₄ H₂₃ ClN₂ O₂ S: C, 52.73; H, 7.27; N, 8.78, Cl,11.12; S, 10.06. Found: C, 52.52; H, 7.35; N, 8.84; S, 10.88: Cl, 10.88.¹ H NMR δ (DMSO): 9.70 (br, 2H), 7.75 (d, 1H), 7.45 (d, 1H), 7.28-7.41(m, 3H), 4.83 (brt 1H), 3.31-3.62 (m, 3H), 3.10-3.30 (m, 3H), 2.89 (m,1H), 2.43 (m, 1H), 2.22 (m, 1H), 1.13 (d,6H)ppm MS: 566 (2MH, 40), 283(MH, 100), 132 (20), 117 (15). IR (KBr): 3128, 2976, 2824. 1322, 1121cm⁻¹.

EXAMPLE 71 2-(1-Indanamino)-N-(1-indanyl)ethanesulphonamide.HCl

2-Chloroethanesulphonyl chloride (2.1 g, 20 mmoles) in ether (10 ml) wascooled to 10° C. and while stirred mechanically, treated dropwise with1-indanamine (10.2 ml, 80 mmoles) in ether (40 ml). After the addition,the mixture was stirred at RT for 2.5 hours. It was then filtered, thewhite solid (indanamine hydrochloride) washed thoroughly with ether andthe combined filtrates evaporated to a thick yellow oil. Purification bychromatography (EtOAc:hexane 2:1) afforded the free base which was takenup in ether (20 ml) and treated carefully with a 24% solution of HCl inisopropanol (ca 3 ml). The sticky mass gradually broke up on triturationin ether, filtered to give a white solid (3.06 g) crystallized fromEtOH/Et2O and dried, (1.31 g, 3.3 mmole, 17%).

Melting point 186°-187° C. Anal. calc. for C₂₀ H₂₅ ClN₂ O₂ S: C, 61.13;H, 6.41; N, 7.13; S, 8.16: Cl, 9.02:: Found: C, 60.83; H, 6.51; N, 7.28.¹ H NMR δ (DMSO): 9.82 (br s, 2H), 8.01 (d, 1H), 7.78 (d, 1H), 7.2-7.4(m, 8H), 4.79 (q, 1H), 4.84 (br s, 1H), 3.68 (m, 2H), 3.32 (m, 2H), 3.17(m, 1H), 2.77,2.92 (m, 3H), 2.56,2.46 (m), 2.25 (m, 1H), 1.88 (m,1H)ppm. MS: 357 (MH, 100), 132 (98), 117 (18). IR (KBr): 3074, 2940,1446, 1327, 1148 cm⁻¹.

EXAMPLE 72 (R,R)-2-(1-Indanamino)-N-(1-indanyl) ethanesulphonamide.HCl

The free base (2.8 g) was obtained by the same procedure as in Example71 using (R)-1-aminoindan (10.66 g, 80 mmole). It was triturated withhexane and the resultant solid recrystallized from ethanol (15 ml), togive a white crystalline solid (1.185 g). The free base was thendissolve in warm abs. ethanol (32 ml) and 0.1N HCl(33.5 ml, 3.31 mmole)was added. The solution was evaporated in vacuo at 55° C.(bath). It wasevaporated again with ethanol, the residual white foam dissolved in warmethanol (10 ml) and diluted with ether (20 ml). The solid was collectedby filtration, washed with alcohol/ether and ether, and dried to give1.15 g (2.9 mmole, 8%) of title compound.

Melting point 172°-173° C. Anal. calc. for C₂₀ H₂₅ ClN₂ O₂ S: C, 61.13;H, 6.41; N, 7.13: S, 8.16: Cl, 9.02: Found: C, 60.14; H, 6.40; N, 7.13,S, 8.16; Cl, 8.39. ¹ H NMR δ (DMSO): 9.76 (br s, 2H), 8.01 (1H), 7.7(1H) 7.19-7.41 (m, 6H), 4.80 (q, 1H), 4.86 (br m, 1H), 3.68 (m, 2H),3.3,3.17 (m, 1H), 2.76 (quint) and 2.92 (m, 3H), 2.55 (m, 1H), 2.44 (m1H), 2.22 (m, 1H), 1.88 (m, 1H)ppm. MS: 357 (100), 241 (40), 159 (10),132 (20). IR (KBr): 3167, 2940, 2719, 1458, 1336, 1144 cm⁻¹.

EXAMPLE 73 N,N'-Bis-(1-indanyl)adipamide

Racemic 1-aminoindan (5.7 g, 43 mmole) in ether (20 ml) stirred in ice,was treated dropwise with adipoyl chloride (1.83 g, lommole) in ether(10 ml). After 30 min. the solid was filtered and slurried with waterfor 45 min. The insoluble solid was collected, air dried (2.82 g) andcrystallized from HOAc/H₂ O, washed with acetic acid/water (1:1),ethanol and ether and then dried to give 2.26 g (60% title compound.

Melting point: 227° C. Anal. calc. for C₂₄ H₂₈ N₂ O₂ : C, 76.56; H,7.50; N, 7.44. Found: C, 76.35; H, 7.69; N, 7.61. ¹ H NMR δ (DMSO): 8.17(d, 1H, NH), 7.14-7.26 (m, 4H, Ar), 5.28 (q, 1H, C1-H), 2.91,2.78 (m,m,2H, C3-H₂), 2.37 (m, 1H, C2-H), 2.14 (br, 2H, α-CH₂), 1.76 (m, 1H,C2-H), 1.56 (br, 2H, β-CH₂)ppm. IR (KBr): 3288, 2936, 1638, 1539, 1256,749 cm⁻¹.

EXAMPLE 74 N,N'-Bis-((R)-1-indanyl)adipamide

This was prepared by the same procedure as in Example 73 starting from(R)-1-aminoindan (5.32 g, 40 mmole), with an additionalrecrystallization from ethanol (20 ml) and acetic acid (15 ml) to givethe white product (2.37 g, 62.9%). Melting point: 244°-7° C.

Anal. calc. for C₂₄ H₂₈ N₂ O₂ : C, 76.56; H, 7.50; N, 7.44. Found: C,76.28; H, 7.59; N, 7.74. ¹ H NMR δ (DMSO): 8.16 (d, 1H, NH), 7.10-7.30(m, 4H, Ar), 5.28 (q, 1H, C1-H), 2.92,2.78 (m,m, 2H, C3-H₂), 2.36 (m,1H, C2-H), 2.14 (br, 2H, α-CH₂), 1.76 (m, 1H, C2-H), 1.56 (br, 2H,β-CH₂)ppm. MS: 377(MH⁺, 25), 253 (45), 132 (100). IR (KBr): 3289, 2959,1642, 1541, 1254, 745 cm⁻¹.

EXAMPLE 75 N,N'-Bis-((R)-1-indanyl)succinamide

This was prepared by the same procedure as in Example 73 starting from(R)-1-aminoindan (8.02 g, 60 mmole) and succinoyl chloride (2.32 g, 14mmole), to give the white product, (1.30 g, 26.7%). Melting point:266°-9° C.

Anal. calc. for C₂₂ H₂₄ N₂ O₂ : C, 75.83; H, 6.94; N, 8.09. Found: C,74.50; H, 7.03; N, 8.16. ¹ H NMR δ (DMSO): 8.22 (d, 1H, NH), 7.10-7.26(m, 4H, Ar), 5.29 (q, 1H, C1-H), 2.92 (ddd, 2H, C3-H), 2.78 (m, 1H,C3-H), 2.30-2.46 (m, 1H, C2-H and α-CH₂), 1.77 (m, 1H, C2-H)ppm. MS:349(MH⁺, 78), 233 (25), 216 (5), 132 (100).

Examples 76 to 82 exemplify the preparation of compounds of Formulas 2and 3.

EXAMPLE 76 Racemic N-benzyl-1-aminoindan base

Approximately 22.1 g of HCl gas was introduced into indene (technicalgrade 90%, 80 g, 0.62 mole) at 25°-3° C. over a period of 4 hours andexcess HCl gas was removed under vacuo.

A mixture of 272 ml of toluene and 199.5 g benzylamine was prepared andheated to 90° C. The chlorindan was added dropwise to the mixture over a30 minute period. The reaction mixture was heated to 115° C. for tenhours. The reaction mixture was cooled to ambient temperature and 300 mlof water was added. The resulting heterogeneous mixture was then broughtto pH2.2 by the addition of 33% H₂ SO₄. The phases were separated andthe organic layer discarded. The pH of the aqueous layer was adjusted topH6.0 prior to extraction with 300 ml of toluene. A further 100 ml oftoluene was then added and the aqueous phase discarded. The toluene wasremoved under vacuo from the combined organic layer leaving 104.3 gracemic N-benzyl-1-aminoindan base as an oil (72.5% yield).

¹ H-NMR (δ , CDCl₃): 1.82-1.94 (m,1H), 2.36-2.48 (m,1H), 2.73-2.86(m,1H), 2.96-3.70 (m,1H), 3.75-4.30 (m,2H), 4.30 (t,J=3 HZ,1H),7.16-7.44 (aromatic,9H)ppm M.S. (CI,CH₄)MH⁺ 224.0

EXAMPLE 77 R-(+)-N-benzyl-1-aminoindan-L-mandelate mono ethanoate

To a solution of racemic N-benzyl-1-aminoindan base (61.6 g, 0.276 mole)in absolute ethanol (208 ml) at 50° C., a solution of L-(+)-mandelicacid (22.2 g, 0.146 mole) in absolute ethanol (100 ml) was addeddropwise. The reaction mixture was heated to 75° C. whereupon completedissolution had occurred, and then cooled slowly to 10° C. over a 3 hourperiod. The crystals formed were collected by filtration andrecrystallized in 260 ml absolute ethanol by repeating the heating andcooling steps. The crystals were collected by suction filtration anddried in a vacuum oven at 40°-50° C. producing an 46.5 g of the titlecompound (40% yield).

m.p. 94°-97° C. α!D22 =+38.9° (1.86% acetone) ¹ H-NMR (δ, aceton d₆):1.11 (t,J=6 Hz,3Hethanol) 2.10-2.30 (m,2H), 2.66-2.80 (m,1H), 2.97-3.08(m,1H) 3.55 (q,J=6 Hz,2Hethanol), 3.89 (s,2H), 4.42-4.46 (m,1H), 4.75(s,1H), 7.04-7.50 (aromatic,14H)ppm M.S. (CI, NH₃) MH⁺ 224.1

EXAMPLE 78 S-(-)-N-benzyl-1-aminoindan-L-mandelate mono ethanolate

The title compound is prepared by the same process of Example 77, withthe exception that D-(-)-mandelic acid was used as the resolving agent.Similar yields were obtained.

melting point 92°-94° C. α!D22 =-40.10 (1.71% aceton) ¹ H-NMR (δ, acetond₆) 1.11 (t,J=6 Hz,3Hethanol) 2.10-2.20 (m,1H), 2.20-2.34 (m,1H),2.68-2.82 (m,1H), 2.96-3.09 (m,1H), 3.56 (q,J=6 Hz,2Hethanol), 3.94(s,2H), 4.43-4.48 (m,1H), 4.79 (s,1H)ppm.

EXAMPLE 79 R-(+)-N-benzyl-1-aminoindan (base)

R-(+)-N-benzyl-1-aminoindan-L-mandelate mono ethanolate (57.7 g),prepared as in Example 77, was suspended in a mixture of 70 ml water and75 ml toluene. The mixture was stirred vigorously and adjusted topH₁₃₋₁₄ by the addition of 40% NaOH solution. The extraction wasrepeated with further 50 ml of toluene. The toluene was removed in vacuofrom the combined organic layers to provide the title compound as acolorless oil (99.5% yield).

α!D22 =+3.7° (10.9%, methanol)

EXAMPLE 80 S-(-)-N-benzyl-1-aminoindan (base)

The title compound was prepared by the process of Example 79, exceptthat S-(31 )-N-benzyl-1-aminoindan-D-mandelate mono ethanolate was usedas the starting material.

α!D22 =-4.0° (10.9%, methanol)

EXAMPLE 81 R-(-)-1-aminoindan

(R)-N-benzyl-1-aminoindan (5.73 g, 26.8 mmole), as prepared in Example79, was dissolved in 60 ml absolute ethanol and ethanolic HCl solution19% w/w (6.2 g, 32.1 mmole, 1.2 equivalents) was added to this solution.The mixture was reduced using hydrogen gas in the presence of a 5% Pd/Ccatalyst (0.45 g, 3% on a dry basis) at 75° C. and 3 atm. hydrogenpressure for a period of 7 hours. The volatiles were removed byevaporation in vacuo. The solid material was partitioned between 50 mlwater and 30 ml toluene. The pH of the aqueous phase was adjusted topH2.3 by adding 10% NaOH solution and the phases were then separated.Toluene (50 ml) was added to the aqueous phase and the pH increased to12.5 with 45% NaOH. The organic phase was separated and the aqueousphase re-extracted with 30 ml toluene. The combined toluene phases wereevaporated in vacuo and the crude compound purified by distillation, (20mmHg/117.5°-119° C.) to give 2.57 g R-(-)-1-aminoindan (72% yield).Optical purity 99.4% by chiral chromatography.

EXAMPLE 82 S-(+)-1-aminoindan

The title compound was prepared by the process of Example 81, exceptthat (S)-N-benzyl-1-aminoindan was used as the starting material.

B. EXPERIMENTAL EXAMPLES

EXAMPLE 1 EFFECT OF 1-AMINOINDANS IN AN EXPERIMENTAL MODEL OFDOPAMINERGIC HYPOFUNCTION

Experiments 1A and 1B. Alpha-MpT- induced hypokinesia in hypoxic rat

Procedure

Experiment 1A. Wistar male rats, 15-19 month-old, were exposed to asingle hypoxic episode which is assumed to decrease the level ofdopamine in the brain. Four to five rats were kept for six hours in aglass chamber equipped with an inlet and outlet tubes for the admissionof an atmosphere of premixed nitrogen (92%) and oxygen (8%) at a flowrate of 3 L/min. Control rats received room air from a compressed tankunder similar conditions. 1-R-aminoindan HCl (hereinafter R-AI) ordeprenyl (an MAO B inhibitor) were administered to the rats immediatelyfollowing the conclusion of the hypoxic episode at the standard dose of0.5 mg/kg/Day for 70-80 days. Given the different ratios of amine tosalt in these compounds, the dose of free amine (the active species)corresponding to 0.5 mg/kg salt is actually 0.39 mg/kg for R-AI and 0.42mg/kg for deprenyl. The drugs were administered by gavage, using aspecial syringe equipped with rounded tip that could be directed intothe stomach. The dose was contained in 0.3-0.5 mL of distilled water.

The rats were pretreated for 70-80 days with daily doses of the testdrugs and received intra-peritoneal (i.p.) α-MpT (α-methyl-p-tyrosine)at a dose of 100 mg/kg in 0.3-0.5 mL saline. Controls received saline.α-MpT is assumed to inhibit the formation of L-Dopa from tyrosine and,consequently the formation of dopamine itself. Lack of central dopamineis expressed as hypokinesia. Following the injection of α-MpT, motoractivity was recorded for the duration of 10 hours. Locomotion scoreswere taken in seven fully-computerized cages (26×25 cm) having a grid ofinfra-red beams at 4 cm-intervals.

Crossing of a beam initiated an electric signal which was fed into acomputer. The number of crossings over a given period provided a measureof locomotion. The records gave two data categories: (a) "smallmovements" originating in stationary activities such as grooming andscratching and (b) "big movements" originating in ambulation andrecorded as the simultaneous crossing of more than two beams. "Totalmovements" include both categories.

Counts of motor activity in the presence of α-MpT were related aspercent with respect to counts in its absence in the correspondingcontrol group (unlesioned or hypoxia-lesioned). Motor activity counts ofdrug-treated rats were related to the hypoxia saline-treated as 100%.All behavioral tests were performed 90-120 min. after administration ofthe last dose of the test compound.

Results

Experiment 1A.

"Total movements" after α-MpT are given in Table 1 and FIGS. 1 and 2. InFIGS. 1 and 2, hours after alpha-methyl-p-tyrosine injection are givenon the x-axis and percent response as compared to the relevant controlis given on the y-axis. FIG. 1 shows the effect the hypoxic episode hadas compared to the control animals, whereas FIG. 2 shows the effect thedrug treated group compared to the untreated hypoxic group.

                  TABLE 1    ______________________________________    Locomotor activity after α-MpT treatment,    recorded as total movements.                                Hypoxia +                                       Hypoxia +    Hour    Control  Hypoxia    R-AI   deprenyl    ______________________________________    1        77 ± 11                     39 ± 12 67 ± 8                                        88 ± 23    2        92 ± 20                     36 ± 8   79 ± 12                                       131 ± 30    3       115 ± 44                     61 ± 15 198 ± 60                                       141 ± 26    4       186 ± 44                     105 ± 42                                196 ± 17                                       191 ± 45    5       168 ± 46                     60 ± 28 138 ± 19                                       229 ± 40    6        61 ± 23                     32 ± 15  77 ± 17                                        82 ± 14    7        84 ± 22                     32 ± 19 173 ± 30                                       204 ± 7    8       114 ± 23                     29 ± 15 104 ± 18                                       131 ± 23    9       114 ± 40                     43 ± 17  95 ± 16                                       137 ± 21    10      103 ± 31                     29 ± 15 114 ± 41                                       116 ± 22    ______________________________________

Control rats underwent two phases of hypokinesia. The first at hour 1-2after α-MpT followed by full recovery and rebound at hour 3. Then,another phase of hypokinesia at hours 6-7 followed by full recovery tocontrol level at hours 7-8.

In the hypoxic group, the decrease in motor activity was more pronouncedduring the first phase at hours 1-2, with some recovery at hour 4,followed by a second phase of hypokinesia which lasted till hour 10 withno signs of recovery.

Hypoxic rats that had been pretreated with R-AI or deprenyl behavedsimilarly (FIG. 2). In either case the two-phase cyclic pattern ofdepression-rebound-depression found for α-MpT-treated hypoxic controlscould be observed. However, the level of activity of the R-AI anddeprenyl-treated groups was much higher than the corresponding controlgroup controls. In fact, in either case the levels and fluctuations ofmotor activity were not different from hypoxia-unlesioned control ratsthat had received α-MpT alone.

The score of "big movements" is given in Table 2 and FIGS. 3 and 4, theFigures having the same axes as FIGS. 1 and 2.

                  TABLE 2    ______________________________________    Locomotor activity after α-MpT treatment,    recorded as big movements.                                 Hypoxia +                                        Hypoxia ±    Hour    Control   Hypoxia    R-AI   deprenyl    ______________________________________    1        85 ± 25                      43 ± 11 109 ± 27                                        61 ± 15    2       187 ± 56                      48 ± 18 125 ± 29                                        103 ± 22    3       195 ± 94                      69 ± 34 151 ± 36                                        184 ± 39    4       119 ± 71                      67 ± 40 165 ± 40                                        85 ± 34    5       224 ± 93                      71 ± 43 254 ± 55                                        171 ± 61    6       107 ± 64                      50 ± 24 201 ± 50                                        65 ± 17    7       123 ± 37                      39 ± 20 201 ± 50                                        96 ± 29    8       113 ± 46                      26 ± 15  89 ± 23                                        91 ± 40    9       220 ± 72                      45 ± 18 121 ± 52                                        84 ± 23    10       269 ± 106                      25 ± 10 190 ± 34                                        29 ± 10    ______________________________________     N = 7-10 in a group.     Results are given as Mean ± SEM.

α-MpT produced a paradoxical effect in control rats, with outbursts ofhyperkinesia which lasted for as long as ten hours after an initialsmall decrease in activity which may not be significant.

In contradistinction, hypoxia-lesioned rats were hypokinetic for as longas ten hours with no signs of recovery. R-AI corrected the hypokineticsyndrome in the hypoxia group, bringing the level of activity almost tothat seen in the control hypoxia-unlesioned group. There were at leastthree outbursts of hyperactivity during he ten hour-observation period.Deprenyl was less effective in this respect, with outbursts ofhyperactivity alternating with periods of depression.

Experiment 1B. The procedure of Experiment 1A was repeated with thefollowing changes:

(1) Animal: 11-14 month-old rats.

(2) Drug treatment: R-AI and deprenyl at a daily dose of 0.3 mg/Kg in0.2 mL. The drugs were given i.p.

(3) Duration of the treatment: 21 days.

(4) Dose of α-MpT: 70 mg/Kg.

Results

Experiment 1B

Total movements after α-MpT are given in Table 3 and FIG. 5. The scoreof big movements is given in Table 4 and FIG. 6. In FIGS. 5 and 6 hoursafter alpha-methyl-p-tyrosine injection are given on the x-axis andpercent response as compared to the relevant control is given on they-axis. FIG. 5 shows the fate of the groups treated with R-AI ordeprenyl as compared to the hypoxic group over the first four hours,with respect to total movements. FIG. 6 shows the same data with respectto big movements. Antagonism to α-MpT by R-AI and deprenyl is bestperceived within the 2-4 hours after the α-MpT injection as shown inFIGS. 5 and 6. Note that in the first hour the level of motor activity(total movements) of R-AI treated rats was almost normal (80%), but notin the hypoxic group (50%). None of the drugs was active at the secondphase of hypokinesia, except deprenyl which showed some activity.

                  TABLE 3    ______________________________________    Locomotor activity after α-MpT treatment,    recorded as total movements.                                Hypoxia +                                       Hypoxia +    Hour    Control  Hypoxia    R-AI   deprenyl    ______________________________________    1       69 ± 7                     52 ± 10 80 ± 15                                       68 ± 9    2       90 ± 13                     119 ± 12                                87 ± 13                                       95 ± 11    3       117 ± 35                     93 ± 24 132 ± 25                                       126 ± 22    4       93 ± 24                     104 ± 8 115 ± 24                                       118 ± 20    5       92 ± 12                     80 ± 14 65 ± 28                                       83 ± 24    6       65 ± 14                     72 ± 6  76 ± 11                                       78 ± 9    7       71 ± 15                     84 ± 7  65 ± 7                                       56 ± 7    8       75 ± 16                     69 ± 8  40 ± 6                                       85 ± 13    9       79 ± 0                     66 ± 11 72 ± 12                                       111 ± 12    10      86 ± 4                     69 ± 6  69 ± 18                                       61 ± 12    ______________________________________

                  TABLE 4    ______________________________________    Locomotor activity after α-MpT treatment,    recorded as big movements.                                Hypoxia +                                       Hypoxia ±    Hour    Control  Hypoxia    R-AI   deprenyl    ______________________________________    1       75 ± 6                     51 ± 10 96 ± 18                                       70 ± 10    2       55 ± 14                     124 ± 20                                97 ± 16                                       91 ± 19    3       114 ± 42                     83 ± 28 117 ± 45                                       85 ± 19    4       51 ± 16                     95 ± 16 91 ± 11                                       88 ± 23    5       60 ± 18                     52 ± 7  67 ± 11                                       87 ± 11    6       49 ± 21                     60 ± 8  58 ± 14                                       67 ± 8    7       66 ± 14                     69 ± 10 68 ± 15                                       62 ± 9    8       63 ± 16                     77 ± 10 34 ± 6                                       70 ± 9    9       55 ± 19                     90 ± 11 84 ± 19                                       132 ± 24    10      56 ± 13                     63 ± 6  44 ± 6                                       54 ± 13    ______________________________________     N = 4-7 in a group.     Results are given as Mean ± SEM.

Discussion of Experiments 1A and 1B

Experiment 1A demonstrates the ability of R-AI to correct a syndrome ofdopaminergic hypofunction associated with Parkinson's Disease to anextent at least comparable, or in some instances better than that ofdeprenyl. This effect was also evident in the first 2-4 hours ofExperiment 1B. This experiment was carried out over a shorter periodthan Experiment 1A, using a lower dosage of R-AI on a separatepopulation of animals Both these experiments indicate that 1-aminoindansof formula 1 have a role in the treatment of Parkinson's Disease.

Experiment 1C. The procedure of Experiment 1A was repeated with thefollowing changes:

(1) Animal: 11-14 month-old rats.

(2) Drug treatment: Test compounds were administered at the dosagesindicated, as a single i.p. dose 1 hour prior to α-MpT (150 mg/kg).

(3) Animals were placed in an activity cage immediately after drugadministration and total movements were measured for the following 10hours.

The drugs tested with reference to the relevant Chemical Example Nowere:

(R)-1-aminoindan, (RAI), 0.8 mg/kg, n=5

4,5-dimethoxy-1-aminoindan, (31), 0.8 mg/kg, n=6

6-fluoro-(R)-1-aminoindan, (FAI), 1.2 mg/kg, n=3

(R)-N-acetyl-1-aminoindan, (18), 0.8 mg/kg, n=2

(R)-6-hydroxy-1-aminoindan, (35), 1.2 mg/kg, n=3

The results are shown in FIG. 8 from which it can be seen that allcompounds tested antagonized the α-Mpt-induced hypokinesia.

EXAMPLE 2 EFFECT OF 1-AMINOINDANS ON AMPHETAMINE-INDUCED STEREOTYPEBEHAVIOR IN HYPOXIC RAT

Procedure

Experiment 2A. Wistar male rats, 15-19 month-old, were exposed to asingle hypoxic episode as described above. R-AI or deprenyl wereadministered to the rats at the same dose and method used in Example 1A.Rats pretreated for 29 days with daily doses of the test drugs (0.5mg/kg), received a sub-cutaneous (s.c.) injection of D-amphetaminesulfate at a dose of 0.5 mg/kg.

D-amphetamine is known to cause an enhancement of the effects of CNSdopamine by a mechanism involving dopamine release, and blockage of itsuptake and its metabolism by MAO. The behavioral manifestation ofamphetamine action is a stereotypic pattern of lateral head movements.Counts of lateral head movements were taken over two successiveintervals of 1 min each, 45-60 min after the injection of amphetamineand then averaged.

Experiment 2B. The procedure of the second Experiment 2B was similar tothe one used in Experiment 2A with the following changes:

1) Animals: 12 month-old rats.

2) Drug treatment: R-AI and deprenyl at a daily dose of 0.3 mg/kg in 0.2mL. The drugs were given by i.p. injection.

3) Duration of the treatment: 14 days.

Experiment 2C. The procedure of Experiment 2A was repeated with thefollowing changes:

1) None of the rats had previously been exposed to a hypoxic episode.

2) Test compounds were administered as a single treatment, at a dose of1.2 mg/kg (base equivalents) 60 minutes prior to D-amphetamine sulphate(0.6 mg/kg s.c.).

3) Scores of No of head movements were taken 45 minutes afteramphetamine injection.

The compounds tested were, referring to the relevant Chemical ExampleNo.:

(R)-N-acetyl-1-aminoindan (18),

(R)-4,5-dimethoxy-1-aminoindan (29),

(R)-1-aminoindan (R-AI),

(R)-6-hydroxy-1-aminoindan (35),

(R)-6-fluoro-1-aminoindan (R-FAI),

(S)-4,5-dimethoxy-1-aminoindan (30).

Results

The results of Experiment 2A are shown in Table 5. Table 5 shows thetotal number of lateral head movements per minute for each of theexperimental groups.

                  TABLE 5    ______________________________________    Control  Hypoxia      Hypoxia +                                   Hypoxia +    untreated             untreated    R-AI     deprenyl    ______________________________________    63 ± 4             84 ± 2**  108 ± 3**                                   76 ± 3*     n = 8   n = 8        n = 7    n = 6    ______________________________________     Mean ± SEM     *p ≦ 0.05     **p ≦ 0.001     (with respect to corresponding control)

In the hypoxic group, pretreatment with R-AI produced a significantpotentiation of the stereotypic behavior induced by amphetamine withrespect to their respective control (hypoxia and amphetamine). Under thesame conditions, deprenyl pretreatment did not potentiateamphetamine-induced stereotypicity. Drug-untreated hypoxic rats weremore active than drug-untreated control rats, owing perhaps to thedevelopment of dopamine hypersensitivity in response to presynapticdopamine deficiency.

The same test was repeated on day 60 of drug treatment in order to checkfor a possible tolerance to the test compounds that might have developedover time. The results were not different from those found on day 29. InExperiment 2B pretreatment with R-AI produced a significant potentiationof stereotypic behavior as measured by lateral head movements, but notdeprenyl. This is shown in Table 6.

                  TABLE 6    ______________________________________    Control  Hypoxia      Hypoxia +                                   Hypoxia +    untreated             untreated    R-AI     deprenyl    ______________________________________    63 ± 5             79 ± 3*   92 ± 3**                                   77 ± 3     n = 12   n = 12      n = 6     n = 7    ______________________________________     *p ≦ 0.05     **p ≦ 0.01

The results of Experiment 2C. are shown in FIG. 9 from which it can beseen that all compounds tested produced a potentiation of thestereotypic behavior induced by amphetamine.

Discussion of Experiments 2A and 2B

Stereotypic behavior is not caused by amphetamine itself, but by theenhancement of the effect of released dopamine through a combination ofeffects: release, uptake inhibition and MAO inhibition.

Both Experiments 2A and 2B have demonstrated that R-AI, unlike deprenyl,can greatly enhance the effect of amphetamine.

Since the effect of potentiation of stereotype behavior is assumed to bemediated by CNS dopamine, then pretreatment with R-AI must have beeninstrumental in the restoration of presynaptic dopamine levels after thehypoxic insult, thus further demonstrating that 1-aminoindans have arole in correcting the symptoms associated with Parkinson's Disease.

EXAMPLE 3 EXPERIMENTAL MODEL FOR COGNITIVE FUNCTION: PASSIVE AVOIDANCETEST IN HYPOXIC RAT

Procedure

Experiment 3A: Wistar male rats, 15-19 month-old, were exposed to asingle hypoxia episode as described above. R-AI or deprenyl wereadministered to the rats at the same dose and method used in the α-MpTmodel. The passive avoidance test was performed on day 13 afterinitiation the drug treatment. The apparatus consisted of a lit chamberthat can be separated from a dark chamber by a sliding door. Attraining, a rat is placed in the lit chamber for 30 seconds, then thedoor is opened. The rat moves to the dark chamber after a shortdelay--the latency, that is recorded. Upon entry into the dark chamber,the door is shut closed and a 0.3-mA footshock is delivered for 3seconds by a Grass S-88 stimulator. Retention of the experience isdetermined after 48 hours by repeating the test and recording thelatency to an arbitrary maximum of 300 seconds. Longer latencies areascribed to retention of memory and improved cognition.

Results

The latency, in seconds, is shown in Table 7. Pretreatment of thehypoxia rats with R-AI improved their performance to control level.Incontrast, deprenyl-treated hypoxic rats showed no improvement.

                  TABLE 7    ______________________________________    Group       before electroshock                              48 h after electroshock    ______________________________________    Control      75 ± 21   217 ± 34    Hypoxia     59 ± 6      143 ± 33*    Hypoxia + R-AI                53 ± 6      245 ± 33*    Hypoxia + deprenyl                53 ± 7     153 ± 37    ______________________________________     (1) Results are latency of response expressed in seconds as Mean ± SEM     (2) n = 11-13 rats in a group.     (3)*p ≦ 0.05 relative to corresponding control by the student's     ttest.

Experiment 3B: WATER MAZE WORKING MEMORY TEST

The apparatus used consists of a circular water tank 160 cm in diameterfilled with water to a depth of 38 cm. The water was made cloudy by theaddition of milk powder. A clear Plexiglass 15 cm platform, supported bya movable stand rest on the bottom of the tank was submerged to a depthof 2 cm from the water surface. Normally a swimming rat cannot perceivethe location of the platform but it may recall it from a previousexperience and training, unless it suffers from some memory impairment.The time taken to locate the platform is measured in seconds andreferred to as the latency. During the experiment all orientational cuessuch as ceiling lights etc. remained unchanged. Longer latencies areobserved with rats with some impairment to their memory.

As described above the rats were exposed to a hypoxic episode and R-AIwas administered to rats daily as described in Experiment 1A.

Each rat was given two trails a day for four days, entering the poolfrom the same point of entry each day. The position of the platform waschanged daily to one of four predetermined positions. Each rat wastested twice each day over the four days, referred to as runs 1 and 2 onsessions I-IV. Initially the rat was placed on the platform for 60seconds. It was then removed and placed at the point of entry andallowed a maximum of 120 seconds to locate the platform (run 1). Thesecond run for that day followed 60 seconds later (run 2). In the secondrun the rat is expected to find the platform much sooner, havingbenefitted from its earlier experience. Performance is assumed torepresent the rate of acquisition from the more recent experience, hencethis is termed working memory. The average latency of run 1 in foursessions on four different days was then related to the correspondingparameter of run 2. The smaller the ratio of run 1/run 2, the better theshort range learning score.

Results

The results are given in Table 8 and FIG. 7. Performance of the hypoxiagroup was inferior to that of the control group in sessions I-III, butdid not improve in session IV.

Among the R-AI-treated hypoxia group tended towards superior performanceto the hypoxia group. Table 8. Performance of hypoxia-lesioned rats inthe water maze-working memory test after pretreatment with1-R-aminoindan (AI) or deprenyl at the dose of 0.5 mg/kg/day for theduration of 60 days. The data are the latencies in seconds±SEM that ittook a given group to locate a submerged and invisible platform thelocation of which was shifted from one session to the other. The timeinterval between sessions was one day, and that between successive runswas 60 seconds. (n=7-8 rats per group)

                                      TABLE 8    __________________________________________________________________________    Session I     Session II                          Session III                                  Session IV         Run  Run Run Run Run Run Run Run    Group         1    2   1   2   1   2   1   2    __________________________________________________________________________    Control         43 ± 13              20 ± 8                  11 ± 2                      9 ± 2                           9 ± 2                              6 ± 1                                  11 ± 3                                      7 ± 1    Hypoxia         47 ± 19              50 ± 17                  31 ± 12                      20 ± 10                          29 ± 6                              10 ± 2                                   8 ± 2                                      15 ± 8    Hypoxia +         50 ± 16              25 ± 12                  25 ± 8                      14 ± 3                          19 ± 5                              14 ± 3                                  15 ± 5                                      6 ± 2    AI    Hypoxia +         42 ± 16              40 ± 17                  42 ± 18                      35 ± 16                          32 ± 15                              8 ± 2                                  19 ± 6                                      12 ± 4    deprenyl    __________________________________________________________________________

Discussion of Experiments 3A and 3B

In learning and memory tests, normal performance in the passiveavoidance response is generally related to unimpaired cholinergicfunction. For example, treatment with the potent muscarinic antagonistscopolamine results in amnesia in humans and an inferior performance inpassive avoidance in rats. Tacrine, a cholinesterase inhibitor, has beenreported recently to be of value in the restoration of memory in seniledementia patients of the Alzheimer type and kainic acid-lesioned rats.In addition, chronic administration of tacrine improved performance inthe passive avoidance test of anoxia-lesioned rats (see FIG. 7 inSpeiser et al.1989 Neuropharm. 28(12) 1325-1332).

These findings demonstrated that R-AI can correct a syndrome ofcognitive dysfunction and loss of memory which are prevalent indementia's such as senile dementia, Parkinson-type dementia and dementiaof the Alzheimer's type.

EXAMPLE 4 EFFECT OF AMINOINDANS ON NEUROTRAUMA

Experiment 4A. The effect of 1-aminoindans following closed head injuryin rats

Methods

1. Induction of trauma.

Head trauma was induced in male rats under ether anesthesia by a wellcalibrated drop weight device. The weight falls over the exposed skull,covering the left cerebral hemisphere, 1-2 mm lateral to the midline inthe midcoronal plane. A detailed description of this method is given inShohami et al. J. Neurotrauma 1993 10(2) 109.

2. Evaluation of motor function.

One hour after the induction of trauma the rats were tested by a set ofcriteria to evaluate their neurological status. These criteria arelisted in Shohami supra. as is the scoring method thereof which isreferred to as the Neurological Severity Status (NSS). Points are givenbased on the absence of these criteria, thus a high NSS indicates ahighly traumatized rat whereas a low NSS indicates a non-traumatizedrat. Consequently a high ANSS indicates that a good recovery hasoccurred. The rats were re-evaluated 24 hours after the induction oftrauma.

3. Evaluation of brain oedema.

After the second evaluation of motor function, the animals weresacrificed and the brains were removed. A piece of tissue was weighed toyield a wet weight (WW), then dried in an oven for 24 hours at 95° C.and re-weighed to yield a dry weight(DW). Percentage water content inthe tissue was calculated as (WW-DW)×100/WW.

4. Drug treatment.

1-R-aminoindan (RAI) was dissolved in water and injected into the ratsby an intra-peritoneal route at a dose of 0.1 mg/kg at 0,4,8, and 12hours post-trauma. The control group received similar volumes of waterat the same times.

Results.

Table 9 below shows the NSS scores taken 1 hour and 24 hourspost-trauma. ANSS is the change in NSS over that time.

                  TABLE 9    ______________________________________           NSS                     % water in           1 hr 24 hr    ΔNSS                                   the brain    ______________________________________    Control  16.6   12.3     4.3 ± 0.5                                     85.4 ± 0.4    (n = 6)    RAI      16.8    8.3      8.5 ± 0.5*                                      81.5 ± 0.5**    (n = 6)    SAI      16.4   10.8     5.6 ± 0.5                                     84.0 ± 0.8    (n = 6)    ______________________________________     *p < 0.01 (MannWhitney test)     **p < 0.001 (ttest)

From Table 9 it is clear that the 1-aminoindanes have a role inimproving post-trauma motor function and in decreasing the traumainduced cerebral oedema. This latter point is more relevant whenconsidering that the normal non-traumatized brain has a water content of78.5% (see Shohami et al. page 116, FIG. 2). Thus the activity of RAIshown above represents a 50, reduction in trauma-induced oedema.

Experiment 4B. The method of Experiment 1A was repeated with RAI and1-S-aminoindan (SAI) being administered at a 0.1 mg/kg dosage once a dayfor a period of 14 days. NSS assessment was performed at 1 hour, 24hours, 7 days and 14 days. The results are shown in Table 10 below fromwhich it can be seen that aminoindans have an improved effect on posttrauma motor function when administered over a prolonged period and thatRAI can restore almost complete motor function to a traumatized rat.

                  TABLE 10    ______________________________________    NSS        ΔNSS                        ΔNSS                                 ΔNSS                                         ΔNSS    at 1 hr    at 24 hr at 48 hr at 7 d  at 14 d    ______________________________________    Control          15.2 ± 0.2                   4.0 ± 0.3                            4.8 ± 0.5                                   5.6 ± 0.2                                           6.4 ± 0.2    (n = 5    RAI 35          17.7 ± 0.5                   7.3 ± 0.8                            9.3 ± 0.8                                   11.8 ± 0.5                                           14.0 ± 0.4    (n = 6)    SAI   16.6 ± 0.3                   5.5 ± 0.4                            6.8 ± 2.7                                   8.3 ± 1.0                                           9.5 ± 1.0    (n = 6)    ______________________________________

Experiment 4C. The method above was repeated using a range of doses ofRAI from 0.03 mg/kg to 3 mg/kg. The results are shown in the same manneras above in Table 11 from which it is evident that a maximal responsewas observed at 0.3 mg/kg and this level of response was retainedthereafter.

                  TABLE 11    ______________________________________    RAI      NSS                      % water in    mg/kg    1 hr   24 hr      ΔNSS                                      the brain    ______________________________________    Control  16.9   12.7       4.2 ± 0.4                                      83.6 ± 0.4    0.03     16.3   10.4       5.9 ± 0.3                                      81.0 ± 0.7    0.1      16.2   10.4       5.8 ± 0.4                                      81.8 ± 0.6    0.3      16.6    8.5       8.1 ± 0.5                                      81.8 ± 0.7    1.0      16.8    8.8       8.0 ± 0.5                                      81.5 ± 0.5    3.0      16.4    7.8       8.6 ± 0.7                                      81.9 ± 0.7    ______________________________________

Experiment 4D: The method of Experiment 4A was repeated using a lmg/kgdosage of RAI at the time of trauma induction (t=0) and at differenttimes thereafter e.g. 4 hr, 8 hr and 12 hr after trauma induction, i.e.a total of only two treatments. An addition control comparison wasperformed administering RAI at 0, 4, 8 and 12 hours. The results areshown in Table 12 below from which it can be seen that both regardlessof the number and timing of administration, all treated groups showedthe same degree of improvement of both NSS and oedema.

                  TABLE 12    ______________________________________    Times of RAI             % water in    administration               ΔNSS    the brain                                      n    ______________________________________    Control    4.8 ± 0.3  83.3 ± 0.6                                      6    0           8.8 ± 10.8                             81.2 ± 0.6                                      6    0 ± 4 h 8.0 ± 1.0  81.2 ± 0.4                                      6    0 ± 8 h 8.0 ± 0.1  81.8 ± 0.5                                      6    0 ± 12 h               8.7 ± 0.6  80.7 ± 0.5                                      6    0,4,8,12 h 8.2 ± 0.7  81.5 ± 0.5                                      6    ______________________________________

Experiment 4E: In order to obtain an idea as to the effective"therapeutic window" during which RAI can be given and still beeffective, Experiment 4A was repeated giving RAI at 1 mg/kg 1, 2 or 3hours post induction of head trauma. As shown in Table 13 below RAI wasstill effective even if given 3 hours after the induction of headtrauma.

                  TABLE 13    ______________________________________    Time of RAI    administration            % water in    (post head trauma)                 ΔNSS   the brain                                       n    ______________________________________    Control      4.8 ± 0.3 84.5 ± 0.4                                       7    +1 h         8.4 ± 0.6 81.7 ± 0.4                                       8    +2 h         7.0 ± 0.5 82.5 ± 0.4                                       8    +3 h         7.4 ± 0.5 81.8 ± 0.5                                       8    ______________________________________

Rate of MAO inhibition

The brains of some rats from each experimental group in Exp. 1 (chronictreatment of 80 days) and Exp. 2 (acute treatment of 14 days) were exvivo analyzed for MAO-A and MAO-B activity. Results are shown in Table14 below.

                  TABLE 14    ______________________________________    % inhibition of MAO A                         % inhibition of MAO B            chronic    acute     chronic acute    Treatment            treatment  treatment treatment                                         treatment    ______________________________________    R-AI     6         13        44      21    deprenyl            23         18        90      89    ______________________________________

Chronic or acute treatment of R-AI does not have an effect on MAO-Aactivity. These findings also indicate that only chronic treatment ofRAI can partially inhibit the MAO-B activity. As expected, acute orchronic treatment with deprenyl can strongly and selectively inhibit theactivity of MAO-B.

EXAMPLE 5 Anticonvulsive Activity of Aminoindans

Compounds provided herein were screened for their ability to protectagainst electrical and chemically induced convulsions. The standardelectrically induced test model is the Maximal electroshock (MES) model.This model is used to show efficacy for antiepileptic agents againstgeneralized and partial seizures. The standard model for chemicallyinduced seizures is the subcutaneous pentylenetetrazol (s.c.Met) seizurethreshold test model. This model is used to show efficacy for agentsagainst absence seizures. In these studies, convulsions wereadministration in rats after oral (p.o.) administration, and/or in miceafter intraperitoneal (i.p.) administration of the compound. Both theMES and s.c.Met models are described in E. A. Swinyard et al., in"Antiepileptic Drugs" E. R. H. Levy et al., Raven Press, New York(1985). The methods described therein were followed in the presentexamples.

Results

The results of the MES model are shown in Table 15 and where relevantthe results of scMet in Table 16. All results in the Tables are inmg/kg. Compounds are deemed to be within the scope of the invention ifthey displayed an ED50 of less than 200 mg/kg in at least one of themodels.

In both tables as well as in the text following Table 16 the compoundsare referred to with reference to an Example number, with reference to aletter code identified in the key beneath Table 15, or with reference toa number code identified in the text.

                  TABLE 15    ______________________________________           RATS          MICE             MES                   MES    COMPOUND 50      PI      TD50  ED50  PI    TD50    ______________________________________    A        36      >4.7    >168  <100  >1    >100    B        184     2.7     492   80    1.1   71    C        17      >29.4   >500  18    1.4   25    18       14      >35.7   >500  31    2.4   75    19       24      >20.8   >500  40    1.5   61     4                             <100     1       50      >1      >50   77    2.6   198     2       21      >23     >500  39    3.5   137    D        105     >1.7    >180  83    >1.5  127    E        <50     >1      >50   79    >1.9  153    F                              <300  >1    >300    G        57      >9      >500  57    >9    >500    H        50                    50    2.8   141    14       94      >1.5    >142  <100  >1    100    15       50              >50               <100    I        <50     >1      >50   66    1.1   58    J        <50     >1      >50   65    1.2   78    K                              115         <250    L        50      >1      >50   74    2.5   188     5                             <100  >3    >300    34                             <300        >300    31                       >50   <100        <100    25       50      >1            <100  <1    >100    M        <50     >1      >50   <100        <100    39       <50     >1      >50   <100        <100    28       <50     >1      >50   <100        <100    38       50      >1      >50   <100        <100    40       <50     >1      >50   <100        <100    21       21              >500  40          137     8       24              >500    17                             33    3     90    23       25      20      >500  65    2.2   155    26       40      12.5    >500    46                             82    6     500     5*                            58    2.6   138     3*                            83    1.6   127    16       50      >1      >50   <50    11       <50     >1      >50   <300  1     <300    27       <50     >1      >50   <100  >1    >100    20       <50     >1      >50   <100  >1    100    22       <50     >1      >50   <100  >1    >100    43       <50     >1      >50   <100  1     <100     3       <50     >1      >50   <100  >1    >100    42       <50     >1      >50    ______________________________________     A. 1aminoindan     B. (R)1-aminoindan     C. (S)1-aminoindan     D. HCl salt of 1     E. (R)N-propargyl-1-aminoindan HCl salt     F. (R)N-propargyl-1-aminoindan mesylate salt     G. (S)N-propargyl-1-aminoindan HCl salt     H. (S)N-propargyl-1-aminoindan mesylate salt     I. 6fluoro-1-aminoindan     J. (R)6-fluoro-1-aminoindan     K. (S)6-fluoro-1-aminoindan     L. 6fluoro-N-propargyl-1-aminoindan     M. aminotetralin     5*base of compound 5     3*base of compound 3

                  TABLE 16    ______________________________________           RATS          MICE             scMet                 scMet    COMPOUND ED50     PI     TD50  ED50   PI   TD50    ______________________________________    A        >250        >168              >100    B        >250        492     >100      71    C        >250        >500     >60      25    18       >250        >500     66       75    19       >250        >500     86       61     4     1                   >50     >200      198     2       >250        >500    >150      137    D                    >180    >130      127    E        >154        >50               153    F                                      >300    G        >250        >500    >250      >500    H                            >200      141    14        >71        >142              100    15                   >50               <100    I        >100        >50               58    J        >100        >50               78    K                                      <250    L        >300        >50               188    21       >250        >500     150      137     8       >250        >500    17                              71.5   90    23       >250        >500     155      155    26       >250        >500    46                           >500      >500     5*                          >200      138     3*                          >130      127     3                            36       126    ______________________________________

The racemic and individual enantiomers of 1-aminoindan showed activityin the MES model, indicating an activity in generalized and partialseizures. Surprisingly, there were significant differences between theactivities of the (R) and (S) enantiomers. In the MES test in rats,whereas the racemic compound A had an median effective dose of 36 mg/kg,the (R) enantiomer B had an ED50 of 184. The ED50 of the (S) enantiomerC was 17. This difference was also observed in mice. The (R) isomer hadan ED50 of 80, whereas the (S) isomer had an ED50 of 18.

An activity against generalized and partial seizures was also observedin with N-acetyl analogs of 1-aminoindan. Compound 18 ((R)-N-acetylaminoindan) had an ED50 of 14 in the MES test in rats, and 31 in mice.This value in rats is approximately 35 times lower than that observedfor valproic acid, 2 times lower than that found for phenytoin and 1.6times that found for Carbamazepine. As these three agents are consideredto be the drugs of choice for generalized an partial epilepsy, efficacyagainst these seizures are also indicated for this compound and theother compounds specified as active in the application. Compound 19((S)-N-acetylaminoindan) had an ED50 of 24 in MES test in rats, and 40in mice. These compounds also showed activity in the s.c. Met model inmice, which is representative of absence seizures. Compound 18 had anED50 of 66, whereas Compound 19 had an ED50 of 86.

The high activity observed with the above compounds was also observedwhen the 1-amino moiety was substituted with a glycinamide moiety. Aswith the 1-aminoindan compounds, the glycinamide analogs also showeddifferences between the (R) and (S) enantiomers, and whether thecompound was the HCl salt of free base. Compound 2((R)-Indanylglycinamide-free base) had an ED50 of 21 in rats and 39 inmice. D ((R)-Indanylglycinamide-HCl salt) had an ED50 in rats of 105 and83 in mice.

Compounds were also found to be active when the 1-amino moiety wassubstituted with propargyl moiety. The compounds were also found to beactive whether they were HCl or mesylate salts. E((R)-Propargylaminoindan-HCl) had an ED50 less than 50 in rats and 79 inmice. G (S)-Propargyl aminoindan had an ED50 of 57 in rats and mice. Themesylate salt of this compound H also had an ED50 of 50 or less in miceand rats in the MES test.

Activity was also found with compounds in which the 1-amino moiety wassubstituted with aliphatic side chains. Compound 14 ((S)-N-methylaminoindan) showed activity in the MES test in both rats (ED50=94) andmice (ED50<100).

Fluorinated analogs of 1-aminoindan also had activity in the MES test."I" has approximately the same efficacy. J had a better efficacyprofile. The ED50 was less than 50 in rats, 3 times more efficaciousthan that observed for B. K also showed activity in the MES model inmice. Compound 5 also showed activity in mice in the MES model. L alsoshowed activity in mice in this model.

Hydroxylated analogs of 1-aminoindan, also show activity in the MESmodel. Compound 34 (6-hydroxy analog of 1-aminoindan) showed activity inthe MES test in mice.

Activity in the MES model was also observed in methoxy analogs of1-aminoindan. Compound 31 (4,5 dimethoxy 1-aminoindan) showed activityin the mice.

In addition, amino tetralins also showed activity in the MES mode. M(1-amino tetralin) had an ED50 of less than 50 in rats and less than 100in mice. Substitution on the 1-amino group with glycinamide also showedactivity in mice.

EXAMPLE 6 Neurotoxicity and Protective Index

Neurotoxicity of the claimed agents was also assessed in mice (i.p.administration) by the rotorod ataxia test and/or in rats (p.o.administration) by positional sense test and gait stance test. See E. A.Swinyard, et al., in Antiepileptic Drugs," ed. by R. H. Levy, et al.,Raven Press, New York, at 85-200 (1989). The term quantitating theneurotoxicity is the medial neurological toxic dose (TD50), wasdetermined in the above tests. The results obtained in mg/kg are shownin the relevant positions of Tables 15 and 16. In some of the species,the TD50 was only determined to be above a certain level, indicating alower neurotoxicity than specified.

The Protective Index (PI) is defined as the ratio of TD50 and ED50(PI=TD50/ED50). The PI is used to show a useful separation betweenneurotoxicity and antiepileptic activity. The larger the PI, the betterthe separation between the neurotoxic and efficacious doses. Thepreferred embodiment of this application is therefore those compounds inwhich we have already demonstrated a PI>1 in the MES model of one of thespecies tested. Where the TD50 is only listed as greater than aparticular value, the PI will represent a minimum value, and therefore abetter index.

The racemic 1-aminoindan analog A and the individual enantiomers B and Chad PI values in rats of >4.7, 2.7 and >29.4, respectively. The PIvalues of the N-acetyl analogs Compound 17 and Compound 16 was >20.8,and >35.7 respectively. The PI values of the N-glycinamide analogsCompound 1 and Compound 2 is >1, and >23.

EXAMPLE 7 EFFECT OF AMINOINDANS ON MICE HAVING EXPERIENCED A HYPOBARICHYPOXIC EPISODE

The hypobaric hypoxic model is a well accepted model for assessing theactivity of compounds believed to possess neuroprotective activity. Themodel is based on that described in Nakanishi M et al. Life Sci. (1973)13, 467, Oshiro et al., J. Med. Chem. (1991) 34, 2004-2013 and U.S. Pat.No. 4,788,130.

A 121 desiccator (desiccator A) and a 2.5 l desiccator (desiccator B)were separately connected to a vacuum pump. Desiccator B wasdisconnected and allowed to equilibrate with room air whilst desiccatorA was evacuated to a pressure of 100 mmHg. Four male ICR albino mice(22-28 g) were placed in desiccator B. Desiccator B was then closed toroom air and connected to desiccator A. The pressure inside desiccator Bwas monitored using a mercury manometer and at the point were thepressure in desiccator B reached 200 mmHg (usually within 14 seconds),the two desiccators were disconnected from the vacuum pump and the pumpswitched off. The survival time from the moment of induction of hypoxiato the time of cessation of respiration was recorded for each mouse fora maximum of 15 minutes after which time room air was reintroduced todesiccator B. Survivors were monitored for signs of lethargy orvitality.

Effect of drug treatment was assessed as the percent of the survivaltime of the drug treated group with respect to the saline injected orvehicle injected control group. Control groups were run twice, beforeand after each experimental group and consisted of 12-16 mice in groupsof 4 mice. Each experimental group always consisted of 4 mice to ensurea constant residual volume of oxygen in all tests. The effect of eachdose of test drug was determined in duplicate i.e. two groups of 4 mice.The range of survival times of control mice was from 108-180 seconds.All drugs were administered intra-peritoneally at the dose indicated onehour prior to exposure to hypoxia. Reference drugs were administered asfollows; sodium pentobarbital, 20 or 40 mg/kg given 0.5 hour prior tohypoxia, diazepam, 5 or 10 mg/kg given 0.5 hour prior to hypoxia.

The results are shown in Tables 17 and 18 below.

                  TABLE 17    ______________________________________    TREATMENT      PROTECTION % OF             DOSE      RESPECTIVE    SIGNIFICANCE    COMPOUND (mg/kg ip)                       CONTROL       "t" TEST    ______________________________________    Diazepam 10        430 ± 59   p < 0.001             5         249 ± 166  p < 0.05    Pentobarbitone             40         446 ± 10.5                                     p < 0.001             20        325 ± 166  p < 0.002    B        100       395 ± 199  p < 0.001             50        358 ± 224  p < 0.01                       411 ± 174  p < 0.001    C        100       404 ± 244  p < 0.002             50        174 ± 39   p < 0.01                       264 ± 66   p < 0.001    18       100       397 ± 244  p < 0.01             50        271 ± 193  p < 0.05                       383 ± 233  p < 0.01    ______________________________________

                  TABLE 18    ______________________________________    TREATMENT      PROTECTION % OF              DOSE     RESPECTIVE    SIGNIFICANCE    COMPOUND  (mg/kg ip)                       CONTROL       "t" TEST    ______________________________________    (R)-6-fluoro-              100      241 ± 56   p < 0.001    1-aminoindan              50       305 ± 185  p < 0.01    30        100      379 ± 202  p < 0.001              50       265 ± 284  ns    42        100      228 ± 119  p < 0.02              50       179 ± 170  ns    39        100      798 ± 249  P < 0.001              50       609 ± 213  p < 0.001    41        100      644 ± 316  p < 0.001              50       187 ± 41   p < 0.001    28        100      941 ± 34   p < 0.001              50       361 ± 106  p < 0.001    1-Aminotetralin              100      345 ± 134  p < 0.001              50       158 ± 54   p < 0.02    40        100      569 ± 173  p < 0.001              50       374 ± 190  p < 0.001    ______________________________________

EXPERIMENT 8: CULTURES OF MECHANICALLY DISSOCIATED NEONATAL RATCEREBELLUM

A. Reversal of NMDA induced cell death.

The cerebellum was aseptically dissociated from 6 or 7-day old rat pupsand placed in a 15 ml sterile plastic conical tube containing 3 ml ofDulbecco's modified Eagle's medium (DMEM) with a high glucoseconcentration (1 g/ml) and 2 mM (v/v) L-glutamine and an antibioticantimitotic mixture. The cerebella were then dissociated after 20-25passages through a sterile 13 gauge, 10 cm long stainless steel needleattached to a 5 ml syringe with an inserted 45 micrometer pore nylonsieve. The dissociated cells were centrifuged at 200 g for 5 minutes.The supernatant was discarded and the cells resuspended in mediumenriched with 15 (v/v) heat inactivated fetal calf serum. Cell viabilitywas determined by the tryptan blue exclusion test.

Cells were plated at a density of 200/mm² on poly-L-lysine coatedsurfaces. Poly-L-lysine coated glass coverslips were prepared at leastone hour in advance of plating by immersing sterile coverslips insterile distilled water solution containing 15 microgram/mlpoly-L-lysine, and washing in sterile water just prior to use. Theplated cells were covered with enriched medium and incubated at 37° C.in an atmosphere of 5% CO₂ in air and 97% humidity. After three days inculture, the media was replaced with media containing the desired testcompound. Each test compound was tested in duplicate. Toxic-doseresponse was determined for each compound.

Four groups were run in each set of experiments;

I. Control, consisting of enriched media alone,

II. N-methyl-D-aspartate (NMDA, 1 mM for 3 hours) as the cytotoxicchallenge,

III. Test compound plus NMDA, and

IV. Positive control, spermine(0.01 micromoles) plus NMDA.

Nerve cell survival was evaluated by phase contrast microscopy andtryptan blue staining after 24 hours.

Results

The results are shown in Table 19 below. Surviving cells in culture aremeasured relative to control (100%) as described above. Percentprotection is the Cell Survival for the test compound minus the NMDAeffect. Thus, maximal protection is 100% minus 30% NMDA effect i.e. 70%.The Effective Protection was calculated as the percent of the PercentProtection (X) divided by the maximal protection value (e.g. X×100/70).

                                      TABLE 19    __________________________________________________________________________            EXPERMNT'L                    SURVIVING            GROUP   CELL IN PERCENT                                   EFFECTIVE    COMPOUND            Dose (μM)                    CULTURE PROTECTION                                   PROTECTION    __________________________________________________________________________            Control 100            NMDA    30            Max             70     100            protection            Spermine +                    82      52     74            NMDA    18      0.005 + NMDA                    80      50     71            0.010   80      50     71            0.100   55      25     36            1.000   47      17     24            5.000   32      2      3    (R)-6-  0.005   108     78     111    fluoro-1-            0.010   79      49     70    aminoindan            0.100   62      32     46            1.000   53      23     33            5.000   60      30     43    19      0.001   80      50     71            0.005   30      0      0            0.010   42      12     17            1.000   15      -15    --     2      0.005   56      26     37            0.010   51      21     30            0.100   33      3      4    35      0.005   60      30     43            0.010   34      4      6            0.100   30      0      0    (R)-1-  0.005   80      50     71    aminoindan            0.010   30      0      0            0.100   28      -2     --    __________________________________________________________________________

In a separate experiment wherein the Maximum Protection possible was90%, compound C (1-S-aminoindan) displayed an Effective Protection valueof 43% at 0.01 μM and 57% at 0.05 μM.

B. Enhancement of Cell Survival.

Cell cultures were grown as described above but in the absence of NMDAand after 3 days a dose of test compound was added. Cell survival wasmonitored as described above. Naturally (control) the cells die over aperiod of seven days from plating. Measurements of cell survival taken24 hours after the addition of test compound (four days after cellplating) showed that the test compounds enhanced the survival of thecells, delaying their natural death. Table 20 below shows the per centincrease in No of cells present on the fourth day expressed aspercentage of the number of control cells on that day.

                  TABLE 20    ______________________________________    COMPOUND     DOSE μM                          % ENHANCED SURVIVAL    ______________________________________    18           0.01     145                 0.10     130                 1.00     126    19           0.005    120     2           0.005    140                 0.010    125    (R)-1-aminoindan                 0.005    121    ______________________________________

EXAMPLE 9 GLOBAL BRAIN ISCHEMIA IN GERBILS

Male mongolian gerbils, aged 2.5-5 months, housed 4-8 in a cage, weresupplied freely with food and water and maintained at 24° C. with a 12hour day/night cycle. For surgery the animals were anesthetized withhalothane (1.5% in 100% O₂) and the common carotid arteries exposedbilaterally through a midline ventral neck incision. Each artery wasclamped for 5 minutes with aneurysm clips to produce global brainischemia. The anesthesia was discontinued upon clamping. After 5 minutesthe clamps were removed and the wound closed with skin clips.

For treatment, the test compound or vehicle were injectedintra-peritoneally (ip) in a volume of 50 microliters of solvent per 10g body weight. The first injection was given two minutes after clampremoval, and thereafter daily for the next 2 post-operative days (totalof 3 injections).

Seven groups each of 4-8 animals were compared:

I. Control; (sham- or unoperated and saline treated),

II. Vehicle treated, unoperated (when solvent is other than saline),

III. Ischemia--untreated or saline treated),

IV. Ischemia--vehicle treated (when solvent is other than saline),

V. Ischemia--Test compound treated, one sub-group per concentrationtested,

VI. Ischemia and pentobarbital (40 mg/kg) as positive control).

Analysis of neuronal damage was performed 14 days post-ischemia bycounting pyramidal neurons throughout the CA1 layer of the anteriorhippocampus in 4 micromolar thick (paraffin) coronal brain sectionsstained with hematoxylin and erosin.

The Results are shown in the Table 21 below. Percent Protection valuesrepresent the fraction of hippocampi protected from ischemia in a groupof animals treated with the stated dose of compound.

                  TABLE 21    ______________________________________                                % INTACT                                        PERCENT    TEST COMPOUND               (n)   DOSE (mg/kg)                                NEURONS PROTECTION    ______________________________________    Control                     100    Ischemia                    0    Pentobarbital               (8)                      87.5    18               (8)   0.1                25.0               (8)   1.0                25.0               (4)   10.0               66.7    (R)-6-fluoro-1-    aminoindan (8)   0.1                27.5               (8)   1.0                25.0               (8)   10.0               25.0    19               (4)   0.1                25.0               (2)   1.0                0               (4)   10.0               37.5    (R)-1-aminoindan               (4)   0.1                25.0               (4)   1.0                25.0               (4)   10.0               25.0    (S)-1-aminoindan               (4)   0.1                0               (4)   1.0                50.0               (4)   10.0               75.0               (4)   0.1                0               (2)   1.0                50.0               (4)   10.0               37.5    35               (8)   0.1                25.0               (8)   1.0                37.5               (7)   10.0               37.5    ______________________________________

EXAMPLE 10 ELECTRICALLY KINDLED RAT MODEL OF EPILEPSY

The rat electrical kindling model of epilepsy has been known to showefficacy of antiepileptic agents against complex partial seizures thatevolve into generalized motor seizures. In these tests, rats wereelectrically stimulated via corneal electrodes twice daily forapproximately 5 days and then once daily for an additional 10 days. Oncethe seizure criteria, as described by R. J. Racine, et al.,Electroenceph. Clin. Neurophysiol. 32: 281-294 (1972), were met, thetest substance was administered p.o. to rats, and the rat electricallystimulated, and observed for the presence or absence of a seizure. Thedetailed procedure of this test model can be found in, E. A. Swinyard,et al., in "Antiepileptic Drugs," ed. by R. H. Levy, et al., RavenPress, New York, at 85-100 (1989) and Racine, Id.

Further, in the electrically kindled rat model, compound 18(administered p.o.) prevented seizures with an ED₅₀ of 24.6 Mg/kg;compound 17 with an ED₅₀ of <75 mg/kg; and compound 19 with an ED₅₀of >50 mg/kg. The results are therefore indicative of these compoundshaving an efficacy against generalized seizures and complex partialseizures which evolve into generalized motor seizures.

What is claimed is:
 1. A compound selected from the group consisting of(S)-N-formyl-1-aminoindan, (R)-N-acetyl-1-aminoindan,N-acetyl-7-methyl-1-aminoindan, N-acetyl-6-fluoro-1-aminoindan,(R)-N-acetyl-6-fluoro-1-aminoindan, (S)-N-acetyl-6-fluoro-1-aminoindan,N-acetyl-6-methoxy-1-aminoindan, (R)-N-acetyl-6-methoxy-1-amninoindan,(S)-N-acetyl-6-methoxy-1-aminoindan,N-acetyl-4,5,-dimethoxy-1-aminoindan,(R)-Nacetyl-4,5-dimethoxy-1-aminoindan,(S)-N-acetyl-4,5-dimethoxy-1-aminoindan,N-(2-phenylacetyl)-1-aminoindan, N-(m-anisoyl)-1-aminoindan, N-(4'-fluorobenzoyl)-1-aminioindan, N-(p-toluoyl)-1-aminoindan,N-(4-aminobutanoyl)-1-aminoindan, N-(2-acetamido)-1-aminoindan,(R)-N-(2-acetamido)-1-aminoindan, (S)-N-(2-acetamido)-1-aminoindan,N-(2-acetamido)-6-fluoro-1-aminoindan, N-(3-cyanopropyl)-1-aminoindan,N-(2-N-Boc-aminoacetyl)-1-aminoindan, N-(2-aminoacetyl)-1-aminoindan,N-(2-n-propylpentanoyl)-1-aminoindan, N-(4-di-n-propylsulfamoyl)benzoyl-1-aminoindan, N-(2-propionamido)-1-aminoindan,N-N-di-(2-acetamido)-1-aminoindan, N-(1-indanyl)amino-acetonitrile,2-(1-indanamino)-N-isoprpopylethane-sulfonamide,2-(1-indanamino)-N-(1-indanyl) ethane-sulfonamide,(R,R)-2-(1-indanamino)-N-(1-indanyl) ethanesulfonamide,N-N'-bis-(1-indanyl) adipamide, N-N'-bis-(R)-(1-indanyl)adipamide,N-N'-bis-(R)-(1-indanyl)succinamide, and salts thereof.
 2. The saltaccording to claim 1, wherein the salt is a hydrochloride salt, amesylate salt, an ethylsulfonate salt, or a sulfate salt.
 3. Apharmaceutical composition comprising a therapeutically effective amountof the compound of claim 1 and a pharmaceutically acceptable carrier. 4.The pharmaceutical composition according to claim 3 wherein thepharmaceutically acceptable carrier is a solid and the pharmaceuticalcomposition is a tablet.
 5. The pharmaceutical composition according toclaim 4 wherein the therapeutically effective amount is from about 1 mgto about 1000 mg.
 6. The pharmaceutical composition according to claim 5wherein the therapeutically effective amount is from about 10 mg toabout 100 mg.
 7. The pharmaceutical composition according to claim 3wherein the pharmaceutically acceptable carrier is a liquid and thepharmaceutical composition is an injectable solution.
 8. Thepharmaceutical composition according to claim 7 wherein thetherapeutically effective amount is from about 1 mg/ml to about 1000mg/ml.
 9. The pharmaceutical composition according to claim 8 whereinthe therapeutically effective amount is from about 10 mg/ml to about 100mg/ml.
 10. The pharmaceutical composition according to claim 3 whereinthe carrier is a gel and the pharmaceutical composition is asuppository.
 11. The pharmaceutical composition according to claim 3,further comprising a therapeutically effective amount of Levodopa. 12.The pharmaceutical composition according to claim 11, further comprisinga therapeutically effective amount of a decarboxylase inhibitor.
 13. Thepharmaceutical composition according to claim 12 wherein thedecarboxylase inhibitor is L-Carbidopa.
 14. The pharmaceuticalcomposition according to claim 13 wherein the therapeutically effectiveamount of the compound is from about 1 mg to about 1000 mg, thetherapeutically effective amount of Levodopa is from about 50 mg toabout 250 mg, and the therapeutically effective amount of L-Carbidopa isfrom about 10 mg to about 25 mg.
 15. The pharmaceutical compositionaccording to claim 12 wherein the decarboxylase inhibitor isbenserazide.
 16. The pharmaceutical composition of claim 15 wherein thetherapeutically effective amount of the compound is from about 1 mg toabout 1000 mg, the therapeutically effective amount of Levodopa is fromabout 50 mg to about 200 mg, and the therapeutically effective amount ofbenserazide is from about 12.5 mg to about 50 mg. 17.R-(+)-N-benzyl-1-aminoindan.
 18. R-(+)-N-benzyl-1-aminoindan-L-mandelateethanolate.
 19. S-(-)-N-benzyl-1-aminoindan-D-mandelate ethanolate.